

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108945 A2

- (51) International Patent Classification⁷: **C12Q**
- (21) International Application Number:
PCT/US2004/013379
- (22) International Filing Date: 30 April 2004 (30.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/454,663 4 June 2003 (04.06.2003) US
- (71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BENNETT, Frank, C.** [US/US]; 1347 Cassins Street, Carlsbad, CA 92009 (US). **MIRABELLI, Christopher, K.** [US/US]; 6 Pine Street, Dover, MA 02030 (US).
- (74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrel P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION



(57) Abstract: Compositions and methods for the treatment of ophthalmic disorders, particularly preservation of corneal explants and prevention of corneal allograft rejection. These compositions comprise oligonucleotides which are specifically hybridizable with nucleic acids encoding the cellular adhesion molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1).



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

OLIGONUCLEOTIDE MODULATION OF CELL ADHESION**5 INTRODUCTION**

This application is a continuation-in-part of application Serial No. 09/982,262, filed October 18, 2001, which is a continuation-in-part of application Serial No 09/659,288, filed September 12, 2000 (abandoned), which is a continuation of
10 application Serial No. 09/128,496, filed August 3, 1998 (U.S. Patent No. 6,169,079), which is a continuation of application Serial No. 08/440,740, filed May 12, 1995 (U.S., Patent No. 5,843,738), which is a continuation-in-part of application Serial No. 08/063,167 filed May 17, 1993 (U.S. Patent No. 5,514,788),
15 which is a continuation of application Serial No. 07/969,151 filed February 10, 1993 (abandoned), which is a continuation-in-part of application Serial No. 08/007,997 filed January 21, 1993 (U.S. Patent 5,591,623). The entire contents of these applications and patents is incorporated herein by reference.

20

FIELD OF THE INVENTION

This invention relates to diagnostics, research reagents and therapies for disease states which respond to modulation of the synthesis or metabolism of cell adhesion molecules. In
25 particular, this invention relates to antisense oligonucleotide interactions with certain messenger ribonucleic acids (mRNAs) or DNAs involved in the synthesis of proteins that regulate adhesion of white blood cells to other white blood cells and to other cell types. Antisense oligonucleotides designed to hybridize to the
30 mRNA encoding intercellular adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-selectin), and vascular cell adhesion molecule-1 (VCAM-1) are provided. These oligonucleotides have been found to lead to the modulation of the activity of the RNA or DNA, and thus to the
35 modulation of the synthesis and

-2-

metabolism of specific cell adhesion molecules. Palliation and therapeutic effect result.

BACKGROUND OF THE INVENTION

5 Inflammation is a localized protective response elicited by tissues in response to injury, infection, or tissue destruction resulting in the destruction of the infectious or injurious agent and isolation of the injured tissue. A typical inflammatory response proceeds as follows: recognition of an antigen as foreign
10 or recognition of tissue damage, synthesis and release of soluble inflammatory mediators, recruitment of inflammatory cells to the site of infection or tissue damage, destruction and removal of the invading organism or damaged tissue, and deactivation of the system once the invading organism or damage has been resolved. In
15 many human diseases with an inflammatory component, the normal, homeostatic mechanisms which attenuate the inflammatory responses are defective, resulting in damage and destruction of normal tissue.

Cell-cell interactions are involved in the activation of the
20 immune response at each of the stages described above. One of the earliest detectable events in a normal inflammatory response is adhesion of leukocytes to the vascular endothelium, followed by migration of leukocytes out of the vasculature to the site of infection or injury. The adhesion of these leukocytes, or white
25 blood cells, to vascular endothelium is an obligate step in the migration out of the vasculature. Harlan, J.M., *Blood* 1985, 65, 513-525. In general, the first inflammatory cells to appear at the site of inflammation are neutrophils followed by monocytes, and lymphocytes. Cell-cell interactions are also critical for
30 propagation of both B-lymphocytes and T-lymphocytes resulting in enhanced humoral and cellular immune responses, respectively.

The adhesion of white blood cells to vascular endothelium and other cell types is mediated by interactions between specific
35 proteins, termed "adhesion molecules," located on the plasma

-3-

membrane of both white blood cells and vascular endothelium. The interaction between adhesion molecules is similar to classical receptor ligand interactions with the exception that the ligand is fixed to the surface of a cell instead of being soluble. The

5 identification of patients with a genetic defect in leukocyte adhesion has enabled investigators to identify a family of proteins responsible for adherence of white blood cells. Leukocyte adhesion deficiency (LAD) is a rare autosomal trait characterized by recurrent bacterial infections and impaired pus

10 formation and wound healing. The defect was shown to occur in the common B-subunit of three heterodimeric glycoproteins, Mac-1, LFA-1, and p150,95, normally expressed on the outer cell membrane of white blood cells. Anderson and Springer, *Ann. Rev. Med.* **1987**, 38, 175-194. Patients suffering from LAD exhibit a defect in a

15 wide spectrum of adherence-dependent functions of granulocytes, monocytes, and lymphocytes. Three ligands for LFA-1 have been identified, intercellular adhesion molecules 1, 2 and 3 (ICAM-1, ICAM-2 and ICAM-3). Both Mac-1 and p150,95 bind complement fragment C3bi and perhaps other unidentified ligands. Mac-1 also

20 binds ICAM-1.

Other adhesion molecules have been identified which are involved in the adherence of white blood cells to vascular endothelium and subsequent migration out of the vasculature. These include endothelial leukocyte adhesion molecule-1 (ELAM-1),

25 vascular cell adhesion molecule-1 (VCAM-1) and granule membrane protein-140 (GMP-140) and their respective receptors. The adherence of white blood cells to vascular endothelium appears to be mediated in part if not *in toto* by the five cell adhesion molecules ICAM-1, ICAM-2, ELAM-1, VCAM-1 and GMP-140. Dustin and

30 Springer, *J. Cell Biol.* **1987**, 107, 321-331. Expression on the cell surface of ICAM-1, ELAM-1, VCAM-1 and GMP-140 adhesion molecules is induced by inflammatory stimuli. In contrast, expression of ICAM-2 appears to be constitutive and not sensitive to induction by cytokines. In general, GMP-140 is induced by

35 autocooids such as histamine, leukotriene B₄, platelet activating

-4-

factor, and thrombin. Maximal expression on endothelial cells is observed 30 minutes to 1 hour after stimulation, and returns to baseline within 2 to 3 hours. The expression of ELAM-1 and VCAM-1 on endothelial cells is induced by cytokines such as interleukin-1 β and tumor necrosis factor, but not gamma-interferon. Maximal expression of ELAM-1 on the surface of endothelial cells occurs 4 to 6 hours after stimulation, and returns to baseline by 16 hours. ELAM-1 expression is dependent on new mRNA and protein synthesis. Elevated VCAM-1 expression is detectable 2 hours following treatment with tumor necrosis factor, is maximal 8 hours following stimulation, and remains elevated for at least 48 hours following stimulation. Rice and Bevilacqua, *Science* **1989**, 246, 1303-1306. ICAM-1 expression on endothelial cells is induced by cytokines interleukin-1 tumor necrosis factor and gamma-interferon. Maximal expression of ICAM-1 follows that of ELAM-1 occurring 8 to 10 hours after stimulation and remains elevated for at least 48 hours.

GMP-140 and ELAM-1 are primarily involved in the adhesion of neutrophils to vascular endothelial cells. VCAM-1 primarily binds T and B lymphocytes. In addition, VCAM-1 may play a role in the metastasis of melanoma, and possibly other cancers. ICAM-1 plays a role in adhesion of neutrophils to vascular endothelium, as well as adhesion of monocytes and lymphocytes to vascular endothelium, tissue fibroblasts and epidermal keratinocytes. ICAM-1 also plays a role in T-cell recognition of antigen presenting cell, lysis of target cells by natural killer cells, lymphocyte activation and proliferation, and maturation of T cells in the thymus. In addition, recent data have demonstrated that ICAM-1 is the cellular receptor for the major serotype of rhinovirus, which account for greater than 50% of common colds. Staunton et al., *Cell* **1989**, 56, 849-853; Greve et al., *Cell* **1989**, 56, 839-847.

Expression of ICAM-1 has been associated with a variety of inflammatory skin disorders such as allergic contact dermatitis, fixed drug eruption, lichen planus, and psoriasis; Ho et al., *J. Am. Acad. Dermatol.* **1990**, 22, 64-68; Griffiths and Nickoloff, *Am.*

-5-

J. Pathology **1989**, 135, 1045-1053; Lisby et al., *Br. J. Dermatol.* **1989**, 120, 479-484; Shiohara et al., *Arch. Dermatol.* **1989**, 125, 1371-1376. In addition, ICAM-1 expression has been detected in the synovium of patients with rheumatoid arthritis; Hale et al.,
5 *Arth. Rheum.* **1989**, 32, 22-30, pancreatic B-cells in diabetes; Campbell et al., *Proc. Natl. Acad. Sci. U.S.A.* **1989**, 86, 4282-4286; thyroid follicular cells in patients with Graves' disease; Weetman et al., *J. Endocrinol.* **1989**, 122, 185-191; and with renal and liver allograft rejection; Faull and Russ, *Transplantation*
10 **1989**, 48, 226-230; Adams et al., *Lancet* **1989**, 1122-1125. ICAM-1 is also expressed on corneal endothelial cells and is induced on corneal endothelial cells in response to inflammatory stimuli.

It is has been hoped that inhibitors of ICAM-1, VCAM-1 and ELAM-1 expression would provide a novel therapeutic class of anti-
15 inflammatory agents with activity towards a variety of inflammatory diseases or diseases with an inflammatory component such as asthma, rheumatoid arthritis, allograft rejections, inflammatory bowel disease, various dermatological conditions, and psoriasis. In addition, inhibitors of ICAM-1, VCAM-1, and ELAM-1
20 may also be effective in the treatment of colds due to rhinovirus infection, AIDS, Kaposi's sarcoma and some cancers and their metastasis. To date, there are no known therapeutic agents which effectively prevent the expression of the cellular adhesion molecules ELAM-1, VCAM-1 and ICAM-1. The use of neutralizing
25 monoclonal antibodies against ICAM-1 in animal models provide evidence that such inhibitors if identified would have therapeutic benefit for asthma; Wegner et al., *Science* **1990**, 247, 456-459, renal allografts; Cosimi et al., *J. Immunol.* **1990**, 144, 4604-4612, and cardiac allografts; Isobe et al., *Science* **1992**, 255, 1125-
30 1127. The use of a soluble form of ICAM-1 molecule was also effective in preventing rhinovirus infection of cells in culture. Marlin et al., *Nature* **1990**, 344, 70-72.

Current agents which affect intercellular adhesion molecules include synthetic peptides, monoclonal antibodies, and soluble
35 forms of the adhesion molecules. To date, synthetic peptides

- 6 -

which block the interactions with VCAM-1 or ELAM-1 have not been identified. Monoclonal antibodies may prove to be useful for the treatment of acute inflammatory response due to expression of ICAM-1, VCAM-1 and ELAM-1. However, with chronic treatment, the host animal develops antibodies against the monoclonal antibodies thereby limiting their usefulness. In addition, monoclonal antibodies are large proteins which may have difficulty in gaining access to the inflammatory site. Soluble forms of the cell adhesion molecules suffer from many of the same limitations as monoclonal antibodies in addition to the expense of their production and their low binding affinity. Thus, there is a long felt need for molecules which effectively inhibit intercellular adhesion molecules. Antisense oligonucleotides avoid many of the pitfalls of current agents used to block the effects of ICAM-1, VCAM-1 and ELAM-1.

PCT/US90/02357 (Hession et al.) discloses DNA sequences encoding Endothelial Adhesion Molecules (ELAMs), including ELAM-1 and VCAM-1 and VCAM-1b. A number of uses for these DNA sequences are provided, including (1) production of monoclonal antibody preparations that are reactive for these molecules which may be used as therapeutic agents to inhibit leukocyte binding to endothelial cells; (2) production of ELAM peptides to bind to the ELAM ligand on leukocytes which, in turn, may bind to ELAM on endothelial cells, inhibiting leukocyte binding to endothelial cells; (3) use of molecules binding to ELAMS (such as anti-ELAM antibodies, or markers such as the ligand or fragments of it) to detect inflammation; (4) use of ELAM and ELAM ligand DNA sequences to produce nucleic acid molecules that intervene in ELAM or ELAM ligand expression at the translational level using antisense nucleic acid and ribozymes to block translation of a specific mRNA either by masking mRNA with antisense nucleic acid or cleaving it with a ribozyme. It is disclosed that coding regions are the targets of choice. For VCAM-1, AUG is believed to be most likely; a 15-mer hybridizing to the AUG site is specifically disclosed in Example 17.

-7-

In the United States, 40,000 corneal transplants are performed per year. Human corneal allograft rejection is a major problem in corneal clinical practice. To date, no totally reliable and reproducible medication regimen provides assurance that allograft rejection will not occur in high risk patients, including those with corneal neovascularization and previous rejections. Corneal transplants require months of meticulous follow-up care, and significantly restrict the physical activity of recipients. In addition, corneal transplantation often necessitates general anesthesia and is very expensive. Therefore, allograft rejection presents significant personal, economic and anesthetic risks to patients. Thus, there is a need for compositions and methods which will prevent corneal allograft rejection.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is the mRNA sequence of human intercellular adhesion molecule-1 (ICAM-1).

FIGURE 2 is the mRNA sequence of human endothelial leukocyte adhesion molecule-1 (ELAM-1).

FIGURE 3 is the mRNA sequence of human vascular cell adhesion molecule-1 (VCAM-1).

FIGURE 4 is a graphical representation of the induction of ICAM-1 expression on the cell surface of various human cell lines by interleukin-1 and tumor necrosis factor.

FIGURE 5 is a graphical representation of the effects of selected antisense oligonucleotides on ICAM-1 expression on human umbilical vein endothelial cells.

FIGURE 6A and 6B are a graphical representation of the effects of an antisense oligonucleotide on the expression of ICAM-1 in human umbilical vein endothelial cells stimulated with tumor necrosis factor and interleukin-1.

FIGURE 7 is a graphical representation of the effect of antisense oligonucleotides on ICAM-1 mediated adhesion of DMSO differentiated HL-60 cells to control and tumor necrosis factor

-8-

treated human umbilical vein endothelial cells.

FIGURE 8 is a graphical representation of the effects of selected antisense oligonucleotides on ICAM-1 expression in A549 human lung carcinoma cells.

5 FIGURE 9 is a graphical representation of the effects of selected antisense oligonucleotides on ICAM-1 expression in primary human keratinocytes.

10 FIGURE 10 is a graphical representation of the relationship between oligonucleotide chain length, T_m and effect on inhibition of ICAM-1 expression.

FIGURE 11 is a graphical representation of the effect of selected antisense oligonucleotides on ICAM-1 mediated adhesion of DMSO differentiated HL-60 cells to control and tumor necrosis factor treated human umbilical vein endothelial cells.

15 FIGURE 12 is a graphical representation of the effects of selected antisense oligonucleotides on ELAM-1 expression on tumor necrosis factor-treated human umbilical vein endothelial cells.

FIGURE 13 is a graphical representation of the human ELAM-1 mRNA showing target sites of antisense oligonucleotides.

20 FIGURE 14 is a graphical representation of the human VCAM-1 mRNA showing target sites of antisense oligonucleotides.

FIGURE 15 is a line graph showing inhibition of ICAM-1 expression in C8161 human melanoma cells following treatment with antisense oligonucleotides complementary to ICAM-1.

25 FIGURE 16 is a bar graph showing the effect of ISIS 3082 on dextran sulfate (DSS)-induced inflammatory bowel disease.

FIGURE 17 is a graph showing the effects of ICAM-1 antisense oligonucleotides (ISIS 13315 and 17481) on airway resistance in an ovalbumin-induced mouse asthma model after intratracheal oligonucleotide administration. Penh is a measure of airway resistance. Naïve mice were not sensitized with ovalbumin.

30 FIGURE 18 is a graph showing the effects of ICAM-1 antisense oligonucleotides (ISIS 13315 and 17481) on the number of eosinophils in bronchiolar lavage (BAL) fluid in an ovalbumin-induced mouse asthma model after intratracheal oligonucleotide

35

- 9 -

administration.

FIGURE 19 is a graph showing the effects of ICAM-1 antisense oligonucleotides (ISIS 13315 and 17481) on the number of neutrophils in bronchiolar lavage (BAL) fluid in an ovalbumin-induced mouse asthma model after intratracheal oligonucleotide administration.

FIGURE 20 is a graph showing the effect of pretreatment with an ICAM-1 antisense oligonucleotide (ISIS 10984) on pulmonary methacholine responsiveness in ascaris sensitive cynomolgus monkeys.

SUMMARY OF THE INVENTION

In accordance with the present invention, oligonucleotides are provided which specifically hybridize with nucleic acids encoding intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1). The oligonucleotides are designed to bind either directly to mRNA or to a selected DNA portion forming a triple stranded structure, thereby modulating the amount of mRNA made from the gene. This relationship is commonly denoted as "antisense."

Oligonucleotides are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes, for example to distinguish between the functions of various members of a biological pathway. This specific inhibitory effect has, therefore, been harnessed for research use. This specificity and sensitivity is also harnessed by those of skill in the art for diagnostic uses.

It is preferred to target specific genes for antisense attack. "Targeting" an oligonucleotide to the associated ribonucleotides, in the context of this invention, is a multistep process. The process usually begins with identifying a nucleic

-10-

acid sequence whose function is to be modulated. This may be, as examples, a cellular gene (or mRNA made from the gene) whose expression is associated with a particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the target is a cellular gene associated with a particular disease state. The targeting process also includes determination of a site or sites within this region for the oligonucleotide interaction to occur such that the desired effect, either detection of or modulation of expression of the protein will result. Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

"Hybridization", in the context of this invention, means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them. "Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the oligonucleotide. It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment or, in the case of *in vitro* assays, under conditions in which the assays are conducted.

-11-

It is understood in the art that the sequence of the oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligomeric compound may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). It is preferred that the oligomeric compounds of the present invention comprise at least 70% sequence complementarity to a target region within the target nucleic acid, more preferably that they comprise 90% sequence complementarity and even more preferably comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an oligomeric compound in which 18 of 20 nucleobases of the oligomeric compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an oligomeric compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an oligomeric compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).

In the present invention the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions under which an oligomeric compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will vary with different circumstances and in the context of this invention;

-12-

"stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated.

5 It has been discovered that the genes coding for ICAM-1, VCAM-1 and ELAM-1 are particularly useful for this approach. Inhibition of ICAM-1, VCAM-1 and ELAM-1 expression is expected to be useful for the treatment of inflammatory diseases, diseases with an inflammatory component, allograft rejection, psoriasis and
10 other skin diseases, inflammatory bowel disease, cancers and their metastasis, and viral infections.

 Methods of modulating cell adhesion comprising contacting the animal with an oligonucleotide hybridizable with nucleic acids encoding a protein capable of modulating cell adhesion are
15 provided. Oligonucleotides hybridizable with an RNA or DNA encoding ICAM-1, VCAM-1 and ELAM-1 are preferred.

 The present invention is also useful in diagnostics and in research. Since the oligonucleotides of this invention hybridize to ICAM-1, ELAM-1 or VCAM-1, sandwich and other assays can easily
20 be constructed to exploit this fact. Provision of means for detecting hybridization of an oligonucleotide with one of these intercellular adhesion molecules present in a sample suspected of containing it can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable
25 detection system. A number of assays may be formulated employing the present invention, which assays will commonly comprise contacting a tissue sample with a detectably labeled oligonucleotide of the present invention under conditions selected to permit hybridization and measuring such hybridization by
30 detection of the label.

 For example, radiolabeled oligonucleotides can be prepared by ³²P labeling at the 5' end with polynucleotide kinase. Sambrook et al., *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1989, Volume 2, pg. 10.59.
35 Radiolabeled oligonucleotides are then contacted with tissue or

-13-

cell samples suspected of containing an intercellular adhesion molecule and the sample is washed to remove unbound oligonucleotide. Radioactivity remaining in the sample indicates bound oligonucleotide (which in turn indicates the presence of an intercellular adhesion molecule) and can be quantitated using a scintillation counter or other routine means. Expression of these proteins can then be detected.

Radiolabeled oligonucleotides of the present invention can also be used to perform autoradiography of tissues to determine the localization, distribution and quantitation of intercellular adhesion molecules for research, diagnostic or therapeutic purposes. In such studies, tissue sections are treated with radiolabeled oligonucleotide and washed as described above, then exposed to photographic emulsion according to routine autoradiography procedures. The emulsion, when developed, yields an image of silver grains over the regions expressing a intercellular adhesion molecule. Quantitation of the silver grains permits expression of these molecules to be detected and permits targeting of oligonucleotides to these areas.

Analogous assays for fluorescent detection of expression of intercellular adhesion molecules can be developed using oligonucleotides of the present invention which are conjugated with fluorescein or other fluorescent tag instead of radiolabeling. Such conjugations are routinely accomplished during solid phase synthesis using fluorescently labeled amidites or CPG (e.g., fluorescein-labeled amidites and CPG available from Glen Research, Sterling VA).

Each of these assay formats is known in the art. One of skill could easily adapt these known assays for detection of expression of intercellular adhesion molecules in accordance with the teachings of the invention providing a novel and useful means to detect expression of these molecules. Antisense oligonucleotide inhibition of the expression of intercellular adhesion molecules *in vitro* is useful as a means to determine a proper course of therapeutic treatment. For example, before a

-14-

patient is treated with an oligonucleotide composition of the present invention, cells, tissues or a bodily fluid from the patient can be treated with the oligonucleotide and inhibition of expression of intercellular adhesion molecules can be assayed.

5 Effective *in vitro* inhibition of the expression of molecules in the sample indicates that the expression will also be modulated *in vivo* by this treatment.

Kits for detecting the presence or absence of intercellular adhesion molecules may also be prepared. Such kits include an

10 oligonucleotide targeted to ICAM-1, ELAM-1 or VCAM-1.

The oligonucleotides of this invention may also be used for research purposes. Thus, the specific hybridization exhibited by the oligonucleotides may be used for assays, purifications, cellular product preparations, and in other methodologies which

15 may be appreciated by persons of ordinary skill in the art.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Antisense oligonucleotides hold great promise as therapeutic agents for the treatment of many human diseases. Oligonucleotides

20 specifically bind to the complementary sequence of either pre-mRNA or mature mRNA, as defined by Watson-Crick base pairing, inhibiting the flow of genetic information from DNA to protein. The properties of antisense oligonucleotides, which make them specific for their target sequence, also make them extraordinarily

25 versatile. Because antisense oligonucleotides are long chains of four monomeric units they may be readily synthesized for any target RNA sequence. Numerous recent studies have documented the utility of antisense oligonucleotides as biochemical tools for studying target proteins. Rothenberg et al., *J. Natl. Cancer Inst.*

30 **1989**, 81, 1539-1544; Zon, G. *Pharmaceutical Res.* **1988**, 5, 539-549). Because of recent advances in synthesis of nuclease resistant oligonucleotides, which exhibit enhanced cell uptake, it is now possible to consider the use of antisense oligonucleotides as a novel form of therapeutics.

35 Antisense oligonucleotides offer an ideal solution to the

-15-

problems encountered in prior art approaches. They can be designed to selectively inhibit a given isoenzyme, they inhibit the production of the enzyme, and they avoid non-specific mechanisms such as free radical scavenging or binding to multiple
5 receptors. A complete understanding of enzyme mechanisms or receptor-ligand interactions is not needed to design specific inhibitors.

DESCRIPTION OF TARGETS

10 The acute infiltration of neutrophils into the site of inflammation appears to be due to increased expression of GMP-140, ELAM-1 and ICAM-1 on the surface of endothelial cells. The appearance of lymphocytes and monocytes during the later stages of an inflammatory reaction appear to be mediated by VCAM-1 and ICAM-
15 1. ELAM-1 and GMP-140 are transiently expressed on vascular endothelial cells, while VCAM-1 and ICAM-1 are chronically expressed.

Human ICAM-1 is encoded by a 3.3-kb mRNA resulting in the synthesis of a 55,219 dalton protein (Figure 1). ICAM-1 is
20 heavily glycosylated through N-linked glycosylation sites. The mature protein has an apparent molecular mass of 90 kDa as determined by SDS-polyacrylamide gel electrophoresis. Staunton et al., *Cell* **1988**, 52, 925-933. ICAM-1 is a member of the immunoglobulin supergene family, containing 5 immunoglobulin-like
25 domains at the amino terminus, followed by a transmembrane domain and a cytoplasmic domain. The primary binding site for LFA-1 and rhinovirus are found in the first immunoglobulin-like domain. However, the binding sites appear to be distinct. Staunton et al., *Cell* **1990**, 61, 243-354. Recent electron micrographic studies
30 demonstrate that ICAM-1 is a bent rod 18.7 nm in length and 2 to 3 nm in diameter. Staunton et al., *Cell* **1990**, 61, 243-254.

ICAM-1 exhibits a broad tissue and cell distribution, and may be found on white blood cells, endothelial cells, fibroblast, keratinocytes and other epithelial cells. The expression of ICAM-
35 1 can be regulated on vascular endothelial cells, fibroblasts,

-16-

keratinocytes, astrocytes and several cell lines by treatment with bacterial lipopolysaccharide and cytokines such as interleukin-1, tumor necrosis factor, gamma-interferon, and lymphotoxin. See, e.g., Frohman et al., *J. Neuroimmunol.* **1989**, 23, 117-124. The molecular mechanism for increased expression of ICAM-1 following cytokine treatment has not been determined.

ELAM-1 is a 115-kDa membrane glycoprotein (Figure 2) which is a member of the selectin family of membrane glycoproteins. Bevilacqua et al., *Science* **1989**, 243, 1160-1165. The amino terminal region of ELAM-1 contains sequences with homologies to members of lectin-like proteins, followed by a domain similar to epidermal growth factor, followed by six tandem 60-amino acid repeats similar to those found in complement receptors 1 and 2. These features are also shared by GMP-140 and MEL-14 antigen, a lymphocyte homing antigen. ELAM-1 is encoded for by a 3.9-kb mRNA. The 3'-untranslated region of ELAM-1 mRNA contains several sequence motifs ATTTA which are responsible for the rapid turnover of cellular mRNA consistent with the transient nature of ELAM-1 expression.

ELAM-1 exhibits a limited cellular distribution in that it has only been identified on vascular endothelial cells. Like ICAM-1, ELAM-1 is inducible by a number of cytokines including tumor necrosis factor, interleukin-1 and lymphotoxin and bacterial lipopolysaccharide. In contrast to ICAM-1, ELAM-1 is not induced by gamma-interferon. Bevilacqua et al., *Proc. Natl. Acad. Sci. USA* **1987**, 84, 9238-9242; Wellicome et al., *J. Immunol.* **1990**, 144, 2558-2565. The kinetics of ELAM-1 mRNA induction and disappearance in human umbilical vein endothelial cells precedes the appearance and disappearance of ELAM-1 on the cell surface. As with ICAM-1, the molecular mechanism for ELAM-1 induction is not known.

VCAM-1 is a 110-kDa membrane glycoprotein encoded by a 3.2-kb mRNA (Figure 3). VCAM-1 appears to be encoded by a single-copy gene which can undergo alternative splicing to yield products with either six or seven immunoglobulin domains. Osborn et al., *Cell*

-17-

1989, 59, 1203-1211. The receptor for VCAM-1 is proposed to be CD29 (VLA-4) as demonstrated by the ability of monoclonal antibodies to CD29 to block adherence of Ramos cells to VCAM-1. VCAM-1 is expressed primarily on vascular endothelial cells. Like
5 ICAM-1 and ELAM-1, expression of VCAM-1 on vascular endothelium is regulated by treatment with cytokines. Rice and Bevilacqua, *Science* **1989**, 246, 1303-1306; Rice et al., *J. Exp. Med.* **1990**, 171, 1369-1374. Increased expression appears to be due to induction of the mRNA.

10 For therapeutics, an animal suspected of having a disease which can be treated by decreasing the expression of ICAM-1, VCAM-1 and ELAM-1 is treated by administering oligonucleotides in accordance with this invention. Oligonucleotides may be formulated in a pharmaceutical composition, which may include
15 carriers, thickeners, diluents, buffers, preservatives, surface active agents, liposomes or lipid formulations and the like, in addition to the oligonucleotide. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like, in
20 addition to oligonucleotide.

The pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally,
25 intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection.

In another embodiment, the administration is pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, dry powder inhaler, or metered dose
30 inhaler; intratracheal or intranasal.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers,
35 aqueous, powder or oily bases, thickeners and the like may be

-18-

necessary or desirable. Coated condoms or gloves may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable. Compositions for oral administration also include pulsatile delivery compositions and bioadhesive composition as described in copending U.S. Patent Application Serial Nos. 09/944,493, filed August 22, 2001, and 09/935,316, filed August 22, 2001, the entire disclosures of which are incorporated herein by reference.

Formulations for parenteral administration may include sterile aqueous solutions, which may also contain buffers, liposomes, diluents and other suitable additives. Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until a cure is effected or a diminution of disease state is achieved. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.

The present invention employs oligonucleotides for use in antisense inhibition of the function of RNA and DNA corresponding to proteins capable of modulating inflammatory cell adhesion. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages as well as oligomers having non-naturally occurring portions, which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of properties such as, for example, enhanced cellular uptake and increased stability in the presence of nucleases.

While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as double-

-19-

stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing.

The first evidence that dsRNA could lead to gene silencing in animals came in 1995 from work in the nematode, *Caenorhabditis elegans* (Guo and Kempheus, *Cell*, **1995**, 81, 611-620). Montgomery et al. have shown that the primary interference effects of dsRNA are posttranscriptional (Montgomery et al., *Proc. Natl. Acad. Sci. USA*, **1998**, 95, 15502-15507). The posttranscriptional antisense mechanism defined in *Caenorhabditis elegans* resulting from exposure to double-stranded RNA (dsRNA) has since been designated RNA interference (RNAi). This term has been generalized to mean antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of endogenous targeted mRNA levels (Fire et al., *Nature*, **1998**, 391, 806-811). Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the dsRNAs which are the potent inducers of RNAi (Tijsterman et al., *Science*, **2002**, 295, 694-697).

The oligonucleotides of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the oligonucleotide. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine (or uridine if RNA), guanosine or cytidine at this position. This may be done at any of the positions of the oligonucleotide. Thus, a 20-mer may comprise 60 variations (20 positions x 3 alternates at each position) in which the original nucleotide is substituted with any of the three alternate nucleotides. These oligonucleotides are then tested using the methods described herein to determine their ability to inhibit expression of ICAM-1, VCAM-1 or ELAM-1.

35

Oligomer and Monomer Modifications

-20-

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleo-
5 tides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate
10 groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally preferred. In addition, linear compounds may have internal nucleobase
15 complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside linkage or in conjunction with the sugar ring the backbone of the oligonucleotide. The normal
20 internucleoside linkage that makes up the backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Modified Internucleoside Linkages

Specific examples of preferred antisense oligomeric
25 compounds useful in this invention include oligonucleotides containing modified e.g. non-naturally occurring internucleoside linkages. As defined in this specification, oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom and internucleoside
30 linkages that do not have a phosphorus atom. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

35 In the *C. elegans* system, modification of the internucleotide linkage (phosphorothioate) did not significantly

-21-

interfere with RNAi activity. Based on this observation, it is suggested that certain preferred oligomeric compounds of the invention can also have one or more modified internucleoside linkages. A preferred phosphorus containing modified
5 internucleoside linkage is the phosphorothioate internucleoside linkage.

Preferred modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters,
10 aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates,
15 thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to
20 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the
25 preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111;
30 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In more preferred embodiments of the invention, oligomeric
35 compounds have one or more phosphorothioate and/or heteroatom internucleoside linkages, in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-$

-22-

N(CH₃)-O-CH₂- [known as a methylene (methyylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester internucleotide linkage is represented as -O-P(=O)(OH)-O-CH₂-]. The MMI type
5 internucleoside linkages are disclosed in the above referenced U.S. patent 5,489,677. Preferred amide internucleoside linkages are disclosed in the above referenced U.S. patent 5,602,240.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed
10 by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside);
15 siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones;
20 amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134;
25 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this
30 application, and each of which is herein incorporated by reference.

Oligomer Mimetics

Another preferred group of oligomeric compounds amenable to
35 the present invention includes oligonucleotide mimetics. The term mimetic as it is applied to oligonucleotides is intended to


-23-

include oligomeric compounds wherein only the furanose ring or both the furanose ring and the internucleotide linkage are replaced with novel groups, replacement of only the furanose ring is also referred to in the art as being a sugar surrogate. The heterocyclic base moiety or a modified heterocyclic base moiety is maintained for hybridization with an appropriate target nucleic acid. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA oligomeric compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA oligomeric compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA oligomeric compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

One oligonucleotide mimetic that has been reported to have excellent hybridization properties is peptide nucleic acids (PNA). The backbone in PNA compounds is two or more linked aminoethylglycine units which gives PNA an amide containing backbone. The heterocyclic base moieties are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

PNA has been modified to incorporate numerous modifications since the basic PNA structure was first prepared. The basic structure is shown below:

-24-



wherein

Bx is a heterocyclic base moiety;

T₄ is hydrogen, an amino protecting group, -C(O)R₅,
 5 substituted or unsubstituted C₁-C₁₀ alkyl, substituted or
 unsubstituted C₂-C₁₀ alkenyl, substituted or unsubstituted C₂-C₁₀
 alkynyl, alkylsulfonyl, arylsulfonyl, a chemical functional group,
 a reporter group, a conjugate group, a D or L α-amino acid linked
 via the α-carboxyl group or optionally through the ω-carboxyl
 10 group when the amino acid is aspartic acid or glutamic acid or a
 peptide derived from D, L or mixed D and L amino acids linked
 through a carboxyl group, wherein the substituent groups are
 selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl,
 nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and
 15 alkynyl;

T₅ is -OH, -N(Z₁)Z₂, R₅, D or L α-amino acid linked via the α-
 amino group or optionally through the ω-amino group when the
 amino acid is lysine or ornithine or a peptide derived from D, L
 or mixed D and L amino acids linked through an amino group, a
 20 chemical functional group, a reporter group or a conjugate group;

Z₁ is hydrogen, C₁-C₆ alkyl, or an amino protecting group;

Z₂ is hydrogen, C₁-C₆ alkyl, an amino protecting group, -
 C(=O)-(CH₂)_n-J-Z₃, a D or L α-amino acid linked via the α-carboxyl
 group or optionally through the ω-carboxyl group when the amino
 25 acid is aspartic acid or glutamic acid or a peptide derived from
 D, L or mixed D and L amino acids linked through a carboxyl group;

Z₃ is hydrogen, an amino protecting group, -C₁-C₆ alkyl,
 -C(=O)-CH₃, benzyl, benzoyl, or -(CH₂)_n-N(H)Z₁;

each J is O, S or NH;

30 R₅ is a carbonyl protecting group; and

-25-

n is from 2 to about 50.

Another class of oligonucleotide mimetic that has been studied is based on linked morpholino units (morpholino nucleic acid) having heterocyclic bases attached to the morpholino ring.


5 A number of linking groups have been reported that link the morpholino monomeric units in a morpholino nucleic acid. A preferred class of linking groups have been selected to give a non-ionic oligomeric compound. The non-ionic morpholino-based oligomeric compounds are less likely to have undesired

10 interactions with cellular proteins. Morpholino-based oligomeric compounds are non-ionic mimics of oligonucleotides which are less likely to form undesired interactions with cellular proteins (Dwaine A. Braasch and David R. Corey, *Biochemistry*, **2002**, 41(14), 4503-4510). Morpholino-based oligomeric compounds are disclosed

15 in United States Patent 5,034,506, issued July 23, 1991. The morpholino class of oligomeric compounds have been prepared having a variety of different linking groups joining the monomeric subunits.

Morpholino nucleic acids have been prepared having a variety

20 of different linking groups (L_2) joining the monomeric subunits. The basic formula is shown below:



25

wherein

T_1 is hydroxyl or a protected hydroxyl;

T_5 is hydrogen or a phosphate or phosphate derivative;

L_2 is a linking group; and

-26-

n is from 2 to about 50.


A further class of oligonucleotide mimetic is referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in an DNA/RNA molecule is replaced with a cyclohexenyl ring.

5 CeNA DMT protected phosphoramidite monomers have been prepared and used for oligomeric compound synthesis following classical phosphoramidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific positions modified with CeNA have been prepared and studied (see Wang et al., *J. Am.*

10 *Chem. Soc.*, **2000**, 122, 8595-8602). In general the incorporation of CeNA monomers into a DNA chain increases its stability of a DNA/RNA hybrid. CeNA oligoadenylates formed complexes with RNA and DNA complements with similar stability to the native complexes. The study of incorporating CeNA structures into

15 natural nucleic acid structures was shown by NMR and circular dichroism to proceed with easy conformational adaptation. Furthermore the incorporation of CeNA into a sequence targeting RNA was stable to serum and able to activate *E. coli* RNase resulting in cleavage of the target RNA strand.

20 The general formula of CeNA is shown below:




wherein

- 25 each Bx is a heterocyclic base moiety;
T₁ is hydroxyl or a protected hydroxyl; and
T₂ is hydroxyl or a protected hydroxyl.


Another class of oligonucleotide mimetic (anhydrohexitol nucleic acid) can be prepared from one or more anhydrohexitol nucleosides (see, Wouters and Herdewijn, *Bioorg. Med. Chem. Lett.*, **1999**, 9, 1563-1566) and would have the general formula:

30

-27-



A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C,4'-C-oxymethylene linkage thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene $(-\text{CH}_2-)_n$ group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2 (Singh et al., Chem. Commun., 1998, 4, 455-456). LNA and LNA analogs display very high duplex thermal stabilities with complementary DNA and RNA ($T_m = +3$ to $+10$ C), stability towards 3'-exonucleolytic degradation and good solubility properties. The basic structure of LNA showing the bicyclic ring system is shown below:



The conformations of LNAs determined by 2D NMR spectroscopy have shown that the locked orientation of the LNA nucleotides, both in single-stranded LNA and in duplexes, constrains the phosphate backbone in such a way as to introduce a higher population of the N-type conformation (Petersen et al., J. Mol.

-28-

Recognit., 2000, 13, 44-53). These conformations are associated with improved stacking of the nucleobases (Wengel et al., Nucleosides Nucleotides, 1999, 18, 1365-1370).

LNA has been shown to form exceedingly stable LNA:LNA
5 duplexes (Koshkin et al., J. Am. Chem. Soc., 1998, 120, 13252-13253). LNA:LNA hybridization was shown to be the most thermally stable nucleic acid type duplex system, and the RNA-mimicking character of LNA was established at the duplex level. Introduction of 3 LNA monomers (T or A) significantly increased
10 melting points ($T_m = +15/+11$) toward DNA complements. The universality of LNA-mediated hybridization has been stressed by the formation of exceedingly stable LNA:LNA duplexes. The RNA-mimicking of LNA was reflected with regard to the N-type conformational restriction of the monomers and to the secondary
15 structure of the LNA:RNA duplex.

LNAs also form duplexes with complementary DNA, RNA or LNA with high thermal affinities. Circular dichroism (CD) spectra show that duplexes involving fully modified LNA (esp. LNA:RNA) structurally resemble an A-form RNA:RNA duplex. Nuclear
20 magnetic resonance (NMR) examination of an LNA:DNA duplex confirmed the 3'-endo conformation of an LNA monomer. Recognition of double-stranded DNA has also been demonstrated suggesting strand invasion by LNA. Studies of mismatched sequences show that LNAs obey the Watson-Crick base pairing
25 rules with generally improved selectivity compared to the corresponding unmodified reference strands.

Novel types of LNA-oligomeric compounds, as well as the LNAs, are useful in a wide range of diagnostic and therapeutic applications. Among these are antisense applications, PCR
30 applications, strand-displacement oligomers, substrates for nucleic acid polymerases and generally as nucleotide based drugs. Potent and nontoxic antisense oligonucleotides containing LNAs have been described (Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638.) The authors
35 have demonstrated that LNAs confer several desired properties to antisense agents. LNA/DNA copolymers were not degraded readily


-29-

in blood serum and cell extracts. LNA/DNA copolymers exhibited potent antisense activity in assay systems as disparate as G-protein-coupled receptor signaling in living rat brain and detection of reporter genes in *E. coli*. Lipofectin-mediated
5 efficient delivery of LNA into living human breast cancer cells has also been accomplished.

The synthesis and preparation of the LNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition
10 properties have been described (Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). LNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226.

The first analogs of LNA, phosphorothioate-LNA and 2'-thio-LNAs, have also been prepared (Kumar et al., Bioorg. Med. Chem.
15 Lett., 1998, 8, 2219-2222). Preparation of locked nucleoside analogs containing oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (Wengel et al., PCT International Application WO 98-DK393 19980914). Furthermore, synthesis of 2'-amino-LNA, a novel conformationally
20 restricted high-affinity oligonucleotide analog with a handle has been described in the art (Singh et al., J. Org. Chem., 1998, 63, 10035-10039). In addition, 2'-Amino- and 2'-methylamino-LNA's have been prepared and the thermal stability of their duplexes with complementary RNA and DNA strands has been previously
25 reported.


Further oligonucleotide mimetics have been prepared to include bicyclic and tricyclic nucleoside analogs having the formulas (amidite monomers shown):



(see Steffens et al., *Helv. Chim. Acta*, **1997**, 80, 2426-2439; Steffens et al., *J. Am. Chem. Soc.*, **1999**, 121, 3249-3255; and Renneberg et al., *J. Am. Chem. Soc.*, **2002**, 124, 5993-6002). These modified nucleoside analogs have been oligomerized using the phosphoramidite approach and the resulting oligomeric compounds containing tricyclic nucleoside analogs have shown increased thermal stabilities (T_m 's) when hybridized to DNA, RNA and itself. Oligomeric compounds containing bicyclic nucleoside analogs have shown thermal stabilities approaching that of DNA duplexes.

Another class of oligonucleotide mimetic is referred to as phosphonomonoester nucleic acids incorporate a phosphorus group in a backbone the backbone. This class of oligonucleotide mimetic is reported to have useful physical and biological and pharmacological properties in the areas of inhibiting gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries for use in molecular biology.

20 The general formula (for definitions of Markush variables
see: United States Patents 5,874,553 and 6,127,346 herein
incorporated by reference in their entirety) is shown below.



25 Another oligonucleotide mimetic has been reported wherein the furanosyl ring has been replaced by a cyclobutyl moiety.

Modified sugars

Oligomeric compounds of the invention may also contain one
30 or more substituted sugar moieties. Preferred oligomeric
compounds comprise a sugar substituent group selected from: OH; F;
O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or

-31-


O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and
5 O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise a sugar substituent group selected from: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂,
10 heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other
15 substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a
20 O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂.

Other preferred sugar substituent groups include methoxy (-O-CH₃), aminopropoxy (-OCH₂CH₂CH₂NH₂), allyl (-CH₂-CH=CH₂), -O-allyl (-O-CH₂-CH=CH₂) and fluoro (F). 2'-Sugar substituent groups may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligomeric compound,
30 particularly the 3' position of the sugar on the 3' terminal nucleoside or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligomeric compounds may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that
35 teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080;

-32-

5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Further representative sugar substituent groups include groups of formula Ia or IIa:




wherein:

R_b is O, S or NH;

R_d is a single bond, O, S or C(=O);

R_e is C₁-C₁₀ alkyl, N(R_k)(R_m), N(R_k)(R_n), N=C(R_p)(R_q),

15 N=C(R_p)(R_r) or has formula IIIa;



IIIa

R_p and R_q are each independently hydrogen or C₁-C₁₀ alkyl;

R_r is -R_x-R_y;

each R_s, R_t, R_u and R_v is, independently, hydrogen, C(O)R_w,
 20 substituted or unsubstituted C₁-C₁₀ alkyl, substituted or
 unsubstituted C₂-C₁₀ alkenyl, substituted or unsubstituted C₂-C₁₀
 alkynyl, alkylsulfonyl, arylsulfonyl, a chemical functional
 group or a conjugate group, wherein the substituent groups are
 selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl,
 25 nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and
 alkynyl;

or optionally, R_u and R_v, together form a phthalimido moiety
 with the nitrogen atom to which they are attached;

-33-

each R_w is, independently, substituted or unsubstituted C_1 - C_{10} alkyl, trifluoromethyl, cyanoethoxy, methoxy, ethoxy, t-butoxy, allyloxy, 9-fluorenylmethoxy, 2-(trimethylsilyl)-ethoxy, 2,2,2-trichloroethoxy, benzyloxy, butyryl, iso-butyryl, phenyl or aryl;

R_k is hydrogen, a nitrogen protecting group or $-R_x-R_y$;

R_p is hydrogen, a nitrogen protecting group or $-R_x-R_y$;

R_x is a bond or a linking moiety;

R_y is a chemical functional group, a conjugate group or a solid support medium;

each R_m and R_n is, independently, H, a nitrogen protecting group, substituted or unsubstituted C_1 - C_{10} alkyl, substituted or unsubstituted C_2 - C_{10} alkenyl, substituted or unsubstituted C_2 - C_{10} alkynyl, wherein the substituent groups are selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, alkynyl; NH_3^+ , $N(R_u)(R_v)$, guanidino and acyl where said acyl is an acid amide or an ester;

or R_m and R_n , together, are a nitrogen protecting group, are joined in a ring structure that optionally includes an additional heteroatom selected from N and O or are a chemical functional group;

R_i is OR_z , SR_z , or $N(R_z)_2$;

each R_z is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, $C(=NH)N(H)R_u$, $C(=O)N(H)R_u$ or $OC(=O)N(H)R_u$;

R_f , R_g and R_h comprise a ring system having from about 4 to about 7 carbon atoms or having from about 3 to about 6 carbon atoms and 1 or 2 heteroatoms wherein said heteroatoms are selected from oxygen, nitrogen and sulfur and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic;

R_j is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(R_k)(R_m)$ OR_k , halo, SR_k or CN;

m_a is 1 to about 10;

-34-

each mb is, independently, 0 or 1;
mc is 0 or an integer from 1 to 10;
md is an integer from 1 to 10;
me is from 0, 1 or 2; and

5 provided that when mc is 0, md is greater than 1.

Representative substituents groups of Formula I are disclosed in United States Patent Application Serial No. 09/130,973, filed August 7, 1998, entitled "Capped 2'-Oxyethoxy Oligonucleotides," hereby incorporated by reference in its
10 entirety.

Representative cyclic substituent groups of Formula II are disclosed in United States Patent Application Serial No. 09/123,108, filed July 27, 1998, entitled "RNA Targeted 2'-Oligomeric compounds that are Conformationally Preorganized,"
15 hereby incorporated by reference in its entirety.

Particularly preferred sugar substituent groups include $O[(CH_2)_nO]_mCH_3$, $O(CH_2)_nOCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10.

Representative guanidino substituent groups that are shown
20 in formula III and IV are disclosed in co-owned United States Patent Application 09/349,040, entitled "Functionalized Oligomers", filed July 7, 1999, hereby incorporated by reference in its entirety.

Representative acetamido substituent groups are disclosed
25 in United States Patent 6,147,200 which is hereby incorporated by reference in its entirety.

Representative dimethylaminoethoxyethyl substituent groups are disclosed in International Patent Application PCT/US99/17895, entitled "2'-O-Dimethylaminoethoxyethyl-Oligomeric compounds",
30 filed August 6, 1999, hereby incorporated by reference in its entirety.

Modified Nucleobases/Naturally occurring nucleobases

Oligomeric compounds may also include nucleobase (often
35 referred to in the art simply as "base" or "heterocyclic base moiety") modifications or substitutions. As used herein,

-35-


"unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases also referred herein as heterocyclic base moieties include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex

-36-

stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

In one aspect of the present invention oligomeric compounds are prepared having polycyclic heterocyclic compounds in place of one or more heterocyclic base moieties. A number of tricyclic heterocyclic compounds have been previously reported. These compounds are routinely used in antisense applications to increase the binding properties of the modified strand to a target strand. The most studied modifications are targeted to guanosines hence they have been termed G-clamps or cytidine analogs. Many of these polycyclic heterocyclic compounds have the general formula:



Representative cytosine analogs that make 3 hydrogen bonds with a guanosine in a second strand include 1,3-diazaphenoxazine-2-one (R₁₀ = O, R₁₁ - R₁₄ = H) [Kurchavov, et al., *Nucleosides and Nucleotides*, 1997, 16, 1837-1846], 1,3-diazaphenothiazine-2-one (R₁₀ = S, R₁₁ - R₁₄ = H), [Lin, K.-Y.; Jones, R. J.; Matteucci, M. J. Am. Chem. Soc. 1995, 117, 3873-3874] and 6,7,8,9-tetrafluoro-1,3-diazaphenoxazine-2-one (R₁₀ = O, R₁₁ - R₁₄ = F) [Wang, J.; Lin, K.-Y., Matteucci, M. *Tetrahedron Lett.* 1998, 39, 8385-8388]. Incorporated into oligonucleotides these base modifications were shown to hybridize with complementary guanine and the latter was also shown to hybridize with adenine and to enhance helical thermal stability by extended stacking interactions (also see U.S.

-37-

Patent Application entitled "Modified Peptide Nucleic Acids" filed May 24, 2002, Serial number 10/155,920; and U.S. Patent Application entitled "Nuclease Resistant Chimeric Oligonucleotides" filed May 24, 2002, Serial number 10/013,295, 5 both of which are commonly owned with this application and are herein incorporated by reference in their entirety).

Further helix-stabilizing properties have been observed when a cytosine analog/substitute has an aminoethoxy moiety attached to the rigid 1,3-diazaphenoxazine-2-one scaffold ($R_{10} = O$, $R_{11} = -O-(CH_2)_2-NH_2$, $R_{12-14}=H$) [Lin, K.-Y.; Matteucci, M. J. Am. Chem. Soc. 1998, 120, 8531-8532]. Binding studies demonstrated that a single incorporation could enhance the binding affinity of a model oligonucleotide to its complementary target DNA or RNA with a ΔT_m of up to 18° relative to 5-methyl cytosine (dC5^{me}), which is the 15 highest known affinity enhancement for a single modification, yet. On the other hand, the gain in helical stability does not compromise the specificity of the oligonucleotides. The T_m data indicate an even greater discrimination between the perfect match and mismatched sequences compared to dC5^{me}. It was suggested that 20 the tethered amino group serves as an additional hydrogen bond donor to interact with the Hoogsteen face, namely the O6, of a complementary guanine thereby forming 4 hydrogen bonds. This means that the increased affinity of G-clamp is mediated by the combination of extended base stacking and additional specific 25 hydrogen bonding.

Further tricyclic heterocyclic compounds and methods of using them that are amenable to the present invention are disclosed in United States Patent Serial Number 6,028,183, which issued on May 22, 2000, and United States Patent Serial Number 30 6,007,992, which issued on December 28, 1999, the contents of both are commonly assigned with this application and are incorporated herein in their entirety.

The enhanced binding affinity of the phenoxazine derivatives together with their uncompromised sequence specificity makes them 35 valuable nucleobase analogs for the development of more potent

-38-

antisense-based drugs. In fact, promising data have been derived from in vitro experiments demonstrating that heptanucleotides containing phenoxazine substitutions are capable to activate RNaseH, enhance cellular uptake and exhibit an increased antisense activity [Lin, K-Y; Matteucci, M. J. Am. Chem. Soc. 1998, 120, 8531-8532]. The activity enhancement was even more pronounced in case of G-clamp, as a single substitution was shown to significantly improve the in vitro potency of a 20mer 2'-deoxyphosphorothioate oligonucleotides [Flanagan, W. M.; Wolf, J.J.; Olson, P.; Grant, D.; Lin, K.-Y.; Wagner, R. W.; Matteucci, M. Proc. Natl. Acad. Sci. USA, 1999, 96, 3513-3518]. Nevertheless, to optimize oligonucleotide design and to better understand the impact of these heterocyclic modifications on the biological activity, it is important to evaluate their effect on the nuclease stability of the oligomers.

Further modified polycyclic heterocyclic compounds useful as heterocyclic bases are disclosed in but not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,434,257; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,646,269; 5,750,692; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, and United States Patent Application Serial number 09/996,292 filed November 28, 2001, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

The oligonucleotides of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the oligonucleotide. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the oligonucleotide. Thus, a 20-mer may comprise 60 variations (20 positions x 3 alternates at each position) in which the original nucleotide is substituted with any of the three alternate nucleotides. These oligonucleotides are then tested using the methods described

-39-

herein to determine their ability to inhibit expression of HCV mRNA and/or HCV replication.

Conjugates

5 A further preferred substitution that can be appended to the oligomeric compounds of the invention involves the linkage of one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the resulting oligomeric compounds. In one embodiment such modified oligomeric
10 compounds are prepared by covalently attaching conjugate groups to functional groups such as hydroxyl or amino groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and
15 groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of
20 this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution,
25 metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety
30 (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, *86*, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Let.*, **1994**, *4*, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, *660*, 306-309; Manoharan et al., *Bioorg. Med. Chem. Let.*, **1993**, *3*, 2765-2770), a
35 thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, *20*, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl

-40-

residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, *10*, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, *259*, 327-330; Svinarchuk et al., *Biochimie*, **1993**, *75*, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, *18*, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, *14*, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, *1264*, 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, *277*, 923-937).

The oligomeric compounds of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142;

-41-

5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

5

Chimeric oligomeric compounds

It is not necessary for all positions in an oligomeric compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligomeric compound or even at a single monomeric subunit such as a nucleoside within a oligomeric compound. The present invention also includes oligomeric compounds which are chimeric oligomeric compounds. "Chimeric" oligomeric compounds or "chimeras," in the context of this invention, are oligomeric compounds that contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a nucleic acid based oligomer.

Chimeric oligomeric compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligomeric compound may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligomeric compounds when chimeras are used, compared to for example phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric oligomeric compounds of the invention may be formed as composite structures of two or more oligonucleotides, oligonucleotide analogs, oligonucleosides and/or oligonucleotide

-42-


mimetics as described above. Such oligomeric compounds have also been referred to in the art as hybrids hemimers, gapmers or inverted gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

3'-endo modifications

In one aspect of the present invention oligomeric compounds include nucleosides synthetically modified to induce a 3'-endo sugar conformation. A nucleoside can incorporate synthetic modifications of the heterocyclic base, the sugar moiety or both to induce a desired 3'-endo sugar conformation. These modified nucleosides are used to mimic RNA like nucleosides so that particular properties of an oligomeric compound can be enhanced while maintaining the desirable 3'-endo conformational geometry. There is an apparent preference for an RNA type duplex (A form helix, predominantly 3'-endo) as a requirement (e.g. trigger) of RNA interference which is supported in part by the fact that duplexes composed of 2'-deoxy-2'-F-nucleosides appears efficient in triggering RNAi response in the *C. elegans* system. Properties that are enhanced by using more stable 3'-endo nucleosides include but aren't limited to modulation of pharmacokinetic properties through modification of protein binding, protein off-rate, absorption and clearance; modulation of nuclease stability as well as chemical stability; modulation of the binding affinity and specificity of the oligomer (affinity and specificity for enzymes as well as for complementary sequences); and increasing efficacy of RNA cleavage. The present invention provides oligomeric triggers of RNAi having one or more nucleosides modified in such a way as to favor a C3'-endo type conformation.

Scheme 1

-43-



C2'-endo/Southern

C3'-endo/Northern


Nucleoside conformation is influenced by various factors including substitution at the 2', 3' or 4'-positions of the pentofuranosyl sugar. Electronegative substituents generally prefer the axial positions, while sterically demanding substituents generally prefer the equatorial positions (Principles of Nucleic Acid Structure, Wolfgang Sanger, 1984, Springer-Verlag.) Modification of the 2' position to favor the 3'-endo conformation can be achieved while maintaining the 2'-OH as a recognition element, as illustrated in Figure 2, below (Gallo et al., Tetrahedron (2001), 57, 5707-5713. Harry-O'kuru et al., J. Org. Chem., (1997), 62(6), 1754-1759 and Tang et al., J. Org. Chem. (1999), 64, 747-754.) Alternatively, preference for the 3'-endo conformation can be achieved by deletion of the 2'-OH as exemplified by 2'deoxy-2'F-nucleosides (Kawasaki et al., J. Med. Chem. (1993), 36, 831-841), which adopts the 3'-endo conformation positioning the electronegative fluorine atom in the axial position. Other modifications of the ribose ring, for example substitution at the 4'-position to give 4'-F modified nucleosides (Guillerm et al., Bioorganic and Medicinal Chemistry Letters (1995), 5, 1455-1460 and Owen et al., J. Org. Chem. (1976), 41, 3010-3017), or for example modification to yield methanocarba nucleoside analogs (Jacobson et al., J. Med. Chem. Lett. (2000), 43, 2196-2203 and Lee et al., Bioorganic and Medicinal Chemistry Letters (2001), 11, 1333-1337) also induce preference for the 3'-endo conformation. Along similar lines, oligomeric triggers of RNAi response might be composed of one or more nucleosides modified in such a way that conformation is locked into a C3'-endo type conformation, i.e. Locked Nucleic Acid (LNA, Singh et al, Chem. Commun. (1998), 4, 455-456), and ethylene bridged Nucleic Acids (ENA, Morita et al, Bioorganic & Medicinal Chemistry Letters

-44-

(2002), 12, 73-76.) Examples of modified nucleosides amenable to the present invention are shown below in Table I. These examples are meant to be representative and not exhaustive.

-45-

Table I



5 The preferred conformation of modified nucleosides and their oligomers can be estimated by various methods such as molecular dynamics calculations, nuclear magnetic resonance spectroscopy and CD measurements. Hence, modifications predicted to induce RNA

-46-

like conformations, A-form duplex geometry in an oligomeric context, are selected for use in the modified oligonucleotides of the present invention. The synthesis of numerous of the modified nucleosides amenable to the present invention are known in the art (see for example, Chemistry of Nucleosides and Nucleotides Vol 1-3, ed. Leroy B. Townsend, 1988, Plenum press., and the examples section below.) Nucleosides known to be inhibitors/substrates for RNA dependent RNA polymerases (for example HCV NS5B

In one aspect, the present invention is directed to oligonucleotides that are prepared having enhanced properties compared to native RNA against nucleic acid targets. A target is identified and an oligonucleotide is selected having an effective length and sequence that is complementary to a portion of the target sequence. Each nucleoside of the selected sequence is scrutinized for possible enhancing modifications. A preferred modification would be the replacement of one or more RNA nucleosides with nucleosides that have the same 3'-endo conformational geometry. Such modifications can enhance chemical and nuclease stability relative to native RNA while at the same time being much cheaper and easier to synthesize and/or incorporate into an oligonucleotide. The selected sequence can be further divided into regions and the nucleosides of each region evaluated for enhancing modifications that can be the result of a chimeric configuration. Consideration is also given to the 5' and 3'-termini as there are often advantageous modifications that can be made to one or more of the terminal nucleosides. The oligomeric compounds of the present invention include at least one 5'-modified phosphate group on a single strand or on at least one 5'-position of a double stranded sequence or sequences. Further modifications are also considered such as internucleoside linkages, conjugate groups, substitute sugars or bases, substitution of one or more nucleosides with nucleoside mimetics and any other modification that can enhance the selected sequence for its intended target. The terms used to describe the conformational geometry of homoduplex nucleic acids are "A Form" for RNA and "B Form" for DNA. The respective conformational

-47-

geometry for RNA and DNA duplexes was determined from X-ray diffraction analysis of nucleic acid fibers (Arnott and Hukins, *Biochem. Biophys. Res. Comm.*, **1970**, *47*, 1504.) In general, RNA:RNA duplexes are more stable and have higher melting

5 temperatures (T_m 's) than DNA:DNA duplexes (Sanger et al., *Principles of Nucleic Acid Structure*, 1984, Springer-Verlag; New York, NY.; Lesnik et al., *Biochemistry*, 1995, *34*, 10807-10815; Conte et al., *Nucleic Acids Res.*, 1997, *25*, 2627-2634). The increased stability of RNA has been attributed to several

10 structural features, most notably the improved base stacking interactions that result from an A-form geometry (Searle et al., *Nucleic Acids Res.*, 1993, *21*, 2051-2056). The presence of the 2' hydroxyl in RNA biases the sugar toward a C3' endo pucker, i.e., also designated as Northern pucker, which causes the duplex to

15 favor the A-form geometry. In addition, the 2' hydroxyl groups of RNA can form a network of water mediated hydrogen bonds that help stabilize the RNA duplex (Egli et al., *Biochemistry*, 1996, *35*, 8489-8494). On the other hand, deoxy nucleic acids prefer a C2' endo sugar pucker, i.e., also known as Southern pucker, which is

20 thought to impart a less stable B-form geometry (Sanger, W. (1984) *Principles of Nucleic Acid Structure*, Springer-Verlag, New York, NY). As used herein, B-form geometry is inclusive of both C2'-endo pucker and O4'-endo pucker. This is consistent with Berger, et. al., *Nucleic Acids Research*, **1998**, *26*, 2473-2480, who pointed

25 out that in considering the furanose conformations which give rise to B-form duplexes consideration should also be given to a O4'-endo pucker contribution.

DNA:RNA hybrid duplexes, however, are usually less stable than pure RNA:RNA duplexes, and depending on their sequence may be

30 either more or less stable than DNA:DNA duplexes (Searle et al., *Nucleic Acids Res.*, **1993**, *21*, 2051-2056). The structure of a hybrid duplex is intermediate between A- and B-form geometries, which may result in poor stacking interactions (Lane et al., *Eur. J. Biochem.*, **1993**, *215*, 297-306; Fedoroff et al., *J. Mol. Biol.*, **1993**, *233*, 509-523; Gonzalez et al., *Biochemistry*, **1995**, *34*, 4969-

35

-48-

4982; Horton et al., *J. Mol. Biol.*, **1996**, 264, 521-533). The stability of the duplex formed between a target RNA and a synthetic sequence is central to therapies such as but not limited to antisense and RNA interference as these mechanisms require the binding of a synthetic oligonucleotide strand to an RNA target strand. In the case of antisense, effective inhibition of the mRNA requires that the antisense DNA have a very high binding affinity with the mRNA. Otherwise the desired interaction between the synthetic oligonucleotide strand and target mRNA strand will occur infrequently, resulting in decreased efficacy.

One routinely used method of modifying the sugar pucker is the substitution of the sugar at the 2'-position with a substituent group that influences the sugar geometry. The influence on ring conformation is dependent on the nature of the substituent at the 2'-position. A number of different substituents have been studied to determine their sugar pucker effect. For example, 2'-halogens have been studied showing that the 2'-fluoro derivative exhibits the largest population (65%) of the C3'-endo form, and the 2'-iodo exhibits the lowest population (7%). The populations of adenosine (2'-OH) versus deoxyadenosine (2'-H) are 36% and 19%, respectively. Furthermore, the effect of the 2'-fluoro group of adenosine dimers (2'-deoxy-2'-fluoroadenosine - 2'-deoxy-2'-fluoro-adenosine) is further correlated to the stabilization of the stacked conformation.

As expected, the relative duplex stability can be enhanced by replacement of 2'-OH groups with 2'-F groups thereby increasing the C3'-endo population. It is assumed that the highly polar nature of the 2'-F bond and the extreme preference for C3'-endo pucker may stabilize the stacked conformation in an A-form duplex. Data from UV hypochromicity, circular dichroism, and ¹H NMR also indicate that the degree of stacking decreases as the electronegativity of the halo substituent decreases. Furthermore, steric bulk at the 2'-position of the sugar moiety is better accommodated in an A-form duplex than a B-form duplex. Thus, a 2'-substituent on the 3'-terminus of a dinucleoside monophosphate is thought to exert a number of effects on the stacking

-49-

conformation: steric repulsion, furanose puckering preference, electrostatic repulsion, hydrophobic attraction, and hydrogen bonding capabilities. These substituent effects are thought to be determined by the molecular size, electronegativity, and hydrophobicity of the substituent. Melting temperatures of complementary strands is also increased with the 2'-substituted adenosine diphosphates. It is not clear whether the 3'-endo preference of the conformation or the presence of the substituent is responsible for the increased binding. However, greater overlap of adjacent bases (stacking) can be achieved with the 3'-endo conformation.

One synthetic 2'-modification that imparts increased nuclease resistance and a very high binding affinity to nucleotides is the 2-methoxyethoxy (2'-MOE, 2'-OCH₂CH₂OCH₃) side chain (Baker et al., *J. Biol. Chem.*, **1997**, 272, 11944-12000). One of the immediate advantages of the 2'-MOE substitution is the improvement in binding affinity, which is greater than many similar 2' modifications such as O-methyl, O-propyl, and O-aminopropyl. Oligonucleotides having the 2'-O-methoxyethyl substituent also have been shown to be antisense inhibitors of gene expression with promising features for *in vivo* use (Martin, P., *Helv. Chim. Acta*, **1995**, 78, 486-504; Altmann et al., *Chimia*, **1996**, 50, 168-176; Altmann et al., *Biochem. Soc. Trans.*, **1996**, 24, 630-637; and Altmann et al., *Nucleosides Nucleotides*, **1997**, 16, 917-926). Relative to DNA, the oligonucleotides having the 2'-MOE modification displayed improved RNA affinity and higher nuclease resistance. Chimeric oligonucleotides having 2'-MOE substituents in the wing nucleosides and an internal region of deoxy-phosphorothioate nucleotides (also termed a gapped oligonucleotide or gapmer) have shown effective reduction in the growth of tumors in animal models at low doses. 2'-MOE substituted oligonucleotides have also shown outstanding promise as antisense agents in several disease states. One such MOE substituted oligonucleotide is presently being investigated in clinical trials for the treatment of CMV retinitis.

Chemistries Defined

Unless otherwise defined herein, alkyl means C₁-C₁₂, preferably C₁-C₈, and more preferably C₁-C₆, straight or (where possible) branched chain aliphatic hydrocarbyl.

5 Unless otherwise defined herein, heteroalkyl means C₁-C₁₂, preferably C₁-C₈, and more preferably C₁-C₆, straight or (where possible) branched chain aliphatic hydrocarbyl containing at least one, and preferably about 1 to about 3, hetero atoms in the chain, including the terminal portion of the chain. Preferred
10 heteroatoms include N, O and S. Unless otherwise defined herein, cycloalkyl means C₃-C₁₂, preferably C₃-C₈, and more preferably C₃-C₆, aliphatic hydrocarbyl ring.

Unless otherwise defined herein, alkenyl means C₂-C₁₂, preferably C₂-C₈, and more preferably C₂-C₆ alkenyl, which may be
15 straight or (where possible) branched hydrocarbyl moiety, which contains at least one carbon-carbon double bond.

Unless otherwise defined herein, alkynyl means C₂-C₁₂, preferably C₂-C₈, and more preferably C₂-C₆ alkynyl, which may be straight or (where possible) branched hydrocarbyl moiety, which
20 contains at least one carbon-carbon triple bond.

Unless otherwise defined herein, heterocycloalkyl means a ring moiety containing at least three ring members, at least one of which is carbon, and of which 1, 2 or three ring members are other than carbon. Preferably the number of carbon atoms varies
25 from 1 to about 12, preferably 1 to about 6, and the total number of ring members varies from three to about 15, preferably from about 3 to about 8. Preferred ring heteroatoms are N, O and S. Preferred heterocycloalkyl groups include morpholino, thiomorpholino, piperidinyl, piperazinyl, homopiperidinyl,
30 homopiperazinyl, homomorpholino, homothiomorpholino, pyrrolodiny, tetrahydrooxazolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydroisoxazolyl, tetrahydropyrrazolyl, furanyl, pyranal, and tetrahydroisothiazolyl.

Unless otherwise defined herein, aryl means any hydrocarbon
35 ring structure containing at least one aryl ring. Preferred aryl rings have about 6 to about 20 ring carbons. Especially preferred

-51-

aryl rings include phenyl, naphthyl, anthracenyl, and phenanthrenyl.

Unless otherwise defined herein, hetaryl means a ring moiety containing at least one fully unsaturated ring, the ring consisting of carbon and non-carbon atoms. Preferably the ring system contains about 1 to about 4 rings. Preferably the number of carbon atoms varies from 1 to about 12, preferably 1 to about 6, and the total number of ring members varies from three to about 15, preferably from about 3 to about 8. Preferred ring heteroatoms are N, O and S. Preferred hetaryl moieties include pyrazolyl, thiophenyl, pyridyl, imidazolyl, tetrazolyl, pyridyl, pyrimidinyl, purinyl, quinazolinyl, quinoxalinyl, benzimidazolyl, benzothiophenyl, etc.

Unless otherwise defined herein, where a moiety is defined as a compound moiety, such as hetarylalkyl (hetaryl and alkyl), aralkyl (aryl and alkyl), etc., each of the sub-moieties is as defined herein.

Unless otherwise defined herein, an electron withdrawing group is a group, such as the cyano or isocyanato group that draws electronic charge away from the carbon to which it is attached. Other electron withdrawing groups of note include those whose electronegativities exceed that of carbon, for example halogen, nitro, or phenyl substituted in the ortho- or para-position with one or more cyano, isothiocyanato, nitro or halo groups.

Unless otherwise defined herein, the terms halogen and halo have their ordinary meanings. Preferred halo (halogen) substituents are Cl, Br, and I.

The aforementioned optional substituents are, unless otherwise herein defined, suitable substituents depending upon desired properties. Included are halogens (Cl, Br, I), alkyl, alkenyl, and alkynyl moieties, NO₂, NH₃ (substituted and unsubstituted), acid moieties (e.g. -CO₂H, -OSO₃H₂, etc.), heterocycloalkyl moieties, hetaryl moieties, aryl moieties, etc.

In all the preceding formulae, the squiggle (~) indicates a bond to an oxygen or sulfur of the 5'-phosphate.

Phosphate protecting groups include those described in US

-52-

Patents No. US 5,760,209, US 5,614,621, US 6,051,699, US 6,020,475, US 6,326,478, US 6,169,177, US 6,121,437, US 6,465,628 each of which is expressly incorporated herein by reference in its entirety.

5 Affinity of an oligonucleotide for its target (in this case a nucleic acid encoding HCV RNA) is routinely determined by measuring the T_m of an oligonucleotide/target pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spectrophotometrically. The higher the
10 T_m , the greater the affinity of the oligonucleotide for the target. In a more preferred embodiment, the region of the oligonucleotide which is modified to increase HCV RNA binding affinity comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl or 2'-fluoro-
15 modified nucleotide. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher T_m (i.e., higher target binding affinity) than 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance antisense
20 oligonucleotide inhibition of HCV RNA function. RNase H is a cellular endonuclease that cleaves the RNA strand of RNA:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of antisense inhibition. Cleavage of the RNA target can be routinely
25 demonstrated by gel electrophoresis. In another preferred embodiment, the chimeric oligonucleotide is also modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic acids. A number of nucleotide and nucleoside modifications have been shown to make
30 the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide. Nuclease resistance is routinely measured by incubating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact
35 oligonucleotide remaining over time, usually by gel

-53-

electrophoresis. Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides. A variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance. In some cases, oligonucleotide modifications which enhance target binding affinity are also, independently, able to enhance nuclease resistance. Oligonucleotides which contain at least one phosphorothioate modification are presently more preferred.

The oligonucleotides in accordance with this invention preferably comprise from about 8 to about 80 nucleic acid base units. It is more preferred that such oligonucleotides comprise from about 12 to 50 nucleic acid base units, and still more preferred to have from about 15 to 30 nucleic acid base units. As will be appreciated, a nucleic acid base unit is a base-sugar combination suitably bound to an adjacent nucleic acid base unit through phosphodiester or other bonds.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; however, the actual synthesis of the oligonucleotides are well within the talents of the routineer. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA identified by the open reading frames (ORFs) of the DNA from which they are transcribed includes not only the information from the ORFs of the DNA, but also associated ribonucleotides which form regions known to such persons as the 5'-untranslated region, the 3'-untranslated region, and intervening sequence ribonucleotides. Thus, oligonucleotides may be formulated in accordance with this invention, which are targeted wholly or in part to these

-54-

associated ribonucleotides as well as to the informational ribonucleotides. In preferred embodiments, the oligonucleotide is specifically hybridizable with a transcription initiation site, a translation initiation site, an intervening sequence and sequences in the 3'-untranslated region.

In accordance with this invention, the oligonucleotide is specifically hybridizable with portions of nucleic acids encoding a protein involved in the adhesion of white blood cells either to other white blood cells or other cell types. In preferred embodiments, said proteins are intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and endothelial leukocyte adhesion molecule-1. Oligonucleotides comprising the corresponding sequence, or part thereof, are useful in the invention. For example, Figure 1 is a human intercellular adhesion molecule-1 mRNA sequence. A preferred sequence segment, which may be useful in whole or in part, is:

5'	3'	SEQ ID NO:
TGGGAGCCATAGCGAGGC		1
GAGGAGCTCAGCGTCGACTG		2
GACACTCAATAAATAGCTGGT		3
GAGGCTGAGGTGGGAGGA		4
CGATGGGCAGTGGGAAAG		5
GGGCGCGTGATCCTTATAGC		6
CATAGCGAGGCTGAGGTTGC		7
CGGGGGCTGCTGGGAGCCAT		8
TCAGGGAGGCGTGGCTTGTG		13
CCTGTCCCGGGATAGGTTCA		14
TTGAGAAAGCTTTATTAAC		16
CCCCCACCACCTTCCCCTCTC.		15

30

Figure 2 is a human endothelial leukocyte adhesion molecule-1 mRNA sequence. A preferred sequence segment, which may be useful in whole or in part, is:

5'	3'	SEQ ID NO:
CAATCATGACTTCAAGAGTTCT		28

35

-55-

	TCACTGCTGCCTCTGTCTCAGG	73
	TGATTCTTTTGAAGTTAAAAGGA	74
	TTAAAGGATGTAAGAAGGCT	75
	CATAAGCACATTTATTGTC	76
5	TTTTGGGAAGCAGTTGTTCA	77
	AACTGTGAAGCAATCATGACT	78
	CCTTGAGTGGTGCATTCAACCT	79
	AATGCTTGCTCACACAGGCATT	80.

10 Figure 3 is a human vascular cell adhesion molecule-1 mRNA sequence. A preferred sequence segment, which may be useful in whole or in part, is:

	5'		3'	SEQ ID NO:
		CCAGGCATTTTAAGTTGCTGT		40
15		CCTGAAGCCAGTGAGGCCCCG		41
		GATGAGAAAATAGTGGAACCA		42
		CTGAGCAAGATATCTAGAT		43
		CTACACTTTTGATTTCTGT		44
		TTGAACATATCAAGCATTAGCT		45
20		TTTACATATGTACAAATTATGT		46
		AATTATCACTTTACTATACAAA		47
		AGGGCTGACCAAGACGGTTGT		48.

25 While the illustrated sequences are believed to be accurate, the present invention is directed to the correct sequences, should errors be found. Oligonucleotides useful in the invention comprise one of these sequences, or part thereof. Thus, it is preferred to employ any of these oligonucleotides as set forth above or any of the similar oligonucleotides which persons of
30 ordinary skill in the art can prepare from knowledge of the preferred antisense targets for the modulation of the synthesis of inflammatory cell adhesion molecules.

 Several preferred embodiments of this invention are exemplified in accordance with the following nonlimiting examples.
35 The target mRNA species for modulation relates to intercellular

-56-

adhesion molecule-1, endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1. Persons of ordinary skill in the art will appreciate that the present invention is not so limited, however, and that it is generally applicable. The inhibition or modulation of production of the ICAM-1 and/or ELAM-1 and/or VCAM-1 are expected to have significant therapeutic benefits in the treatment of disease. In order to assess the effectiveness of the compositions, an assay or series of assays is performed.

One type of disorder suitable for treatment with the oligonucleotides of the present invention are in inflammatory ophthalmic disorders including redness and inflammation caused by allergens and allergic reactions. The oligonucleotides can also be used as an adjuvant to antibiotic treatment of conjunctivitis. In a preferred embodiment, the oligonucleotides are used to preserve corneal explants ex vivo and to prevent corneal allograft rejection. These oligonucleotides may be placed in solution and administered as eyedrops for topical treatment of the allograft. The solution is suitable for use as a storage medium for corneal explants, and is administered in eye drop form following corneal transplant to prevent corneal allograft rejection.

The following examples are provided for illustrative purposes only and are not intended to limit the invention.

EXAMPLES

Example 1

Expression of ICAM-1, VCAM-1 and ELAM-1 on the surface of cells can be quantitated using specific monoclonal antibodies in an ELISA. Cells are grown to confluence in 96 well microtiter plates. The cells are stimulated with either interleukin-1 or tumor necrosis factor for 4 to 8 hours to quantitate ELAM-1 and 8 to 24 hours to quantitate ICAM-1 and VCAM-1. Following the appropriate incubation time with the cytokine, the cells are gently washed three times with a buffered isotonic solution containing calcium and magnesium such as Dulbecco's phosphate

-57-

buffered saline (D-PBS). The cells are then directly fixed on the microtiter plate with 1 to 2% paraformaldehyde diluted in D-PBS for 20 minutes at 25°C. The cells are washed again with D-PBS three times. Nonspecific binding sites on the microtiter plate are blocked with 2% bovine serum albumin in D-PBS for 1 hour at 37°C. Cells are incubated with the appropriate monoclonal antibody diluted in blocking solution for 1 hour at 37°C. Unbound antibody is removed by washing the cells three times with D-PBS. Antibody bound to the cells is detected by incubation with a 1:1000 dilution of biotinylated goat anti-mouse IgG (Bethesda Research Laboratories, Gaithersburg, MD) in blocking solution for 1 hour at 37°C. Cells are washed three times with D-PBS and then incubated with a 1:1000 dilution of streptavidin conjugated to β -galactosidase (Bethesda Research Laboratories) for 1 hour at 37°C. The cells are washed three times with D-PBS for 5 minutes each. The amount of β -galactosidase bound to the specific monoclonal antibody is determined by developing the plate in a solution of 3.3 mM chlorophenolred- β -D-galactopyranoside, 50 mM sodium phosphate, 1.5 mM $MgCl_2$; pH=7.2 for 2 to 15 minutes at 37°C. The concentration of the product is determined by measuring the absorbance at 575 nm in an ELISA microtiter plate reader.

An example of the induction of ICAM-1 observed following stimulation with either interleukin-1 β or tumor necrosis factor α in several human cell lines is shown in Figure 4. Cells were stimulated with increasing concentrations of interleukin-1 or tumor necrosis factor for 15 hours and processed as described above. ICAM-1 expression was determined by incubation with a 1:1000 dilution of the monoclonal antibody 84H10 (Amac Inc., Westbrook, ME). The cell lines used were passage 4 human umbilical vein endothelial cells (HUVEC), a human epidermal carcinoma cell line (A431), a human melanoma cell line (SK-MEL-2) and a human lung carcinoma cell line (A549). ICAM-1 was induced on all the cell lines, however, tumor necrosis factor was more effective than interleukin-1 in induction of ICAM-1 expression on the cell surface (Figure 4).

-58-

Screening antisense oligonucleotides for inhibition of ICAM-1, VCAM-1 or ELAM-1 expression is performed as described above with the exception of pretreatment of cells with the oligonucleotides prior to challenge with the cytokines. An example of antisense oligonucleotide inhibition of ICAM-1 expression is shown in Figure 5. Human umbilical vein endothelial cells (HUVEC) were treated with increasing concentration of oligonucleotide diluted in Opti MEM (GIBCO, Grand Island, NY) containing 8 μ M N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA) for 4 hours at 37°C to enhance uptake of the oligonucleotides. The medium was removed and replaced with endothelial growth medium (EGM-UV; Clonetics, San Diego, CA) containing the indicated concentration of oligonucleotide for an additional 4 hours. Interleukin-1 β was added to the cells at a concentration of 5 units/ml and incubated for 14 hours at 37°C. The cells were quantitated for ICAM-1 expression using a 1:1000 dilution of the monoclonal antibody 84H10 as described above. The oligonucleotides used were:

COMPOUND 1 - (ISIS 1558) a phosphodiester oligonucleotide designed to hybridize with position 64-80 of the mRNA covering the AUG initiation of translation codon having the sequence 5'-TGGGAGCCATAGCGAGGC-3' (SEQ ID NO: 1).

COMPOUND 2 - (ISIS 1570) a phosphorothioate containing oligonucleotide corresponding to the same sequence as COMPOUND 1.

COMPOUND 3 - a phosphorothioate oligonucleotide complementary to COMPOUND 1 and COMPOUND 2 exhibiting the sequence 5'-GCCTCGCTATGGCTCCCA-3' (SEQ ID NO: 81).

COMPOUND 4 - (ISIS 1572) a phosphorothioate containing oligonucleotide designed to hybridize to positions 2190-2210 of the mRNA in the 3' untranslated region containing the sequence 5'-GACACTCAATAAATAGCTGGT-3' (SEQ ID NO: 3).

COMPOUND 5 - (ISIS 1821) a phosphorothioate containing oligonucleotide designed to hybridize to human 5-lipoxygenase mRNA used as a control containing the sequence 5'-CATGGCGCGGGCCGCGGG-3' (SEQ ID NO: 82).

-59-

The phosphodiester oligonucleotide targeting the AUG initiation of translation region of the human ICAM-1 mRNA (COMPOUND 1) did not inhibit expression of ICAM-1; however, the corresponding phosphorothioate containing oligonucleotide (COMPOUND 2) inhibited ICAM-1 expression by 70% at a concentration of 0.1 μ M and 90% at 1 μ M concentration (Figure 4). The increased potency of the phosphorothioate oligonucleotide over the phosphodiester is probably due to increased stability. The sense strand to COMPOUND 2, COMPOUND 3, modestly inhibited ICAM-1 expression at 10 μ M. If COMPOUND 2 was prehybridized to COMPOUND 3 prior to addition to the cells, the effects of COMPOUND 2 on ICAM-1 expression were attenuated suggesting that the activity of COMPOUND 2 was due to antisense oligonucleotide effect, requiring hybridization to the mRNA. The antisense oligonucleotide directed against 3' untranslated sequences (COMPOUND 4) inhibited ICAM-1 expression 62% at a concentration of 1 μ M (Figure 5). The control oligonucleotide, targeting human 5-lipoxygenase (COMPOUND 5) reduced ICAM-1 expression by 20%. These data demonstrate that oligonucleotides are capable of inhibiting ICAM-1 expression on human umbilical vein endothelial cells and suggest that the inhibition of ICAM-1 expression is due to an antisense activity.

The antisense oligonucleotide COMPOUND 2 at a concentration of 1 μ M inhibits expression of ICAM-1 on human umbilical vein endothelial cells stimulated with increasing concentrations of tumor necrosis factor and interleukin-1 (Figure 6). These data demonstrate that the effects of COMPOUND 2 are not specific for interleukin-1 stimulation of cells.

Analogous assays can also be used to demonstrate inhibition of ELAM-1 and VCAM-1 expression by antisense oligonucleotides.

30

Example 2

A second cellular assay which can be used to demonstrate the effects of antisense oligonucleotides on ICAM-1, VCAM-1 or ELAM-1 expression is a cell adherence assay. Target cells are grown as a monolayer in a multiwell plate, treated with oligonucleotide

35

-60-

followed by cytokine. The adhering cells are then added to the monolayer cells and incubated for 30 to 60 minutes at 37°C and washed to remove nonadhering cells. Cells adhering to the monolayer may be determined either by directly counting the adhering cells or prelabeling the cells with a radioisotope such as ⁵¹Cr and quantitating the radioactivity associated with the monolayer as described. Dustin and Springer, *J. Cell Biol.* **1988**, 107, 321-331. Antisense oligonucleotides may target either ICAM-1, VCAM-1 or ELAM-1 in the assay.

10 An example of the effects of antisense oligonucleotides targeting ICAM-1 mRNA on the adherence of DMSO differentiated HL-60 cells to tumor necrosis factor treated human umbilical vein endothelial cells is shown in Figure 7. Human umbilical vein endothelial cells were grown to 80% confluence in 12 well plates. 15 The cells were treated with 2 µM oligonucleotide diluted in Opti-MEM containing 8 µM DOTMA for 4 hours at 37°C. The medium was removed and replaced with fresh endothelial cell growth medium (EGM-UV) containing 2 µM of the indicated oligonucleotide and incubated 4 hours at 37°C. Tumor necrosis factor, 1 ng/ml, was 20 added to cells as indicated and cells incubated for an additional 19 hours. The cells were washed once with EGM-UV and 1.6 x 10⁶ HL-60 cells differentiated for 4 days with 1.3% DMSO added. The cells were allowed to attach for 1 hour at 37°C and gently washed 4 times with Dulbecco's phosphate-buffered saline (D-PBS) warmed 25 to 37°C. Adherent cells were detached from the monolayer by addition of 0.25 ml of cold (4EC) phosphate-buffered saline containing 5 mM EDTA and incubated on ice for 5 minutes. The number of cells removed by treatment with EDTA was determined by counting with a hemocytometer. Endothelial cells detached from 30 the monolayer by EDTA treatment could easily be distinguished from HL-60 cells by morphological differences.

In the absence of tumor necrosis factor, 3% of the HL-60 cells bound to the endothelial cells. Treatment of the endothelial cell monolayer with 1 ng/ml tumor necrosis factor increased the number 35 of adhering cells to 59% of total cells added (Figure 7).

-61-

Treatment with the antisense oligonucleotide COMPOUND 2 or the control oligonucleotide COMPOUND 5 did not change the number of cells adhering to the monolayer in the absence of tumor necrosis factor treatment (Figure 7). The antisense oligonucleotide, COMPOUND 2 reduced the number of adhering cells from 59% of total cells added to 17% of the total cells added (Figure 7). In contrast, the control oligonucleotide COMPOUND 5 did not significantly reduce the number of cells adhering to the tumor necrosis factor treated endothelial monolayer, i.e., 53% of total cells added for COMPOUND 5 treated cells versus 59% for control cells.

These data indicate that antisense oligonucleotides are capable of inhibiting ICAM-1 expression on endothelial cells and that inhibition of ICAM-1 expression correlates with a decrease in the adherence of a neutrophil-like cell to the endothelial monolayer in a sequence specific fashion. Because other molecules also mediate adherence of white blood cells to endothelial cells, such as ELAM-1, and VCAM-1 it is not expected that adherence would be completely blocked.

20

Example 3

Synthesis and characterization of oligonucleotides

Unmodified DNA oligonucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β -cyanoethyl-diisopropyl-phosphoramidites were purchased from Applied Biosystems (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step.

2'-O-methyl phosphorothioate oligonucleotides were synthesized using 2'-O-methyl β -cyanoethyl-diisopropyl-phosphoramidites (Chemgenes, Needham MA) and the standard cycle

35

-62-

for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. The 3'-base used to start the synthesis was a 2'-deoxyribonucleotide.

2'-fluoro phosphorothioate oligonucleotides were synthesized using 5'-dimethoxytrityl-3'-phosphoramidites and prepared as disclosed in U.S. patent application Serial No. 463,358, filed January 11, 1990, and 566,977, filed August 13, 1990, which are assigned to the same assignee as the instant application and which are incorporated by reference herein. The 2'-fluoro oligonucleotides were prepared using phosphoramidite chemistry and a slight modification of the standard DNA synthesis protocol: deprotection was effected using methanolic ammonia at room temperature.

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides were purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Analytical gel electrophoresis was accomplished in 20% acrylamide, 8 M urea, 45 mM Tris-borate buffer, pH 7.0. Oligodeoxynucleotides and phosphorothioate oligonucleotides were judged from electrophoresis to be greater than 80% full length material.

RNA oligonucleotide synthesis was performed on an ABI model 380B DNA synthesizer. The standard synthesis cycle was modified by increasing the wait step after the pulse delivery of tetrazole to 900 seconds. The bases were deprotected by incubation in methanolic ammonia overnight. Following base deprotections the oligonucleotides were dried *in vacuo*. The t-butyldimethylsilyl protecting the 2' hydroxyl was removed by incubating the oligonucleotide in 1 M tetrabutylammonium-fluoride in tetrahydrofuran overnight. The RNA oligonucleotides were further purified on C₁₈ Sep-Pak cartridges (Waters, Division of Millipore Corp., Milford MA) and ethanol precipitated.

The relative amounts of phosphorothioate and phosphodiester linkages obtained by this synthesis were periodically checked by ³¹P NMR spectroscopy. The spectra were obtained at ambient

-63-

temperature using deuterium oxide or dimethyl sulfoxide-d₆ as solvent. Phosphorothioate samples typically contained less than one percent of phosphodiester linkages.

Secondary evaluation was performed with oligonucleotides purified by trityl-on HPLC on a PRP-1 column (Hamilton Co., Reno, Nevada) using a gradient of acetonitrile in 50 mM triethylammonium acetate, pH 7.0 (4% to 32% in 30 minutes, flow rate = 1.5 ml/min). Appropriate fractions were pooled, evaporated and treated with 5% acetic acid at ambient temperature for 15 minutes. The solution was extracted with an equal volume of ethyl acetate, neutralized with ammonium hydroxide, frozen and lyophilized. HPLC-purified oligonucleotides were not significantly different in potency from precipitated oligonucleotides, as judged by the ELISA assay for ICAM-1 expression.

Example 4

Cell culture and treatment with oligonucleotides

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (Bethesda MD). Cells were grown in Dulbecco's Modified Eagle's Medium (Irvine Scientific, Irvine CA) containing 1 gm glucose/liter and 10% fetal calf serum (Irvine Scientific). Human umbilical vein endothelial cells (HUVEC) (Clonetics, San Diego CA) were cultured in EGM-UV medium (Clonetics). HUVEC were used between the second and sixth passages. Human epidermal carcinoma A431 cells were obtained from the American Type Culture Collection and cultured in DMEM with 4.5 g/l glucose. Primary human keratinocytes were obtained from Clonetics and grown in KGM (Keratinocyte growth medium, Clonetics).

Cells grown in 96-well plates were washed three times with Opti-MEM (GIBCO, Grand Island, NY) prewarmed to 37°C. 100 µl of Opti-MEM containing either 10 µg/ml N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA, Bethesda Research Labs, Bethesda MD) in the case of HUVEC cells or 20 µg/ml DOTMA in the case of A549 cells was added to each well. Oligonucleotides were

-64-

sterilized by centrifugation through 0.2 μ m Centrex cellulose acetate filters (Schleicher and Schuell, Keene, NH). Oligonucleotides were added as 20x stock solution to the wells and incubated for 4 hours at 37°C. Medium was removed and replaced
5 with 150 μ l of the appropriate growth medium containing the indicated concentration of oligonucleotide. Cells were incubated for an additional 3 to 4 hours at 37°C then stimulated with the appropriate cytokine for 14 to 16 hours, as indicated. ICAM-1
10 expression was determined as described in Example 1. The presence of DOTMA during the first 4 hours incubation with oligonucleotide increased the potency of the oligonucleotides at least 100-fold. This increase in potency correlated with an increase in cell uptake of the oligonucleotide.

15 **Example 5**

ELISA screening of additional antisense oligonucleotides for activity against ICAM-1 gene expression in Interleukin-1 β -stimulated cells

20 Antisense oligonucleotides were originally designed that would hybridize to five target sites on the human ICAM-1 mRNA. Oligonucleotides were synthesized in both phosphodiester (P=O; ISIS 1558, 1559, 1563, 1564 and 1565)

-65-

and phosphorothioate (P=S; ISIS 1570, 1571, 1572, 1573, and 1574) forms. The oligonucleotides are shown in Table 1.

Table 1

5

ANTISENSE OLIGONUCLEOTIDES WHICH TARGET HUMAN ICAM-1

ISIS NO.	SEQ ID NO.	TARGET REGION	MODIFICATION
1558	1	AUG Codon (64-81)	P=O
1559	2	5'-Untranslated (32-49)	P=O
1563	3	3'-Untranslated (2190-3010)	P=O
1564	4	3'-Untranslated (2849-2866)	P=O
1565	5	Coding Region (1378-1395)	P=O
1570	1	AUG Codon (64-81)	P=S
1571	2	5'-Untranslated (32-49)	P=S
1572	3	3'-Untranslated (2190-3010)	P=S
1573	4	3'-Untranslated (2849-2866)	P=S
1574	5	Coding Region (1378-1395)	P=S
1930	6	5'-Untranslated (1-20)	P=S
1931	7	AUG Codon (55-74)	P=S
1932	8	AUG Codon (72-91)	P=S
1933	9	Coding Region (111-130)	P=S
1934	10	Coding Region (351-370)	P=S
1935	11	Coding Region (889-908)	P=S
1936	12	Coding Region (1459-1468)	P=S
1937	13	Termination Codon (1651-1687)	P=S
1938	14	Termination Codon (1668-1687)	P=S
1939	15	3'-Untranslated (1952-1971)	P=S
1940	16	3'-Untranslated (2975-2994)	P=S
2149	17	AUG Codon (64-77)	P=S
2163	18	AUG Codon (64-75)	P=S
2164	19	AUG Codon (64-73)	P=S
2165	20	AUG Codon (66-80)	P=S
2173	21	AUG Codon (64-79)	P=S
2302	22	3'-Untranslated (2114-2133)	P=S

-66-

ISIS NO.	SEQ ID NO.	TARGET REGION	MODIFICATION
2303	23	3'-Untranslated (2039-2058)	P=S
2304	24	3'-Untranslated (1895-1914)	P=S
2305	25	3'-Untranslated (1935-1954)	P=S
2307	26	3'-Untranslated (1976-1995)	P=S
2634	1	AUG-Codon (64-81)	2'-fluoro A,C & U; P=S
2637	15	3'-Untrans (1952-1971)	2'-fluoro A, C & U;
2691	1	AUG Codon (64-81)	P=O, except last 3 bases, P=S
2710	15	3'-Untrans. (1952-1971)	2'-O-methyl; P=O
2711	1	AUG Codon (64-81)	2'-O-methyl; P=O
2973	15	3'-Untrans. (1952-1971)	2'-O-methyl; P=S
2974	1	AUG Codon (64-81)	2'-O-methyl; P=S
3064	27	5'-CAP (32-51)	P=S; G & C added as spacer to 3'
3067	84	5'-CAP (32-51)	P=S
3222	84	5'-CAP (32-51)	2'-O-methyl; P=O
3224	84	5'-CAP (32-51)	2'-O-methyl; P=S
3581	85	3'-Untranslated (1959-1978)	P=S

Inhibition of ICAM-1 expression on the surface of interleukin-1 β -stimulated cells by the oligonucleotides was determined by ELISA assay as described in Example 1. The oligonucleotides were tested in two different cell lines. None of the phosphodiester oligonucleotides inhibited ICAM-1 expression. This is probably due to the rapid degradation of phosphodiester oligonucleotides in cells. Of the five phosphorothioate oligonucleotides, the most active was ISIS 1570, which hybridizes to the AUG translation initiation codon. A 2'-o-methyl phosphorothioate oligonucleotide, ISIS 2974, was approximately threefold less effective than ISIS 1570 in inhibiting ICAM-1 expression in HUVEC and A549 cells. A 2'-fluoro oligonucleotide, ISIS 2634, was also less effective.

-67-

Based on the initial data obtained with the five original targets, additional oligonucleotides were designed which would hybridize with the ICAM-1 mRNA. The antisense oligonucleotide (ISIS 3067) which hybridizes to the predicted transcription initiation site (5' cap site) was approximately as active in IL-1 β -stimulated cells as the oligonucleotide that hybridizes to the AUG codon (ISIS 1570), as shown in Figure 8. ISIS 1931 and 1932 hybridize 5' and 3', respectively, to the AUG translation initiation codon. All three oligonucleotides that hybridize to the AUG region inhibit ICAM-1 expression, though ISIS 1932 was slightly less active than ISIS 1570 and ISIS 1931. Oligonucleotides which hybridize to the coding region of ICAM-1 mRNA (ISIS 1933, 1934, 1935, 1574 and 1936) exhibited weak activity. Oligonucleotides that hybridize to the translation termination codon (ISIS 1937 and 1938) exhibited moderate activity.

Surprisingly, the most active antisense oligonucleotide was ISIS 1939, a phosphorothioate oligonucleotide targeted to a sequence in the 3'- untranslated region of ICAM-1 mRNA (see Table 1). Other oligonucleotides having the same sequence were tested, 2'-O-methyl (ISIS 2973) and 2'-fluoro (ISIS 2637); however, they did not exhibit this level of activity. Oligonucleotides targeted to other 3' untranslated sequences (ISIS 1572, 1573 and 1940) were also not as active as ISIS-1939. In fact, ISIS 1940, targeted to the polyadenylation signal, did not inhibit ICAM-1 expression.

Because ISIS 1939 proved unexpectedly to exhibit the greatest antisense activity of the original 16 oligonucleotides tested, other oligonucleotides were designed to hybridize to sequences in the 3'-untranslated region of ICAM-1 mRNA (ISIS 2302, 2303, 2304, 2305, and 2307, as shown in Table 1). ISIS 2307, which hybridizes to a site only five bases 3' to the ISIS 1939 target, was the least active of the series (Figure 8). ISIS 2302, which hybridizes to the ICAM-1 mRNA at a position 143 bases 3' to the ISIS 1939 target, was the most active of the series, with activity comparable to that of ISIS 1939. Examination of the

-68-

predicted RNA secondary structure of the human ICAM-1 mRNA 3'-untranslated region (according to M. Zuker, *Science* **1989**, 244, 48-52) revealed that both ISIS 1939 and ISIS 2302 hybridize to sequences predicted to be in a stable stem-loop structure.

5 Current dogma suggests that regions of RNA secondary structure should be avoided when designing antisense oligonucleotides. Thus, ISIS 1939 and ISIS 2302 would not have been predicted to inhibit ICAM-1 expression.

The control oligonucleotide ISIS 1821 did inhibit ICAM-1
10 expression in HUVEC cells with activity comparable to that of ISIS 1934; however, in A549 cells ISIS 1821 was less effective than ISIS 1934. The negative control, ISIS 1821, was found to have a small amount of activity against ICAM expression, probably due in part to its ability to hybridize (12 of 13 base match) to the
15 ICAM-1 mRNA at a position 15 bases 3' to the AUG translation initiation codon.

These studies indicate that the AUG translation initiation codon and specific 3'-untranslated sequences in the ICAM-1 mRNA were the most susceptible to antisense oligonucleotide inhibition
20 of ICAM-1 expression.

In addition to inhibiting ICAM-1 expression in human umbilical vein cells and the human lung carcinoma cells (A549), ISIS 1570, ISIS 1939 and ISIS 2302 were shown to inhibit ICAM-1 expression in the human epidermal carcinoma A431 cells and in
25 primary human keratinocytes (shown in Figure 9). These data demonstrate that antisense oligonucleotides are capable of inhibiting ICAM-1 expression in several human cell lines. Furthermore, the rank order potency of the oligonucleotides is the same in the four cell lines examined. The fact that ICAM-1
30 expression could be inhibited in primary human keratinocytes is important because epidermal keratinocytes are an intended target of the antisense nucleotides.

Example 6

35 Antisense oligonucleotide inhibition of ICAM-1 expression in cells

-69-

stimulated with other cytokines

Two oligonucleotides, ISIS 1570 and ISIS 1939, were tested for their ability to inhibit TNF- α and IFN- α -induced ICAM-1 expression. Treatment of A549 cells with 1 μ M antisense oligonucleotide inhibited IL-1 β , TNF- α and IFN- α -induced ICAM-1 expression in a sequence-specific manner. The antisense oligonucleotides inhibited IL-1 β and TNF- α -induced ICAM-1 expression to a similar extent, while IFN- α -induced ICAM-1 expression was more sensitive to antisense inhibition. The control oligonucleotide, ISIS 1821, did not significantly inhibit IL-1 β - or TNF- α -induced ICAM-1 expression and inhibited IFN- α -induced ICAM-1 expression slightly, as follows:

Antisense Oligonucleotide
(% Control Expression)

Cytokine	ISIS 1570	ISIS 1939	ISIS 1821
3 U/ml IL-1 α	56.6 " 2.9	38.1 " 3.2	95 " 6.6
1 ng/ml TNF- α	58.1 " 0.9	37.6 " 4.1	103.5 " 8.2
100 U/ml gamma-IFN	38.9 " 3.0	18.3 " 7.0	83.0 " 3.5

Example 7

Antisense effects are abolished by sense strand controls

The antisense oligonucleotide inhibition of ICAM-1 expression by the oligonucleotides ISIS 1570 and ISIS 1939 could be reversed by hybridization of the oligonucleotides with their respective sense strands. The phosphorothioate sense strand for ISIS 1570 (ISIS 1575), when applied alone, slightly enhanced IL-1 β -induced ICAM-1 expression. Premixing ISIS 1570 with ISIS 1575 at equal molar concentrations, prior to addition to the cells, blocked the effects of ISIS 1570. The complement to ISIS 1939 (ISIS 2115) enhanced ICAM-1 expression by 46% when added to the cells alone. Prehybridization of ISIS 2115 to ISIS 1939 completely blocked the inhibition of ICAM-1 expression by ISIS

-70-

1939.

Example 8

Measurement of oligonucleotide T_m (dissociation temperature of
5 oligonucleotide from target)

To determine if the potency of the inhibition of ICAM-1
expression by antisense oligonucleotides was due to their affinity
for their target sites, thermodynamic measurements were made for
each of the oligonucleotides. The antisense oligonucleotides
10 (synthesized as phosphorothioates) were hybridized to their
complementary DNA sequences (synthesized as phosphodiesteres).
Absorbance vs. temperature profiles were measured at 4 μ M each
strand oligonucleotide in 100 mM Na⁺, 10 mM phosphate, 0.1 mM
EDTA, pH 7.0. T_m 's and free energies of duplex formation were
15 obtained from fits of data to a two-state model with linear
sloping baselines (Petersheim, M. and D.H. Turner, *Biochemistry*
1983, 22, 256-263). Results are averages of at least three
experiments.

When the antisense oligonucleotides were hybridized to their
20 complementary DNA sequences (synthesized as phosphodiesteres), all
of the antisense oligonucleotides with the exception of ISIS 1940
exhibited a T_m of at least 50°C. All the oligonucleotides should
therefore be capable of hybridizing to the target ICAM-1 mRNA if
the target sequences were exposed. Surprisingly, the potency of
25 the antisense oligonucleotide did not correlate directly with
either T_m or ΔG_{37} . The oligonucleotide with the greatest
biological activity, ISIS 1939, exhibited a T_m which was lower
than that of the majority of the other oligonucleotides. Thus,
hybridization affinity is not sufficient to ensure biological
30 activity.

Example 9

Effect of oligonucleotide length on antisense inhibition of ICAM-1
expression

35 The effect of oligonucleotide length on antisense activity

-71-

was tested using truncated versions of ISIS 1570 (ISIS 2165, 2173, 2149, 2163 and 2164) and ISIS 1939 (ISIS 2540, 2544, 2545, 2546, 2547 and 2548). In general, antisense activity decreased as the length of the oligonucleotides decreased. Oligonucleotides 16 bases in length exhibited activity slightly less than 18 base oligonucleotides. Oligonucleotides 14 bases in length exhibited significantly less activity, and oligonucleotides 12 or 10 bases in length exhibited only weak activity. Examination of the relationship between oligonucleotide length and T_m and antisense activity reveals that a sharp transition occurs between 14 and 16 bases in length, while T_m increases linearly with length (Figure 10).

Example 10

Specificity of antisense inhibition of ICAM-1

The specificity of the antisense oligonucleotides ISIS 1570 and ISIS 1939 for ICAM-1 was evaluated by immunoprecipitation of ^{35}S -labelled proteins. A549 cells were grown to confluence in 25 cm^2 tissue culture flasks and treated with antisense oligonucleotides as described in Example 4. The cells were stimulated with interleukin- 1β for 14 hours, washed with methionine-free DMEM plus 10% dialyzed fetal calf serum, and incubated for 1 hour in methionine-free medium containing 10% dialyzed fetal calf serum, 1 μM oligonucleotide and interleukin- 1β as indicated. ^{35}S -Methionine/cysteine mixture (Tran ^{35}S -label, purchased from ICN, Costa Mesa, CA) was added to the cells to an activity of 100 $\mu\text{Ci/ml}$ and the cells were incubated an additional 2 hours. Cellular proteins were extracted by incubation with 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1.0% NP-40, 0.5% deoxycholate and 2 mM EDTA (0.5 ml per well) at 4°C for 30 minutes. The extracts were clarified by centrifugation at 18,000 x g for 20 minutes. The supernatants were preadsorbed with 200 μl protein G-Sepharose beads (Bethesda Research Labs, Bethesda MD) for 2 hours at 4°C, divided equally and incubated with either 5 μg ICAM-1 monoclonal antibody (purchased from AMAC Inc., Westbrook ME) or HLA-A,B

-72-

antibody (W6/32, produced by murine hybridoma cells obtained from the American Type Culture Collection, Bethesda, MD) for 15 hours at 4°C. Immune complexes were trapped by incubation with 200 µl of a 50% suspension of protein G-Sepharose (v/v) for 2 hours at 4°C, washed 5 times with lysis buffer and resolved on an SDS-polyacrylamide gel. Proteins were detected by autoradiography.

Treatment of A549 cells with 5 units/ml of interleukin-1β was shown to result in the synthesis of a 95-100 kDa protein migrating as a doublet which was immunoprecipitated with the monoclonal antibody to ICAM-1. The appearance as a doublet is believed to be due to differently glycosylated forms of ICAM-1. Pretreatment of the cells with the antisense oligonucleotide ISIS 1570 at a concentration of 1 µM decreased the synthesis of ICAM-1 by approximately 50%, while 1 µM ISIS 1939 decreased ICAM-1 synthesis to near background. Antisense oligonucleotide ISIS 1940, inactive in the ICAM-1 ELISA assay (Examples 1 and 5) did not significantly reduce ICAM-1 synthesis. None of the antisense oligonucleotides hybridizable with ICAM-1 targets had a demonstrable effect on HLA-A, B synthesis, demonstrating the specificity of the oligonucleotides for ICAM-1. Furthermore, the proteins which nonspecifically precipitated with the ICAM-1 antibody and protein G-Sepharose were not significantly affected by treatment with the antisense oligonucleotides.

Example 11

Screening of additional antisense oligonucleotides for activity against ICAM-1 by cell adhesion assay

Human umbilical vein endothelial (HUVEC) cells were grown and treated with oligonucleotides as in Example 4. Cells were treated with either ISIS 1939, ISIS 1940, or the control oligonucleotide ISIS 1821 for 4 hours, then stimulated with TNF-α for 20 hours. Basal HUVEC minimally bound HL-60 cells, while TNF-stimulated HUVEC bound 19% of the total cells added. Pretreatment of the HUVEC monolayer with 0.3 µM ISIS 1939 reduced the adherence of HL-60 cells to basal levels, as shown in Figure 11. The

-73-

control oligonucleotide, ISIS 1821, and ISIS 1940 reduced the percentage of cells adhering from 19% to 9%. These data indicate that antisense oligonucleotides targeting ICAM-1 may specifically decrease adherence of a leukocyte-like cell line (HL-60) to TNF- α -
5 treated HUVEC.

Example 12

ELISA screening of antisense oligonucleotides for activity against ELAM-1 gene expression

10 Primary human umbilical vein endothelial (HUVEC) cells, passage 2 to 5, were plated in 96-well plates and allowed to reach confluence. Cells were washed three times with Opti-MEM (GIBCO, Grand Island NY). Cells were treated with increasing concentrations of oligonucleotide diluted in Opti-MEM containing
15 10 μ g/ml DOTMA solution (Bethesda Research Labs, Bethesda, MD) for 4 hours at 37°C. The medium was removed and replaced with EGM-UV (Clonetics, San Diego CA) plus oligonucleotide. Tumor necrosis factor α was added to the medium (2.5 ng/ml) and the cells were incubated an additional 4 hours at 37°C.

20 ELAM-1 expression was determined by ELISA. Cells were gently washed three times with Dulbecco's phosphate-buffered saline (D-PBS) prewarmed to 37°C. Cells were fixed with 95% ethanol at 4°C for 20 minutes, washed three times with D-PBS and blocked with 2% BSA in D-PBS. Cells were incubated with ELAM-1
25 monoclonal antibody BBA-1 (R&D Systems, Minneapolis MN) diluted to 0.5 μ g/ml in D-PBS containing 2% BSA for 1 hour at 37°C. Cells were washed three times with D-PBS and the bound ELAM-1 antibody detected with biotinylated goat anti-mouse secondary antibody followed by β -galactosidase-conjugated streptavidin as described
30 in Example 1.

The activity of antisense phosphorothioate oligonucleotides which target 11 different regions on the ELAM-1 cDNA and two oligonucleotides which target ICAM-1 (as controls) was determined using the ELAM-1 ELISA. The oligonucleotide and targets are shown
35 in Table 2.

-74-

Table 2

ANTISENSE OLIGONUCLEOTIDES WHICH TARGET HUMAN ELAM-1

ISIS NO.	SEQ ID NO.	TARGET REGION	MODIFICATION
1926	28	AUG Codon (143-164)	P=S
2670	29	3'-Untranslated (3718-3737)	P=S
2673	30	3'-Untranslated (2657-2677)	P=S
2674	31	3'-Untranslated (2617-2637)	P=S
2678	32	3'-Untranslated (3558-3577)	P=S
2679	33	5'-Untranslated (41-60)	P=S
2680	34	3'-Untranslated (3715-3729)	P=S
2683	35	AUG Codon (143-163)	P=S
2686	36	AUG Codon (149-169)	P=S
2687	37	5'-Untranslated (18-37)	P=S
2693	38	3'-Untranslated (2760-2788)	P=S
2694	39	3'-Untranslated (2934-2954)	P=S

In contrast to what was observed with antisense oligonucleotides
 5 targeted to ICAM-1 (Example 5), the most potent oligonucleotide
 modulator of ELAM-1 activity (ISIS 2679) was hybridizable with
 specific sequences in the 5'-untranslated region of ELAM-1. ISIS
 2687, an oligonucleotide which hybridized to sequences ending
 three bases upstream of the ISIS 2679 target, did not show
 10 significant activity (Figure 12). Therefore, ISIS 2679 hybridizes
 to a unique site on the ELAM-1 mRNA, which is uniquely sensitive
 to inhibition with antisense oligonucleotides. The sensitivity of
 this site to inhibition with antisense oligonucleotides was not
 predictable based upon RNA secondary structure predictions or
 15 information in the literature.

-75-

Example 13

ELISA screening of additional antisense oligonucleotides for activity against ELAM-1 gene expression

Inhibition of ELAM-1 expression by eighteen antisense phosphorothioate oligonucleotides was determined using the ELISA assay as described in Example 12. The target sites of these oligonucleotides on the ELAM-1 mRNA are shown in Figure 13. The sequence and activity of each oligonucleotide against ELAM-1 are shown in Table 3. The oligonucleotides indicated by an asterisk (*) have IC₅₀'s of approximately 50 nM or below and are preferred. IC₅₀ indicates the dosage of oligonucleotide, which results in 50% inhibition of ELAM-1 expression.

TABLE 3

INHIBITION OF HUMAN ELAM-1 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES

ELAM-1 expression is given as % of control

ISIS#	SEQ ID NO:	POSITION	SEQUENCE	VCAM-1 EXPRESSION	
				30 nM oligo	50 nM oligo
*4764	52	5'-UTR 1-19	GAAGTCAGCCAAGAACAGCT	70.2	50.2
2687	37	5'-UTR 17-36	TATAGGAGTTTTGATGTGAA	91.1	73.8
*2679	33	5'-UTR 40-59	CTGCTGCCTCTGTCTCAGGT	6.4	6.0
*4759	53	5'-UTR 64-83	ACAGGATCTCTCAGGTGGGT	30.0	20.2
*2683	35	AUG 143-163	AATCATGACTTCAAGAGTTCT	47.9	48.5
*2686	36	AUG 148-168	TGAAGCAATCATGACTTCAAG	51.1	46.9
*4756	54	I/E 177-196	CCAAAGTGAGAGCTGAGAGA	53.9	35.7
4732	55	Coding 1936-1955	CTGATTCAAGGCTTTGGCAG	68.5	55.3
*4730	56	I/E 3'UTR 2006-2025	TCCCCAGATGCACCTGTTT	14.1	2.3
*4729	57	3'-UTR 2063-2082	GGGCCAGAGACCCGAGGAGA	49.4	46.3
*2674	31	3'-UTR 2617-2637	CACAATCCTTAAGAACTCTTT	33.5	28.1
2673	30	3'-UTR 2656-2676	GTATGGAAGATTATAATATAT	58.9	53.8
2694	39	3'-UTR 2933-2953	GACAATATACAAACCTTCCAT	72.0	64.6
*4719	58	3'-UTR 2993-3012	ACGTTTGGCCTCATGGAAGT	36.8	34.7

-76-

ISIS#	SEQ ID NO:	POSITION	SEQUENCE	VCAM-1 EXPRESSION	
				30 nM oligo	50 nM oligo
4720	59	3'-UTR 3093-3112	GGAATGCAAAGCACATCCAT	63.5	70.6
*2678	32	3'-UTR 3557-3576	ACCTCTGCTGTTCTGATCCT	24.9	15.3
2670	29	3'-UTR 3717-3736	ACCACACTGGTATTTTCACAC	72.2	67.2

I/E indicates Intron/Exon junction

Oligonucleotides with IC50's of approximately 50 nM or below are indicated by an asterisk (*).

- 5 An additional oligonucleotide targeted to the 3'-untranslated region (ISIS 4728) did not inhibit ELAM expression.

Example 14

10 ELISA screening of antisense oligonucleotides for activity against VCAM-1 gene expression

 Inhibition of VCAM-1 expression by fifteen antisense phosphorothioate oligonucleotides was determined using the ELISA assay approximately as described in Example 12, except that cells were stimulated with TNF- α for 16 hours and VCAM-1 expression was
15 detected by a VCAM-1 specific monoclonal antibody (R & D Systems, Minneapolis, MN) used at 0.5 μ g/ml. The target sites of these oligonucleotides on the VCAM-1 mRNA are shown in Figure 14. The sequence and activity of each oligonucleotide against VCAM-1 are shown in Table 4. The oligonucleotides indicated by an asterisk
20 (*) have IC50's of approximately 50 nM or below and are preferred. IC50 indicates the dosage of oligonucleotide which results in 50% inhibition of VCAM-1 expression.

-77-

Table 4
INHIBITION OF HUMAN VCAM-1 EXPRESSION BY ANTISENSE
OLIGONUCLEOTIDES

5

VCAM-1 expression is given as % of control

ISIS#	SEQ ID NO:	POSITION	SEQUENCE	VCAM-1 EXPRESSION	
				30 nM oligo	50 nM oligo
*5884	60	5'-UTR 1-19	CGATGCAGATACCGCGGAGT	79.2	37.2
3791	61	5'-UTR 38-58	CCTGGGAGGGTATTTCAGCT	92.6	58.0
5862	62	5'-UTR 48-68	CCTGTGTGTGCCTGGGAGGG	115.0	3.5
*3792	63	AUG 110-129	GGCATTTTAAGTTGCTGTCG	68.7	33.7
5863	64	CODING 745-764	CAGCCTGCCTTACTGTGGGC	95.8	66.7
*5874	65	CODING 1032-1052	CTTGAACAATTAATTCCACCT	66.5	35.3
5885	66	E/I 1633- 1649+intron	TTACCATTGACATAAAGTGTT	84.4	52.4
*5876	67	CODING 2038-2057	CTGTGTCTCCTGTCTCCGCT	43.5	26.6
*5875	68	CODING 2183-2203	GTCTTTGTTGTTTTCTCTTCC	59.2	34.8
3794	69	TERMIN. 2344-2362	TGAACATATCAAGCATTAGC	75.3	52.6
*3800	70	3'-UTR 2620-2639	GCAATCTTGCTATGGCATAA	64.4	47.7
*3805	71	3'-UTR 2826-2845	CCCGGCATCTTTACAAAACC	7.7	44.9
*3801	50	3'-UTR 2872-2892	AACCCAGTGCTCCCTTTGCT	36.5	21.3
*5847	72	3'-UTR 2957-2976	AACATCTCCGTACCATGCCA	51.8	24.6
*3804	51	3'-UTR 3005-3024	GGCCACATTGGGAAAGTTGC	55.1	29.3

E/I indicates exon/intron junction

Oligonucleotides with IC₅₀'s of approximately 50 nM or below are indicated by an asterisk (*).

-78-

Example 15

ICAM-1 expression in C8161 human melanoma cells

5 Human melanoma cell line C8161 (a gift of Dr. Dan Welch, Hershey Medical Center) was derived from an abdominal wall metastasis from a patient with recurrent malignant melanoma. These cells form multiple metastases in lung, subcutis, spleen, liver and regional lymph nodes after subcutaneous, intradermal and
10 intravenous injection into athymic nude mice. Cells were grown in DMA-F12 medium containing 10% fetal calf serum and were passaged using 2 mM EDTA.

Exposure of C8161 cells to TNF- α resulted in a six-fold increase in cell surface expression of ICAM-1 and an increase in
15 ICAM-1 mRNA levels in these cells. ICAM-1 expression on the cell surface was measured by ELISA. Cells were treated with increasing concentrations of antisense oligonucleotides in the presence of 15 μ g/ml Lipofectin for 4 hours at 37°C. ICAM-1 expression was induced by incubation with 5 ng/ml TNF- α for 16 hours. Cells were
20 washed 3x in DPBS and fixed for 20 minutes in 2% formaldehyde. Cells were washed in DPBS, blocked with 2% BSA for 1 hour at 37°C and incubated with ICAM-1 monoclonal antibody 84H10 (AMAC, Inc., Westbrook, ME). Detection of bound antibody was determined by incubation with a biotinylated goat anti-mouse IgG followed by
25 incubation with β -galactosidase-conjugated streptavidin and developed with chlorophenol red- β -D-galactopyranoside and quantified by absorbance at 575 nm. ICAM-1 mRNA levels were measured by Northern blot analysis.

30

Example 16

Oligonucleotide inhibition of ICAM-1 expression in C8161 human melanoma cells

35 As shown in Figure 15, antisense oligonucleotides ICAM 1570

-79-

(SEQ ID NO: 1), ISIS 1939 (SEQ ID NO: 15) and ISIS 2302 (SEQ ID NO: 22) targeted to ICAM-1 decreased cell surface expression of ICAM-1 (detected by ELISA as in Example 16). ISIS 1822, a negative control oligonucleotide complementary to 5-lipoxygenase, did not affect ICAM-1 expression. The data were expressed as percentage of control activity, calculated as follows: (ICAM-1 expression for oligonucleotide-treated, cytokine-induced cells) - (basal ICAM-1 expression) / (ICAM-1 cytokine-induced expression) - (basal ICAM-1 expression) x 100.

ISIS 1939 (SEQ ID NO: 15) and ISIS 2302 (SEQ ID NO: 22) markedly reduced ICAM-1 mRNA levels (detected by Northern blot analysis), but ISIS 1570 (SEQ ID NO: 1) decreased ICAM-1 mRNA levels only slightly.

Example 17

Experimental metastasis assay

To evaluate the role of ICAM-1 in metastasis, experimental metastasis assays were performed by injecting 1×10^5 C8161 cells into the lateral tail vein of athymic nude mice. Treatment of C8161 cells with the cytokine TNF- α and interferon α has previously been shown to result in an increased number of lung metastases when cells were injected into nude mice [Miller, D.E. and Welch, D.R., *Proc. Am. Assoc. Cancer Res.* **1990**, 13, 353].

After 4 weeks, mice were sacrificed, organs were fixed in Bouin's fixative and metastatic lesions on lungs were scored with the aid of a dissecting microscope. Four-week-old female athymic nude mice (Harlan Sprague Dawley) were used. Animals were maintained under the guidelines of the NIH. Groups of 4-8 mice each were tested in experimental metastasis assays.

Example 18

Antisense oligonucleotides ISIS 1570 and ISIS 2302 decrease metastatic potential of C8161 cells

Treatment of C8161 cells with antisense oligonucleotides ISIS 1570 and ISIS 2302, complementary to ICAM-1, was performed in

-80-

the presence of the cationic lipid, Lipofectin (Gibco/BRL, Gaithersburg, MD). Antisense oligonucleotides were synthesized as described in Example 3. Cells were seeded in 60 mm tissue culture dishes at 10^6 cells/ml and incubated at 37°C for 3 days, washed
5 with OPTI-MEM (Gibco/BRL) 3 times and 100 μ l of OPTI-MEM medium was added to each well. 0.5 μ M oligonucleotide and 15 μ g/ml lipofectin were mixed at room temperature for 15 minutes. 25 μ l of the oligonucleotide-lipofectin mixture was added to the appropriate dishes and incubated at 37°C for 4 hours. The
10 oligonucleotide-lipofectin mixture was removed and replaced with DME-F12 medium containing 10% fetal calf serum. After 4 hours, 500 U/ml TNF- α was added to the appropriate wells and incubated for 18 hours at which time cells were removed from the plates, counted and injected into athymic nude mice.

15 Treatment of C8161 cells with ISIS 1570 (SEQ ID NO: 1) or ISIS 2302 (SEQ ID NO: 22) decreased the metastatic potential of these cells, and eliminated the enhanced metastatic ability of C8161 which resulted from TNF- α treatment. Data are shown in Table 5.

-81-

Table 5
EFFECT OF ANTISENSE OLIGONUCLEOTIDES TO ICAM-1 ON EXPERIMENTAL
METASTASIS OF HUMAN MELANOMA CELL LINE C8161

Treatment	No. Lung Metastases per Mouse (Mean $\pm$ S.E.M.)
Lipofectin only	64 $\pm$ 13
Lipofectin + TNF- α	81 $\pm$ 8
ISIS-1570 + Lipofectin	38 $\pm$ 15
ISIS-2302 + Lipofectin	23 $\pm$ 6
ISIS-1570 + Lipofectin + TNF- α	49 $\pm$ 6
ISIS-2302 + Lipofectin + TNF- α	31 $\pm$ 8

5

Example 19

Murine models for testing antisense oligonucleotides against ICAM-1

Many conditions which are believed to be mediated by intercellular adhesion molecules are not amenable to study in humans. For example, allograft rejection is a condition which is likely to be ameliorated by interference with ICAM-1 expression, but clearly this must be evaluated in animals rather than human transplant patients. Another such example is inflammatory bowel disease, and yet another is neutrophil migration (infiltration). These conditions can be tested in animal models, however, such as the mouse models used here.

Oligonucleotide sequences for inhibiting ICAM-1 expression in murine cells were identified. Murine ICAM-1 has approximately 50% homology with the human ICAM-1 sequence; a series of oligonucleotides which target the mouse ICAM-1 mRNA sequence were designed and synthesized, using information gained from evaluation of oligonucleotides

-82-

targeted to human ICAM-1. These oligonucleotides were screened for activity using an immunoprecipitation assay.

Murine DCEK-ICAM-1 cells (a gift from Dr. Adrienne Brian, University of California at San Diego) were treated with 1 μ M of
5 oligonucleotide in the presence of 20 μ g/ml DOTMA/DOPE solution for 4 hours at 37°C. The medium was replaced with methionine-free medium plus 10% dialyzed fetal calf serum and 1 μ M antisense oligonucleotide. The cells were incubated for 1 hour in methionine-free medium, then 100 μ Ci/ml ³⁵S-labeled
10 methionine/cysteine mixture was added to the cells. Cells were incubated an additional 2 hours, washed 4 times with PBS, and extracted with buffer containing 20 mM Tris, pH 7.2, 20 mM KCl, 5 mM EDTA, 1% Triton X-100, 0.1 mM leupeptin, 10 μ g/ml aprotinin, and 1 mM PMSF. ICAM-1 was immunoprecipitated from the extracts by
15 incubating with a murine-specific ICAM-1 antibody (YN1/1.7.4) followed by protein G-sepharose. The immunoprecipitates were analyzed by SDS-PAGE and autoradiographed. Phosphorothioate oligonucleotides ISIS 3066 and 3069, which target the AUG codon of mouse ICAM-1, inhibited ICAM-1 synthesis by 48% and 63%,
20 respectively, while oligonucleotides ISIS 3065 and ISIS 3082, which target sequences in the 3'-untranslated region of murine ICAM-1 mRNA inhibited ICAM-1 synthesis by 47% and 97%, respectively. The most active antisense oligonucleotide against mouse ICAM-1 was targeted to the 3'-untranslated region. ISIS
25 3082 was evaluated further based on these results; this 20-mer phosphorothioate oligonucleotide comprises the sequence (5' to 3') TGC ATC CCC CAG GCC ACC AT (SEQ ID NO: 83).

-83-

Example 20

Antisense oligonucleotides to ICAM-1 reduce inflammatory bowel disease in murine model system

5 A mouse model for inflammatory bowel disease (IBD) has recently been developed. Okayasu et al., *Gastroenterology* **1990**, 98, 694-702. Administration of dextran sulfate to mice induces colitis that mimics human IBD in almost every detail. Dextran sulfate-induced IBD and human IBD have subsequently been closely
10 compared at the histological level and the mouse model has been found to be an extremely reproducible and reliable model. It is used here to test the effect of ISIS 3082, a 20-base phosphorothioate antisense oligonucleotide which is complementary to the 3' untranslated region of the murine ICAM-1.

15 Female Swiss Webster mice (8 weeks of age) weighing approximately 25 to 30 grams are kept under standard conditions. Mice are allowed to acclimate for at least 5 days before initiation of experimental procedures. Mice are given 5% dextran sulfate sodium in their drinking water (available ad libitum) for
20 5 days. Concomitantly, ISIS 3082 oligonucleotide in pharmaceutical carrier, carrier alone (negative control) or TGF- β (known to protect against dextran sulfate-mediated colitis in mice) is administered. ISIS 3082 was given as daily subcutaneous injection of 1 mg/kg or 10 mg/kg for 5 days. TGF- β was given as 1
25 μ g/mouse intracolonicallly. At 1 mg/kg, the oligonucleotide was as effective as TGF- α in protecting against dextran-sulfate-induced colitis.

Mice were sacrificed on day 6 and colons were subjected to histopathologic evaluation. Until sacrifice, disease activity was
30 monitored by observing mice for weight changes and by observing stools for evidence of colitis. Mice were weighed daily. Stools were observed daily for changes in consistency and for presence of occult or gross bleeding. A scoring system was used to develop a disease activity index by which weight loss, stool consistency and
35 presence of bleeding were graded on a scale of 0 to 3 (0 being

-84-

normal and 3 being most severely affected) and an index was calculated. Drug-induced changes in the disease activity index were analyzed statistically. The disease activity index has been shown to correlate extremely well with IBD in general. Results are shown in Figure 16. At 1 mg/kg, the oligonucleotide reduced the disease index by 40%.

Example 21

Antisense oligonucleotide to ICAM-1 increases survival in murine heterotopic heart transplant model

To determine the therapeutic effects of ICAM-1 antisense oligonucleotide in preventing allograft rejection the murine ICAM-1 specific oligonucleotide ISIS 3082 was tested for activity in a murine vascularized heterotopic heart transplant model. Hearts from Balb/c mice were transplanted into the abdominal cavity of C3H mice as primary vascularized grafts essentially as described by Isobe et al., *Circulation* **1991**, 84, 1246-1255. Oligonucleotides were administered by continuous intravenous administration via a 7-day Alzet pump. The mean survival time for untreated mice was 9.2 ± 0.8 days (8, 9, 9, 9, 10, 10 days). Treatment of the mice for 7 days with 5 mg/kg ISIS 3082 increased the mean survival time to 14.3 ± 4.6 days (11, 12, 13, 21 days).

Example 22

Antisense oligonucleotide to ICAM-1 decreases leukocyte migration

Leukocyte infiltration of tissues and organs is a major aspect of the inflammatory process and contributes to tissue damage resulting from inflammation. The effect of ISIS 3082 on leukocyte migration was examined using a mouse model in which carrageenan-soaked sponges were implanted subcutaneously. Carrageenan stimulates leukocyte migration and edema. Effect of oligonucleotide on leukocyte migration in inflammatory exudates is evaluated by quantitation of leukocytes infiltrating the implanted sponges. Following a four hour fast, 40 mice were assigned randomly to eight groups each containing five mice. Each mouse

-85-

was anesthetized with Metofane and a polyester sponge impregnated with 1 ml of a 20 mg/ml solution of carrageenan was implanted subcutaneously. Saline was administered intravenously to Group 1 at 10 ml/kg four hours prior to sponge implantation and this served as the vehicle control. Indomethacin (positive control) was administered orally at 3 mg/kg at a volume of 20 ml/kg to Group 2 immediately following surgery, again 6-8 hours later and again at 21 hours post-implantation. ISIS 3082 was administered intravenously at 5 mg/kg to Group 3 four hours prior to sponge implantation. ISIS 3082 was administered intravenously at 5 mg/kg to Group 4 immediately following sponge implantation. ISIS 3082 was administered intravenously at 5 mg/kg to Groups 5, 6, 7 and 8 at 2, 4, 8 and 18 hours following sponge implantation, respectively. Twenty-four hours after implantation, sponges were removed, immersed in EDTA and saline (5 ml) and squeezed dry. Total numbers of leukocytes in sponge exudate mixtures were determined.

The oral administration of indomethacin at 3 mg/kg produced a 79% reduction in mean leukocyte count when compared to the vehicle control group.

A 42% reduction in mean leukocyte count was observed following the administration of ISIS 3082 at 5 mg/kg four hours prior to sponge implantation (Group 3). A 47% reduction in mean leukocyte count was observed following the administration of ISIS 3082 at 5 mg/kg immediately following sponge implantation (Group 4). All animals appeared normal throughout the course of study.

Example 23

Compatibility of antisense oligonucleotide with corneal donor storage media and determination of toxicity

The following studies were performed to determine whether antisense oligonucleotides were toxic to normal ocular tissues. A 20-mer antisense phosphorothioate oligonucleotide (APO) in three different concentrations (40, 200 and 400 µg/ml) was stored in OPTISOL™ corneal donor storage media (Bausch & Lomb) for a total

-86-

of 30 days. At day 0, 2, 8 and 30 of incubation, aliquots from each concentration were removed, 2 ml samples were placed in freezer-safe tubes and frozen at -100°C for storage. Samples were thawed and analyzed by capillary gel electrophoresis (CGE).

5 Another 2ml aliquot was obtained for each day for analysis of degradability using by spectrophotometry at 260 nm. The dose response curve in water was linear from 5-200 µg/ml concentrations. The samples containing OPTISOL™ were diluted 1:10 to decrease interference in the spectrophotometer.

10 No degradation or breakdown components of APO over the 30-day storage period was detected by CGE; however, degradation was observed when analysis was performed by spectrophotometry as indicated as decreased absorbance. Absorbance decreased by 39% after 8 days in the 400 µg/ml samples, 37% in the 200 µg/ml

15 samples and 60% in the 40 µg/ml samples on average. Thus, at the concentrations studied, the APO is stable in OPTISOL™ and does not appear to break down as determined by CGE. Human donor corneas that were unsuitable for transplant were incubated with 3 different concentrations of APO in OPTISOL™ and evaluated after

20 1, 3 and 8 days using the same criteria applied to corneas for transplant. Corneas were fixed for histologic evaluation by light and electron microscopy. Although all corneas deteriorated over time, low concentrations of APO did not significantly affect either epithelial or endothelial cellular integrity, deturgescence

25 or tissue viability. Thee results for the 1 and 8 day incubations are summarized in Table 6.

-87-

Table 6
CORNEAL CHANGES OBSERVED AFTER STORAGE FOR 24 HOURS OR 8 DAYS BY
LIGHT MICROSCOPY ANALYSIS

	Edema	Epithelial defect	Inflammation	Absence of polarity
APO (24 h)	1/7	2/7	2/7	3/7
Control (24 h)	0/2	1/2	0/2	0/2
APO (8 days)	3/9	1/9	0/9	7/9
Control (8 days)	1/11	2/11	3/11	9/11

5

Rabbits were treated with topical doses (200 and 400 µg/ml) of APO for 10 days four times per day. A different concentration was used in each of the two groups. The ocular surface was assessed by clinical examination using the MacDonald-Shadduck toxicology scale. No local toxicity was reported on the MacDonald-Shadduck scale or by light microscopy. The results are shown in Table 7.

10

Table 7
MACDONALD-SHADDUCK OCULAR IRRITATION SCORES

	Control ¹	APO (40 µg/ml)	APO (400 µg/ml)
Conjunctiva:			
Injection	Normal	Minor ²	Minor
Chemosis/Swelling	Normal	Minor ³	Minor
Discharge	None	Minimal	Minimal
Light reflex	Normal	Normal	Slightly sluggish (day 4-8)
Cornea:			
Loss of transparency	None	Minimal (d. 6-7) ⁴	Minimal (d. 2-8)
Stromal opacity	None	Minimal (d. 7-8) ⁵	Moderate (d. 2-8) ⁵
Vascularization	None	None	Minimal ⁶
Staining	None	None	None

15 ¹Vehicle-treated control

-88-

²Less than 0.5 on a scale of 3.0=minor flushing of palpebral conjunctiva with some perilimbal injection

³Less than 0.5 on a scale of 4.0=some swelling without eversion of the lids

5 ⁴Less than 0.5 on a scale of 4.0=some loss of transparency in anterior half of stroma on days 7-8

⁵Minimal>0.5 on a scale of 4.0=>10% area of stromal cloudiness

⁶Moderate 1.0 on a scale of 4.0=<25% area of stromal cloudiness

10 In addition, serum and aqueous humor were withdrawn and analyzed for the presence of APO to evaluate the ability to penetrate through the corneal tissues. The amount of APO in the serum was less than the limit of detection of the assay method. Significant amounts of APO were found to have penetrated into the aqueous humor, demonstrating the ability of the APO to penetrate
15 through the cornea. After 10 days, the cornea and conjunctiva were studied by light and electron microscopy. By specular microscopy, there were no significant differences between corneas incubated in OPTISOL™ alone or with APO. Light microscopy demonstrated that epithelial polarity and thickness was unaffected
20 by 200 µg/ml and was minimally affected at 400 µg/ml. Scanning electron microscopy (SEM) indicated that storage of corneas up to 8 days did not further increase the time related corneal endothelial degradation.

25 The experiments described above show that the antisense phosphorothioate oligonucleotides are compatible with corneal storage media, are not toxic to human corneas stored in corneal storage media and are not damaging to normal eye tissue when applied topically.

30 **Example 24**

Effect of ISIS 2302 on corneal integrity and tissue viability

Eleven human corneal donor buttons were stored in OPTISOL™ for 8 days and used as the control group. Additional corneal buttons were used for the experimental group and were stored in
35 OPTISOL™ with either 200 µg/ml ISIS 2302 (n=10) or 400 µg/ml ISIS

-89-

2302 (n=8). Endothelial cell density was evaluated by specular microscopy. After 8 days, all corneas were prepared for SEM and photographs were taken of endothelial and epithelial surfaces.

Analysis by specular microscopy found that after 2 or 8 days of storage, there was no difference in endothelial cell density among the 3 groups. Both surfaces of the control and experimental groups were analyzed for cellular degradation as well as similarities and differences in their appearance. SEM revealed heavy exfoliation of the epithelial surface of the control group and moderate to heavy pitting and enucleation of the endothelial surface. The corneal buttons exposed to 200 or 400 µg/ml ISIS 2302 were similar in appearance to corneas in the control group. Severe pitting and hollowing of the endothelial surface and shedding of the epithelial surface seem to be consistent in both the control and experimental groups.

Although there were no obvious differences between the experimental and control groups, it should be noted that all corneal buttons were 1-2 days out of the orbit before experimentation began. Furthermore, after eight days in storage, sloughing and loss of the surface cells are to be expected. Thus, ISIS 2302 is not markedly toxic to stored human corneas.

Example 25

Effects of ICAM-1 antisense oligonucleotides (ISIS 9125 and 2105) on allograft rejection

The following study was preformed to determine whether pretreating corneal allografts with the rat ICAM-1 antisense oligonucleotides ISIS 9125 (5'-AGGGCCACTGCTCGTCCACA-3', all 2'-deoxyphosphorothioate) (SEQ ID NO: 86) and ISIS 2105 inhibited corneal allograft rejection. Rejection was induced in rat corneas by removing the corneas from anesthetized donor ACI rats and transplanting them to anesthetized recipient Lewis rats. In this model of corneal transplant rejection, Lewis rat recipients normally produce a rejection reaction within 6-8 days. The cornea transplants were performed after pretreatment of the donor ACI

-90-

corneas with either ISIS 9125 or with vehicle (Optisol™) alone. Under surgical anesthesia (ketamine 80 mg/kg, acepromazine 12 mg/kg), a 3 mm section of cornea was removed from one eye of the recipient rat, without damaging internal eye structures. Using
5 the operating microscope, the donor corneal allograft was fitted over the recipient's corneal opening, and 8 to 12 sutures placed aseptically to secure the corneal allograft. Once sutures were in place, the anterior chamber was re-inflated using sterile saline, and tobramycin antibiotic ointment with dexamethasone was applied
10 to the surgical site. The animals were allowed to recover and respiration and behavior were monitored. Some donor corneas were incubated in OPTISOL™ containing 400 µg/ml ISIS 9125 for 24 hours before transplantation.

Rats were examined post-op by slit lamp and rejection was
15 based on the MacDonald-Shadduck scale modified for corneal graft rejection. Rejection criteria included corneal opacity, neovascularization, keratic precipitates and conjunctival inflammation. Following rejection, corneas were harvested for examination under light microscopy (H&E) and SEM. Some corneas
20 were harvested on post-op day 3 for histologic examination. Confocal microscopy was used to document epithelial and endothelial changes *in vivo*.

Corneas transplanted immediately after removal from donor rats rejected an average of 5.94 days (range 4-8 days), while
25 those treated with topical steroid lasted an average of 8.40 days (range 6-11 days). The group whose corneas were incubated in OPTISOL™ for 24 hours rejected an average of 4.80 days (range 3-7 days). Those whose corneas were incubated in OPTISOL™ plus ISIS 9125 for 24 hours rejected an average of 6.33 days (range 6-10
30 days). By day 3 post-surgery, the ISIS 9125 plus OPTISOL™ group was graded 50% better than the OPTISOL™ alone group for cornea opacity and neovascularization; however, the ISIS 9125 group had more corneal edema than the OPTISOL™ alone group.

A similar procedure was used with ISIS 2105 as the antisense
35 oligonucleotide. The percent of allograft recipients showing no

-91-

signs of rejection 3 days post-op in category is shown in Table 8.

Table 8

PERCENT OF ALLOGRAFT RECIPIENTS SHOWING NO SIGNS OF REJECTION 3
DAYS POST-OP IN CATEGORY

Examination item	No pre/post treatment	Post-op steroids alone	24 hr pre-op Optisol storage alone	24 hr pre-op ISIS/Optisol storage
Conjunctival congestion	100	100	100	100
Conjunctival discharge	88	100	100	100
Iris	100	100	100	100
Graft opacity	44	67	50	80
Graft edema	25	33	0	40
Graft neovascularization	0	67	50	100
Graft staining	94	83	100	100
Keratic precipitates	100	100	100	100

The data show the ability of ISIS 9125 and 2105 to inhibit corneal rejection. Data with steroids, which increased days to rejection by 30%, confirms the validity of the transplant model. ISIS 9125 increased days to rejection by 25% over the 24 hour OPTISOL™ incubation control group. More subtle signs of inflammation were documented *in vivo* by confocal microscopy than could be detected by slit lamp. Although the allograft experiments were conducted with ISIS 9125, the use of other antisense oligonucleotides targeted to cellular adhesion molecules, particularly ICAM-1, VCAM-1 and ELAM-1, for inhibiting corneal allograft rejection is also within the scope of the present invention. The ability of any antisense oligonucleotide targeted to a cell adhesion molecule to inhibit corneal allograft rejection can be easily determined without undue experimentation by using the protocols

-92-

described in the present application.

Example 26

Design and screening of duplexed antisense compounds targeting 5 ICAM-1, VCAM-1 or ELAM-1

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target ICAM-1, VCAM-1 or ELAM-1. The nucleobase sequence of the
10 antisense strand of the duplex comprises at least a portion of an oligonucleotide to ICAM-1, VCAM-1 or ELAM-1 as described herein. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the
15 complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. For example, a duplex comprising an
20 antisense strand having the sequence CGAGAGGCGGACGGGACCG (SEQ ID NO:87) and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

```

      cgagaggcggacgggaccgTT (SEQ ID NO:88) Antisense Strand
      |||||
25  TTgctctccgcctgccctggc (SEQ ID NO:89) Complement

```

In another embodiment, a duplex comprising an antisense strand having the same sequence CGAGAGGCGGACGGGACCG may be prepared with blunt ends (no single stranded overhang) as shown:

```

30      cgagaggcggacgggaccg      Antisense Strand
      |||||
      gctctccgcctgccctggc      Complement

```

35 RNA strands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, CO). Once synthesized, the complementary strands are

-93-

annealed. The single strands are aliquoted and diluted to a concentration of 50 uM. Once diluted, 30 uL of each strand is combined with 15uL of a 5X solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume is 75 uL. This solution is incubated for 1 minute at 90°C and then centrifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes are used in experimentation. The final concentration of the dsRNA duplex is 20 uM. This solution can be stored frozen (-20°C) and freeze-thawed up to 5 times.

Once prepared, the duplexed antisense compounds are evaluated for their ability to modulate ICAM-1, VCAM-1 or ELAM-1 expression according to the protocols described herein.

Example 27

Design of phenotypic assays and *in vivo* studies for the use of HCV inhibitors

Phenotypic assays

Once ICAM-1, VCAM-1 or ELAM-1 inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition.

Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of ICAM-1, VCAM-1 or ELAM-1 in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, OR; Perkin-Elmer, Boston, MA), protein-based assays including enzymatic assays (Panvera, LLC, Madison, WI; BD Biosciences, Franklin Lakes, NJ; Oncogene Research Products, San Diego, CA), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs

-94-

Inc., Ann Arbor, MI), triglyceride accumulation (Sigma-Aldrich, St. Louis, MO), angiogenesis assays, tube formation assays, cytokine and hormone assays and metabolic assays (Chemicon International Inc., Temecula, CA; Amersham Biosciences, Piscataway, NJ).

In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with HCV inhibitors identified from the *in vitro* studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest. Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the ICAM-1, VCAM-1 or ELAM-1 inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

Example 28

dsRNA molecules targeting human ICAM-1

A series of double stranded RNA molecules targeting human ICAM_1 (GenBank Accession Number J03132.1, SEQ ID NO: 90) was designed as shown in Table 9 and prepared according to the methods described above. The oligonucleotide listed in the table is the

-95-

antisense strand (shown in the 5' to 3' orientation). The complement of this strand is the sense strand. In all of the RNA compounds described herein, and listed in the various tables, it will be understood that the bases listed as thymidines (T) are, in fact, uridines (U). The corresponding single stranded 5-10-5 MOE gapmer deoxyribonucleotides (all cytidines modified with 5-methyl cytidines) were also tested to compare the activity of the single stranded and double stranded compounds.

RNA inhibition was measured in human T24 cells. The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in real-time quantitative polymerase chain reaction (PCR).

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Table 9: dsRNA molecules targeting human ICAM-1

ISIS #	TARGET SITE	SEQUENCE	%INHIB (DS)	%INHIB (SS)	SEQ ID NO
121725	8	Agaggagctcagcgctcgact	0	0	91
121726	33	Ggctgaggttgcaactctga	0	27	92
121727	256	Ccaggcaggagcaactcctt	0	57	93
121728	321	Ttgaatagcacattgggttg	8	14	94
121729	422	Gccactggctgccaagagg	18	0	95
121730	571	Tctctcctcaccagcaccgt	0	32	96

121731	674	Aaaggtctggagctggtagg	46	0	97
121732	732	Gcgtgtccacctctaggacc	9	15	98
121733	801	Ccagtgccaggtggacctgg	22	0	99
121734	921	Ccagtattactgcacacgtc	32	72	100
121735	1002	Cctctggcttcgtcagaatc	0	0	101
121736	1121	Ggtggccttcagcaggagct	10	28	102
121737	1221	Catacaggacacgaagctcc	57	25	103
121738	1341	Catcctttagacacttgagc	41	20	104
121739	1421	gctcctggccccgacagaggtt	5	7	105
121740	1501	Gctaccacagtgatgatgac	35	37	106
121741	1622	Ttgtgtgttcgggtttcatgg	57	29	107
121742	1633	Ggagggcgtggcttgtgtgtt	2	18	108
121743	1654	Cctgtcccgggataggttca	23	0	109
121744	1666	Cgaggaagaggccctgtccc	51	14	110
121745	1711	Tccactctgttcagtgtggc	23	37	111
121746	1781	Tctgactgaggacaatgccc	61	58	112
121747	1818	Taggtgtgcaggtaccatgg	73	55	113
121748	1924	cctctcatcaggetagactt	50	46	114
121749	1971	Ccagttgtatgtcctcatgg	56	58	115
121750	2012	Gggcctcagcataccaata	43	37	116
121751	2056	Atgctacacatgtctatgga	63	39	117
121752	2100	Gcccaagctggcatccgtca	29	57	118
121753	2103	Agtgcccaagctggcatccg	25	39	119
121754	2221	Gctccgtgaggccagagacc	7	42	120
121755	2291	Caggcactctcctgcagtgt	3	26	121
121756	2341	Gaaaggcaggttggccaatg	29	32	122
121757	2417	Ggtaatctctgaacctgtga	35	54	123
121758	2531	Gtccagacatgaccgctgag	34	45	124
121759	2619	Ctggagctgcaatagtgcaa	5	22	125
121760	2731	Tacacatacacacacacaca	8	54	126
121761	2831	Gctgaggtgggaggatcact	45	57	127
121762	2871	Ggtgtggtgtgtgagccta	42	67	128
121763	2944	Ctaacacaaaggaagtctgg	48	59	129
121764	2104	Cagtgcccaagctggcatcc	41	60	130

-97-

297862	225	Ggtctctatgcccacaactt	ND	ND	131
297863	282	Cagttcatacaccttcgggtt	ND	ND	132
297880	1642	Gtacgtgctgaggcctgcatt	ND	ND	133
348163	1781	Tctgactgaggacaatgccc	ND	ND	134
348164	1781	Tctgactgaggacaatgccc	ND	ND	135
348166	1818	Taggtgtgcaggtaccatgg	ND	ND	136
348167	1818	taggtgtgcaggtaccatgg	ND	ND	137

Example 29**Real-time quantitative PCR analysis of ICAM-1 mRNA levels**

5 Quantitation of ICAM-1 mRNA levels was determined by real-time quantitative PCR using the ABI PRISMJ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput

10 quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide

15 probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA,

20 obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target

25 sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the

-98-

probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISMJ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMANJ buffer A, 5.5 mM $MgCl_2$, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLDJ, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLDJ, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). Probes and primers to human ICAM-1 were designed to hybridize to a human Survivin sequence, using published sequence information (GenBank accession number J03132.1, incorporated herein as SEQ ID NO: 138). For human ICAM-1 the PCR primers were:

forward primer: CATAGAGACCCCGTTGCCTAAA (SEQ ID NO: 139)

reverse primer: TGGCTATCTTCTTGACATTGC (SEQ ID NO: 140) and the

PCR probe was: FAM- CTCCTGCCTGGGAACAACCGGAAX

-TAMRA (SEQ ID NO: 141) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

ISIS 121747 (SEQ ID NO: 113) was chosen for further study. A dose response experiment was done in T24 cells using 10, 25, 50, 100 and 200 nM antisense oligonucleotide or corresponding dsRNA.

-99-

The results are shown in Table 10.

Table 10

Conc. (nM)	% INHIB (ss)	% INHIB (ds)
10	21	47
25	46	60
50	62	72
100	80	81
200	85	81

5

Both the ss and ds compounds inhibited expression of ICAM-1 in a dose-dependent manner, with the ds RNA compound exhibiting greater inhibition at all doses tested with the exception of 200 nM.

10 The dsRNA corresponding to ISIS 2302 (SEQ ID NO: 22) was also tested in T24 cells at 0.5 nM, 5 nM and 50 nM. mRNA levels were measured by Northern blot. Inhibition of mRNA production was 10%, 7% and 20% at these three oligonucleotide concentrations, respectively.

15 ISIS 121734 (SEQ ID NO:100) (dsRNA) was also tested in T24 cells at 50 nM, 100 nM and 200 nM and inhibited ICAM-1 mRNA expression by 40%, 75% and 58%, respectively.

ISIS 121734 was also tested in a dose response experiment in human T47D breast carcinoma cells. (American Type
20 Culture Collection, Manassas VA). T47D cells were cultured in MEM High glucose media supplemented with 10% FBS (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

Cells were plated at 20,000 cells per well for MCF-7 and
25 T47D cells, and allowed to attach to wells overnight. Plates used were 96 well Costar plate 1603 (black sides, transparent bottom). mRNA levels were determined by real-time quantitative polymerase chain reaction (PCR).

Example 30

-100-

Mouse model of allergic inflammation

In the mouse model of allergic inflammation, mice were sensitized and challenged with aerosolized chicken ovalbumin (OVA). Airway responsiveness was assessed by inducing airflow obstruction with a methacholine aerosol using a noninvasive method. This methodology utilized unrestrained conscious mice that are placed into the main chamber of a plthysmograph (Buxco Electronics, Inc., Troy, NY). Pressure differences between this chamber and a reference chamber were used to extrapolate minute volume, breathing frequency and enhanced pause (Penh). Penh is a dimensionless parameter that is a function of total pulmonary airflow in mice (i.e., the sum of the airflow in the upper and lower respiratory tracts) during the respiratory cycle of the animal. The lower the Penh, the greater the airflow. This parameter closely correlates with lung resistance as measured by traditional invasive techniques using ventilated animals (Hamelmann et al., *Proc. Natl. Acad. Sci. U.S.A.* **94**:1350-1355, 1997). Dose-response data were plotted as raw Penh values to increasing concentrations of methacholine. This system was used to test the efficacy of antisense oligonucleotides targeted to ICAM-1.

There are several important features common to human asthma and the mouse model of allergic inflammation. One of these is pulmonary inflammation, in which cytokine expression and Th2 profile is dominant. Another is goblet cell hyperplasia with increased mucus production. Lastly, airway hyperresponsiveness (AHR) occurs resulting in increased sensitivity to cholinergic receptor agonists such as acetylcholine or methacholine. The compositions and methods of the present invention may be used to treat AHR and pulmonary inflammation, particularly asthma.

Ovalbumin-induced allergic inflammation

Balb/c mice (Charles Rivers Laboratory, Taconic Farms, NY), 8-10 weeks of age, weighing about 25 g each, were maintained in micro-isolator cages housed in a specific pathogen-free (SPF)

-101-

facility. The sentinel cages within the animal colony surveyed negative for viral antibodies and the presence of known mouse pathogens. Mice were sensitized and challenged with aerosolized chicken OVA. Briefly, 20 µg alum-precipitated OVA was injected intraperitoneally on days 0 and 14. On day 24, 25 and 26, the animals were exposed for 20 minutes to 1.0% OVA (in saline) by nebulization. The challenge was conducted using an ultrasonic nebulizer (PulmoSonic, The DeVilbiss Co., Somerset, PA). Animals were analyzed about 24 hours following the last nebulization using the Buxco electronics Biosystem. Lung function (Penh), lung histology (cell infiltration and mucus production) inflammation (BAL cell type & number) and spleen weight were determined.

Oligonucleotide administration

Antisense oligonucleotides (ASOs) were dissolved in saline and used to intratracheally dose mice every day, four times per day, from days 15-26 of the OVA sensitization and challenge protocol. There were 10 mice/group for Penh and 4 mice/group for bronchoalveolar (BAL) fluid cell type (neutrophil) analysis. The naïve and vehicle groups had 8 mice/group. The only group not sensitized with OVA was naïve mice. Specifically, the mice were anesthetized with isofluorane and placed on a board with the front teeth hung from a line. The nose was covered and the animal's tongue was extended with forceps and 25 µl of various doses of ASO, or an equivalent volume of saline (control) was placed at the back of the tongue until inhaled into the lung. On day 28, lung function measurements (Penh) were taken. The ICAM-1 oligonucleotides used were ISIS 13315 (5'-TGCATCCCCCAGGCCACCAT-3'; SEQ ID NO: 142) and ISIS 17481 (5'-TCCACAGCAGCTTGACGA-3'; SEQ ID NO: 143). ISIS 13315 contains only phosphorothioate linkages, has 2'-MOE modifications at nucleobases 1-8 and 19, and the cytidines at nucleobases 3, 6, 7 and 8 are 5-methyl cytidines. ISIS 17481 contains only phosphorothioate linkages, has 2'-MOE modifications at nucleobases 13-20, and all cytidines

-102-

are 5-methyl cytidines. The treatment groups are shown in Table 11:

Table 11

5

Groups	Treatment	Dose (mg/kg)	Day 26 sac (BAL)	Day 27 sac (PD)	Day 28 sac (Penh)
1. (N=14)	ISIS 13315	0.03	N=4		N=10
2. (N=14)	ISIS 13315	0.3	N=4		N=10
3. (N=18)	ISIS 13315	3	N=4	N=4	N=10
4. (N=14)	ISIS 17481	0.03	N=4		N=10
5. (N=14)	ISIS 17481	0.3	N=4		N=10
6. (N=18)	ISIS 17481	3	N=4	N=4	N=10
7. (N=18)	vehicle	0	N=4	N=6	N=10
8. (N=18)	Naïve	0	N=4	N=6	N=10

BAL=bronchiolar lavage, PD=pharmacodynamics, Penh=pulmonary airflow

10 Example 31

Collection of bronchial alveolar lavage (BAL) fluid

Animals were injected with a lethal dose of ketamine, the trachea was exposed and a cannula was inserted and secured by sutures. The lungs were lavaged twice with 0.5 ml aliquots of ice cold PBS with 0.2% FCS. The recovered BAL fluid was centrifuged at 1,000 rpm for 10 min at 4°C, frozen on dry ice and stored at -80°C until used. Luminex was used to measure cytokine levels in BAL fluid and serum.

-103-

Example 32**BAL cell counts and differentials**

Cytospins of cells recovered from BAL fluid were prepared using a Shandon Cytospin 3 (Shandon Scientific LTD, Cheshire, England). Cell differentials were performed from slides stained with Leukostat (Fisher Scientific, Pittsburgh, PA). Total cell counts were quantified by hemocytometer and, together with the percent type by differential, were used to calculate specific cell number.

Results of Intratracheal oligonucleotide administration:

The results show a pronounced decrease in Penh after administration of each oligonucleotide which translates to decreased airway hyperresponsiveness in mice after intratracheal administration (Figure 17). As shown in Fig. 22, treatment with ISIS 13315 or ISIS 17481 following allergen (OVA) challenge in the mouse model of asthma reduces the airway response to methacholine (MCH, 100 mg/ml), with ISIS 13315 showing a more pronounced effect. The Penh value in ISIS 13315-treated mice was statistically the same as naïve mice which were not sensitized with the allergen or treated with the antisense oligonucleotide. ISIS 17481 decreased the Penh by one-third at a dose of 3 mg/kg compared to vehicle-treated mice. This shows that ICAM-1 antisense oligonucleotide-treated mice had significantly better airflow, and less inflammation, than mice which were not treated with the antisense oligonucleotide.

The effect of ICAM-1 antisense oligonucleotides on eosinophil and neutrophil recruitment, as measured from BAL fluid, is shown in Figures 18 and 19. Compared to vehicle treated mice, ICAM-1 antisense oligonucleotide-treated mice exhibited reduced number of eosinophils and neutrophils, cells which promote the inflammatory response. The reduction in the

-104-

number of eosinophils by ISIS 13315 and ISIS 17481 was similar (Fig. 18). Both antisense oligonucleotides also resulted in decreased numbers of neutrophils in the BAL fluid, with ISIS 13315 exhibiting a greater effect than ISIS 17481 (Fig. 19).

5 Since increased numbers of eosinophils result from inflammation, this provides further support for the anti-inflammatory properties of ICAM-1 antisense oligonucleotides, particularly in airway and pulmonary inflammatory disorders such as asthma.

10 In summary, ISIS 13315 and 17481 resulted in an inhibition of airway hypersensitivity, reduced eosinophilia and reduced neutrophilia.

15 The combined use of antisense oligonucleotide(s) targeted to ICAM-1 with one or more conventional asthma medications including, but not limited to, montelukast sodium (Singulair™), albuterol, beclomethasone dipropionate, triamcinolone acetonide, ipratropium bromide (Atrovent™), flunisolide, fluticasone propionate (Flovent™) and other steroids is also contemplated.

20 **Example 33**

Primate *Ascaris* asthma model

 Inhalation of *Ascaris suum* antigen by allergic cynomolgus monkeys exposed to *Ascaris suum* in the wild causes an immediate bronchoconstriction and delayed allergic reaction, including a pulmonary inflammatory infiltrate. This model is described in Turner et al. (*J. Clin. Invest.* **97**:381-387, 1996) and Hart et al., *J. Allergy Clin. Immunol.* **108**:250-257, 2001). Cynomolgus monkeys (n=5 per treatment group) were administered increasing doses of aerosolized methacholine (0.0625, 0.125, 1.0, 4.0, 16.0 and 64.0 mg/ml) to determine a baseline, airway resistance measurements (impedance) and BAL. As described for the ova-induced mouse model, increasing concentrations of methacholine result in increased airway resistance. Monkeys were challenged three and four days after the baseline methacholine dose response at a dose which increased airway resistance by 100-200%. 24 hours later,

25
30
35

-105-

another methacholine dose response and BAL were performed at the concentrations listed for the baseline experiment. Experimental animals received 2 mg/kg of aerosolized ICAM-1 antisense oligonucleotide ISIS 10984 (5'-GCCCAAGCTGGCATCCATCA-3'; SEQ ID NO: 144) for four days of treatment: two days and one day prior to antigen challenge and immediately before the two antigen challenges. Monkeys were anesthetized, intubated and maintained on a ventilator for each procedure. ISIS 10984 contains all phosphorothioate linkages.

The minimum response was the 16 mg/ml dose of methacholine for a good responder, and 4 mg/ml for an excellent responder. The results are shown in Fig. 20. In the figure, methacholine doses increase 4 fold; every 10 min. another dose of methacholine is aerosolized; and minimal is defined as that response that elicits at least a 40-50% increase in airway resistance during baseline conditions (pre-antigen). The results show that pretreatment of aerosolized ICAM-1 antisense oligonucleotide (ISIS 10984) significantly reduces airway impedance (resistance) in cynomolgus monkeys at all methacholine concentrations tested. The effect of pretreatment with ISIS 10984 on bronchial cell influx in BAL was also determined 24 hours after two consecutive day antigen challenge in *Ascaris* sensitive cynomolgus monkeys. Pretreatment had no effect on polymorphonuclear cells (PMNs), macrophages or eosinophils following *Ascaris suum* challenge.

Two other oligonucleotides suitable for use in the present invention are ISIS 15839 (5'-GCCCAAGCTGGCATCCGTCA-3'; SEQ ID NO: 145; all phosphorothioate linkages; all cytidines are 5-methyl cytidines, nucleobases 13-20 comprise 2'-MOE modifications) and ISIS 15537 (5'-TCTGAGTAGCAGAGGAGCTC-3'; SEQ ID NO: 146; all phosphorothioate linkages; all cytidines are 5-methyl cytidines; all nucleobases comprise 2'-MOE modifications).

-106-

What is claimed is:

1. An RNA compound between about 8 and 50 nucleobases in length targeted to human ICAM-1 mRNA, wherein said compound specifically hybridizes with said human ICAM-1 mRNA and inhibits the expression of human ICAM-1 mRNA.
2. The compound of claim 2 comprising between about 12 and 50 nucleobases in length.
3. The compound of claim 2 comprising between about 15 and 30 nucleobases in length.
4. The compound of claim 2, wherein said compound comprises SEQ ID NO: 22.
5. The compound of claim 2, wherein said compound is double stranded.
6. A double stranded RNA compound having SEQ ID NO:22
7. A method for treating airway hyperresponsiveness or pulmonary inflammation in an individual in need thereof, comprising administering to said individual an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding ICAM-1 protein to said individual.
8. The method of claim 7, wherein said antisense compound is an antisense oligonucleotide.
9. The method of claim 8, wherein at least one covalent linkage of said antisense compound is a modified covalent linkage.
10. The method of claim 8, wherein at least one nucleotide of said antisense compound has a modified sugar moiety.
11. The method of claim 8, wherein at least one nucleotide of

-107-

said antisense compound has a modified nucleobase.

12. The method of claim 8, further comprising administering an anti-asthma medication to said individual.
13. The method of claim 8 wherein said antisense compound comprises at least one lipophilic moiety which enhances the cellular uptake of said antisense compound.
14. The method of claim 8, wherein said antisense compound is aerosolized and inhaled by said individual.
15. The method of claim 8, wherein said antisense compound is administered intranasally, intrapulmonarily or intratracheally.
16. The method of claim 8, wherein said airway hyperresponsiveness or pulmonary inflammation is associated with asthma.
17. A pharmaceutical composition comprising an antisense oligonucleotide targeted to nucleic acid encoding ICAM-1 in a formulation suitable for intranasal, intrapulmonary or intratracheal administration.
18. The pharmaceutical composition of claim 17, wherein said composition is in a metered dose inhaler or nebulizer.

GCTATAAGGA TCACGGGCCC CAGTCGACGC TGAGCTCCTC TGCTACTCAG AGTTGCAACC TCAGCCTCGCT
 ATG GCT CCC AGC AGC CCC CGG CTG GCG CTG CTC GCA CTC CTG GTC CTG GCG GCT CTG TTC CCA
 MET ALA PRO SER SER PRO ARG PRO ALA LEU PRO ALA LEU LEU VAL LEU LEU GLY ALA LEU PHE PRO
 GGA CCT GGC AAT GCC CAG ACA TCT GTG TCC CCC TCA AAA GTC ATC CTG CCC CGG GGA GGC TCC GTG
 GLY PRO GLY ASN ALA GLN THR SER VAL SER PRO SER LYS VAL ILE LEU PRO ARG GLY GLY SER VAL
 CTG GTG ACA TGC AGC ACC TCC TGT GAC CAG CCC AAG TTG TTG GGC ATA GAG ACC CCG TTG CCT AAA
 LEU VAL THR CYS SER THR SER CYS ASP GLN PRO LYS LEU LEU GLY ILE GLU THR PRO LEU PRO LYS
 AAG GAG TTG CTC CTG CCT GCG AAC AAC CGG AAG GTG TAT GAA CTG AGC AAT GTG CAA GAA GAT AGC
 LYS GLU LEU LEU LEU PRO GLY ASN ASN ARG LYS VAL TYR GLU LEU SER ASN VAL GLN GLU ASP SER
 CAA CCA ATG TGC TAT TCA AAC TGC CCT GAT GCG CAG TCA ACA GCT AAA ACC TTC CTC ACC GTG TAC
 GLN PRO MET CYS TYR SER SER ASN CYS PRO ASP GLY GLN SER THR ALA LYS THR PHE LEU THR VAL TYR
 TGG ACT CCA GAA CGG GTG GAA CTG GCA CCC CTC CCC TCT TGG CAG CCA GTG GGC AAG AAC CTT ACC
 TRP THR PRO GLU ARG VAL GLU LEU ALA PRO LEU PRO SER TRP GLN PRO VAL GLY LYS ASN LEU THR
 CTA CGC TGC CAG GTG GAG GGT GCG GCA CCC CGG GCC AAC CTC ACC GTG GTG CTC CGT GGG GAG
 LEU ARG CYS GLN VAL GLU GLY GLY ALA PRO ARG ALA ASN LEU THR VAL LEU LEU ARG GLY GLU
 AAG GAG CTG AAA CGG GAG CCA GCT GTG GCG GAG CCC GCT GAG GTC ACC ACG GTG CTG GTG AGG
 LYS GLU LEU LYS ARG GLU PRO ALA VAL GLY GLU PRO ALA GLU VAL THR THR VAL LEU VAL ARG
 AGA GAT CAC CAT GGA GCC AAT TTC TCG TGC CGC ACT GAA CTG GAC CTG CGG CCC CAA GGG CTG GAG
 ARG ASP HIS HIS GLY ALA ASN PHE SER CYS ARG THR GLU LEU ASP LEU ARG PRO GLN GLY LEU GLU

FIG. 1A

CTG TTT GAG AAC ACC TCG GCC CCC TAC CAG CTC CAG ACC TTT GTC CTG CCA GCG ACT CCC CCA CAA
 LEU PHE GLU ASN THR SER ALA PRO TYR GLN LEU LEU THR PHE VAL LEU PRO ALA THR PRO PRO GLN

 CTT GTC AGC CCC CGG GTC CTA GAG GTG GAC ACG CAG GGG ACC GTG GTC TGT TCC CTG GAC GGG CTG
 LEU VAL SER PRO ARG VAL LEU GLU VAL ASP THR GLN GLY THR VAL VAL CYS SER LEU ASP GLY LEU

 TTC CCA GTC TCG GAG GCC CAG GTC CAC CTG GCA CTG GGG GAC CAG AGG TTG AAC CCC ACA GTC ACC
 PHE PRO VAL SER GLU ALA GLN VAL HIS LEU ALA LEU GLY ASP GLN ARG LEU ASN PRO THR VAL THR

 TAT GGC AAC GAC TCC TTC TCG GCC AAG GCC TCA GTC AGT GTG ACC GCA GAG GAC GAG GGC ACC CAG
 TYR GLY ASN ASP SER PHE SER ALA LYS ALA SER VAL SER VAL THR ALA GLU ASP GLU GLY THR GLN

 CGG CTG ACG TGT GCA GTA ATA CTG GGG AAC CAG AGC CAG GAG ACA CTG CAG ACA GTG ACC ATC TAC
 ARG LEU THR CYS ALA VAL ILE LEU LEU GLY ASN GLN SER VAL SER GLN GLU THR LEU GLN THR VAL THR ILE TYR

 AGC TTT CCG GCG CCC AAC GTG ATT CTG ACG AAG CCA GAG GTC TCA GAA GGG ACC GAG GTG ACA GTG
 SER PHE PRO ALA PRO ASN VAL ILE LEU THR LYS PRO GLU VAL SER GLU GLY THR GLU VAL THR VAL

 AAG TGT GAG GCC CAC CCT AGA GCC AAG GTG ACG CTG AAT GGG GTT CCA GCC CAG CCA CTG GGC CCG
 LYS CYS GLU ALA HIS PRO ARG ALA LYS VAL THR LEU ASN GLY VAL PRO ALA GLN PRO LEU GLY PRO

 AGG GCC CAG CTC CTG AAG GCC ACC CCA GAG GAC AAC GGG CGC AGC TTC TCC TCC TCT GCA ACC
 ARG ALA GLN LEU LEU LEU LYS ALA THR PRO GLU ASP ASN GLY ARG SER PHE SER CYS SER ALA THR

 CTG GAG GTG GCC GGC CAG CTT ATA CAC AAG AAC CAG ACC CGG GAG CTT CGT GTC CTG TAT GGC CCC
 LEU GLU VAL ALA GLY GLN LEU ILE HIS LYS ASN GLN THR ARG GLU LEU ARG VAL LEU TYR GLY PRO

 CGA CTG GAC GAG AGG GAT TGT CCG GGA AAC TGG ACG TGG CCA GAA AAT TCC CAG CAG ACT CCA ATG
 ARG LEU ASP GLU ARG ASP CYS PRO GLY ASN TRP THR TRP PRO GLU ASN SER GLN GLN THR PRO MET

 TGC CAG GCT TGG GGG AAC CCA TTG CCC GAG CTC AAG TGT CTA AAG GAT GGC ACT TTC CCA CTG CCC
 CYS GLN ALA TRP GLY ASN PRO LEU PRO GLU LEU LYS CYS LEU LYS ASP GLY THR PHE PRO LEU PRO

FIG. 1B

ATC GGG GAA TCA GTG ACT GTC ACT CGA GAT CTT GAG GGC ACC TAC CTC TGT CGG GCC AGG AGC ACT
ILE GLY GLU SER VAL THR VAL THR ARG ASP LEU GLU GLY THR TYR LEU CYS ARG ALA ARG SER THR

CAA GGG GAG GTC ACC CGC GAG GTG ACC GTG AAT GTG CTC TCC CCC CGG TAT GAG ATT GTC ATC ATC
GLN GLY GLU VAL THR ARG GLU VAL THR VAL ASN VAL LEU SER PRO ARG TYR GLU ILE VAL ILE ILE

ACT GTG GTA GCA GCC GCA ATA ATG GGC ACT GCA GGC CTC AGC ACG TAC CTC TAT AAC CGC CAG
THR VAL VAL ALA ALA VAL ILE MET GLY THR ALA GLY LEU SER THR TYR LEU TYR ASN ARG GLN

CGG AAG ATC AAG AAA TAC AGA CTA CAA CAG GCC CAA AAA GGG ACC CCC ATG AAA CCG AAC ACA CAA
ARG LYS ILE LYS LYS TYR ARG LEU GLN ALA GLN LYS GLY THR PRO MET LYS PRO ASN THR GLN

GCC ACG CCT CCC TGA ACCTATCCCG GGACAGGGCC TCTTCCTCGG CCTTCCCATTA TTGGTGGCAG TGGTGCCACA
ALA THR PRO PRO **

CTGAACAGAG TGGAAAGACAT ATGCCATGCA GCTACACCTA CCGGCCCTGG GACGCCGGAG GACAGGGGCAT TGTCTCAGT

CAGATACAA AGCATTTGGG GCCATGGTAC CTGCACACCT AAAACACTAG GCCACGCATC TGATCTGTAG TCACATGACT

AAGCCAAGAG GAAGGAGCAA GACTCAAGAC ATGATTGATG GATGTTAAAG TCTAGCCTGA TGAGAGGGGA AGTGGTGGG

GAGACATAGC CCCACCATGA GGACATACAA CTGGGAAATA CTGAAACTTG CTGCCCTATTG GGTATGCTGA GGCCACACAGA

CTTACAGAAG AAGTGGGCCCT CCATAGACAT GTGTAGCATC AAAACACAAA GGCCACACACT TCCTGACGGA TGCCAGCTTG

GGCACTGCTG TCTACTGACC CCAACCCCTTG ATGATATGTA TTTATTTCATT TGTATTTTTA CCAGCTATTT ATTGAGTGTC

TTTTATGTAG GCTAAATGAA CATAGGTCTC TGGCCTCAGG GAGCTCCAG TCCATGTAC ATTCAAGGTC ACCAGGTACA

GTTGTACAGG TTGTACACTG CAGGAGAGTG CCTGGCAAAA AGATCAAAATG GGGCTGGGAC TTCTCATTTGG CCAACCTGCC

TTTCCCCAGA AGGAGTGATT TTTCTATCGG CACAAAAGCA CTATATGGAC TGGTAATGGT TCACAGGTTT AGAGATTACC

FIG. 1C

CAGTGAGGCC TTATTCTCTCC CTTCCCCCCCCA AAACTGACAC CTTTGTTAGC CACCTCCCCA CCCACATACA TTTCTGCCAG
TGTTACAATG AACTCAGCG GTCATGTCTG GACATGAGTG CCCAGGGAAT ATGCCCAAGC TATGCCCTTGT CCTCTTGTCC
TGTTTGCATT TCACTGGGAG CTTGCACTAT TGCAGCTCCA GTTTCCTGCA GTGATCAGGG TCCTGCAAGC AGTGGGGAAG
GGGGCCAAGG TATTGGAGGA CTCCCTCCCC GCTTTGGAAG GGTCATCCGC GTGTGTGTGT GTGTGTATGT GTAGACAAGC
TCTCGCTCTG TCACCCAGGC TGGAGTGCAG TGGTGCAATC ATGGTTCACT GCAGTCTTGA CCTTTTGGGC TCAAGTGATC
CTCCCACCTC AGCCTCCTGA GTAGCTGGGA CCATAGGCTC ACAACACCAC ACCTGGCAAA TTTGATTTTT TTTTTTTTTT
TCAGAGACGG GGTCTCGCAA CATTGCCCCAG ACTTCCTTIG TGTTAGTTAA TAAAGCTTTC TCAACTGCCA AAAAAAAAAA
AAAAAA

FIG. 1D

FIG. 2A

TTCACATCAA AACTCCTATA CTGACCTGAG ACAGAGGCAG CAGTGATACC CACCTGAGAG ATCCTGTGTT TGA
 ACAACTG CTTCCCAAAA CGGAAAGTAT TTCAAGCCTA AACCTTTGGG TGAAGAAGAC TCTTGAAGTC ATG ATT
 met ile
 GCT TCA CAG TTT CTC TCA GCT CTC ACT TTG GTG CTT CTC ATT AAA GAG AGT GGA GCC TGG
 ala ser gln phe leu ser ala leu thr leu val leu leu ile lys glu ser gly ala trp
 TCT TAC AAC ACC TCC ACG GAA GCT ATG ACT TAT GAT GAG GCC AGT GCT TAT TGT CAG CAA
 ser tyr asn thr ser thr glu ala met thr tyr asp glu ala ser ala tyr cys gln gln
 AGG TAC ACA CAC CTG GTT GCA ATT CAA AAC AAA GAA GAG ATT GAG TAC CTA AAC TCC ATA
 arg tyr thr his leu val ala ile gln asn lys glu glu ile glu tyr leu asn ser ile
 TTG AGC TAT TCA CCA AGT TAT TAC TGG ATT GGA ATC AGA AAA GTC AAC AAT GTG TGG GTC
 leu ser tyr ser pro ser tyr tyr trp ile gly ile arg lys val asn asn val trp val
 TGG GTA GGA ACC CAG AAA CCT CTG ACA GAA GAA GCC AAG AAC TGG GCT CCA GGT GAA CCC
 trp val gly thr gln lys pro leu thr glu glu ala lys asn trp ala pro gly glu pro
 AAC AAT AGG CAA AAA GAT GAG GAC TGC GTG GAG ATC TAC ATC AAG AGA GAA AAA GAT GTG
 asn asn arg gln lys asp glu asp cys val glu ile tyr ile lys arg glu lys asp val
 GGC ATG TGG AAT GAT GAG AGG TGC AGC AAG AAG AAG CTT GCC CTA TGC TAC ACA GCT GCC
 gly met trp asn asp glu arg cys ser lys lys lys leu ala leu cys tyr thr ala ala
 TGT ACC AAT ACA TCC TGC AGT GGC CAC GGT GAA TGT GTA GAG ACC ATC AAT AAT TAC ACT
 cys thr asn thr ser cys ser gly his gly glu cys val glu thr ile asn asn tyr thr
 TGC AAG TGT GAC CCT GGC TTC AGT GGA CTC AAG TGT GAG CAA ATT GTG AAC TGT ACA GCC
 cys lys cys asp pro gly phe ser gly leu lys cys glu gln ile val asn cys thr ala

CTG GAA TCC CCT GAG CAT GGA AGC CTG GTT TGC AGT CAC CCA CTG GGA AAC TTC AGC TAC
 leu glu ser pro glu his gly ser leu val cys ser his pro leu gly asn phe ser tyr

 AAT TCT TCC TGC TCT ATC AGC TGT GAT AGG GGT TAC CTG CCA AGC ATG GAG ACC ATG
 asn ser ser cys ser ile ser cys asp arg gly tyr leu pro ser ser met glu thr met

 CAG TGT ATG TCC TCT GGA GAA TGG AGT GCT CCT ATT CCA GCC TGC AAT GTG GTT GAG TGT
 gln cys met ser ser gly glu trp ser ala pro ile pro ala cys asn val val glu cys

 GAT GCT GTG ACA AAT CCA GCC AAT GGG TTC GTG GAA TGT TTC CAA AAC CCT GGA AGC TTC
 asp ala val thr asn pro ala asn gly phe val glu cys phe gln asn pro gly ser phe

 CCA TGG AAC ACA ACC TGT ACA TTT GAC TGT GAA GAA GGA TTT GAA CTA ATG GGA GCC CAG
 pro trp asn thr thr cys thr phe asp cys glu glu gly phe glu leu met gly ala gln

 AGC CTT CAG TGT ACC TCA TCT GGG AAT TGG GAC AAC GAG AAG CCA ACG TGT AAA GCT GTG
 ser leu gln cys thr ser ser gly asn trp asp asn glu lys pro thr cys lys ala val

 ACA TGC AGG GCC GTC CGC CAG CCT CAG AAT GGC TCT GTG AGG TGC AGC CAT TCC CCT GCT
 thr cys arg ala val arg gln pro gln asn gly ser val arg cys ser his ser pro ala

 GGA GAG TTC ACC TTC AAA TCA TCC TGC AAC TTC ACC TGT GAG GAA GGC TTC ATG TTG CAG
 gly glu phe thr phe lys ser ser cys asn phe thr cys glu glu gly phe met leu gln

 GGA CCA GCC CAG GTT GAA TGC ACC ACT CAA GGG CAG TGG ACA CAG CAA ATC CCA GTT TGT
 gly pro ala gln val glu cys thr thr gln gly gln trp thr gln gln ile pro val cys

 GAA GCT TTC CAG TGC ACA GCC TTG TCC AAC CCC GAG CGA GGC TAC ATG AAT TGT CTT CCT
 glu ala phe gln cys thr ala leu ser asn pro glu arg gly tyr met asn cys leu pro

FIG. 2B

AGT GCT TCT GGC AGT TTC CGT TAT GGG TCC AGC TGT GAG TTC TCC TGT GAG CAG GGT TTT
 ser ala ser gly ser phe arg tyr gly ser ser cys ser cys glu phe ser cys glu gln gly phe

 GTG TTG AAG GGA TCC AAA AGG CTC CAA TGT GGC CCC ACA GGG GAG TGG GAC AAC GAG AAG
 val leu lys gly ser lys arg leu gln cys gly pro thr gly glu trp asp asn glu lys

 CCC ACA TGT GAA GCT GTG AGA TGC GAT GCT GTC CAC CAG CCC CCG AAG GGT TTG GTG AGG
 pro thr cys glu ala val arg cys asp ala val his gln pro pro lys gly leu val arg

 TGT GCT CAT TCC CCT ATT GGA GAA TTC ACC TAC AAG TCC TCT TGT GCC TTC AGC TGT GAG
 cys ala his ser pro ile gly glu phe thr tyr lys ser ser cys ala phe ser cys glu

 GAG GGA TTT GAA TTA TAT GGA TCA ACT CAA CTT GAG TGC ACA TCT CAG GGA CAA TGG ACA
 glu gly phe glu leu leu tyr gly ser thr gln leu glu cys thr ser gln gly gln trp thr

 GAA GAG GTT CCT TCC TGC CAA GTG GTA AAA TGT TCA AGC CTG GCA GTT CCG GGA AAG ATC
 glu glu val pro ser cys gln val val lys cys ser ser leu ala val pro gly lys ile

 AAC ATG AGC TGC AGT GGG GAG CCC GTG TTT GGC ACT GTG TGC AAG TTC GCC TGT CCT GAA
 asn met ser cys ser gly glu pro val phe gly thr val cys lys phe ala cys pro glu

 GGA TGG ACG CTC AAT GGC TCT GCA CCT CGG ACA TGT GGA GCC ACA GGA CAC TGG TCT GGC
 gly trp thr leu asn gly ser ala ala arg thr cys gly ala thr gly his trp ser gly

 CTG CTA CCT ACC TGT GAA GCT CCC ACT GAG TCC AAC ATT CCC TTG GTA GCT GGA CTT TCT
 leu leu pro thr cys glu ala pro thr glu ser asn ile pro leu val ala gly leu ser

 GCT GCT GGA CTC TCC CTC CTG ACA TTA GCA CCA TTT CTC CTC TGG CTT CGG AAA TGC TTA
 ala ala gly leu ser leu leu thr leu ala pro phe leu leu trp leu arg lys cys leu

 CGG AAA GCA AAG AAA TTT GTT CCT GCC AGC AGC TGC CAA AGC CTT GAA TCA GAC GGA AGC
 arg lys ala lys lys phe val pro ala ser ser cys gln ser leu glu ser asp gly ser

FIG. 2C

TAC CAA AAG CCT TCT TAC ATC CTT TAA GTTCAA AGAATCAGAA ACAGGTGCAT CTGGGGAAC T A
tyr gln lys pro ser tyr ile leu ***

GAGGATAC ACTGAAGTTA ACAGAGACAG ATAACTCTCC TCGGGTCTCT GGCCCTTCTT GCCTACTATG CCAG
ATGCCCT TTATGGCTGA AACCGCAACA CCCATCACCA CTTCAATAGA TCAAAGTCCA GCAGGCAAGG ACGGCCT
TCA ACTGAAAAAGA CTCAGTGTTT CCTTTCCTAC TCTCAGGATC AAGAAAGTGT TGGCTAATGA AGGGAAGGA
TATTTTCTTC CAAGCAAAGG TGAAGAGACC AAGACTCTGA AATCTCAGAA TTCCTTTTCT AACTCTCCCT TG
CTCGCTGT AAAATCTTGG CACAGAAACA CAATATTTTG TGGCTTCTT TCTTTTGCCC TTCACAGTGT TTCGA
CAGCT GATTACACAG TTGCTGTCAT AAGAATGAAT AATAATPATC CAGAGTTTAG AGGAAAAAAA TGAATAA
AA TATTATAACT TAAAAAAATG ACAGATGTTG AATGCCACA GGCAATGCA TGGAGGGTTG TTAATGGTGC
AAATCCTFACT GAATGCTCTG TCGGAGGGTT ACTATGCACA ATTTAATCAC TTTCATCCCT ATGGGATTC A GTG
CTTCTTA AAGAGTTCTT AAGGATTGTG ATATTTTAC TTGCATTGAA TATATPATAA TCTTCCATAC TTCCTT
ATTC AATACAAAGTG TGGTAGGGAC TTAATAAACT TGTAATGCT GTCAACTATG ATATGGTAAA AGTTACTTA
T TCTAGATTAC CCCCTCATG TTTATTAAACA AATTATGTTA CATCTGTTTT AAATTATTT CAAAAAGGGA A
ACTATTGTC CCTAGCAAG GCATGATGTT AACCAAGATA AAGTTCTGAG TGTTTTACT ACAGTTGTTT TTTG
AAAAA TGGTAGAATT GGAGAGTAAA AACTGAATGG AAGGTTTGT TATTGTCAGA TATTTTTC A GAAATAT
GTG GTTCCACGA TGAATAACTT CCATGAGGCC AAACGTTTG AACTAATAA AGCATAAATG CAAACACACA
AAGGTATAAT TTTATGAATG TCTTTGTTGG AAAAGAATAC AGAAAGATGG ATGTGCTTG CATTCCTACA AA
GATGTTTG TCAGATGTGA TATGTAAACA TAATTCTTGT ATATTATGA AGATTTTAAA TTCACAATAG AAAC T

FIG. 2D

CACCA TGTAAGAAGAG TCATCTGGTA GATTTTAAAC GAATGAAGAT GTCTAATAGT TATTCCTAT TTGTTTTC
TT CTGTATGTTA GGGTGCTCTG GAAAGAGAGGA ATGCCTGTGT GAGCAAGCAT TTATGTTTAT TTATAAGCAG
ATTAAACAAT TCCAAAGGAA TCTCCAGTTT TCAGTTGATC ACTGGCAATG AAAAATTCTC AGTCAGTAAT TGC
CAAAGCT GCTCTAGCCT TGAGGAGTGT GAGAAATCAAA ACTCTCCTAC ACTTCCATTA ACTTAGCATG TGTGTA
AAA AAAAGTTCA GAGAAGTTCT GGCTGAACAC TGGCAACGAC AAAGCCAACA GTCAAAACAG AGATGTGAT
A AGGATCAGAA CAGCAGAGGT TCTTTTAAAG GGCAGAAAA ACTCTGGGAA ATAAGAGAGA ACAACTACTG T
GATCAGGCT ATGTATGGAA TACAGTGTTA TTTTCTTTGA AATTGTTTAA GTGTGTAA TATTATGTA AACT
GCATTA GAAATTAGCT GTGTGAAATA CCAGTGTGGT TTGTGTTTGA GTTTTATTGA GAATTTTAAA TTATAAC
TTA AAATATTTTA TAATTTTAA AGTATATATT TATTAAAGCT TATGTCAGAC CTATTGACA TAACACTATA
AAGGTTGACA ATAAATGTGC TTATGTTT

FIG. 2E

FIG. 3A

CCGGCCCTCAC TGGCTTCAGG AGCTGAATAC CCTCCAGGC ACACACAGGT GGGACACAAA TAAGGGTTTT GGA
 ACCACTA TTTTCTCATC ACGACAGCAA CTTAAA ATG CCT GGG AAG ATG GTC GTG ATC CTT GGA GCC
 met pro gly lys met val val ile leu gly ala
 TCA AAT ATA CTT TGG ATA ATG TTT GCA GCT TCT CAA GCT TTT AAA ATC GAG ACC ACC CCA
 ser asn ile leu trp ile met phe ala ala ser gln ala phe lys ile glu thr thr pro
 GAA TCT AGA TAT CTT GCT CAG ATT GGT GAC TCC GTC TCA TTG ACT TGC AGC ACC ACA GGC
 glu ser arg tyr leu ala gln ile gly asp ser val ser leu thr cys ser thr thr gly
 TGT GAG TCC CCA TTT TTC TCT TGG AGA ACC CAG ATA GAT AGT CCA CTG AAT GGG AAG GTG
 cys glu ser pro phe phe ser trp arg thr gln ile asp ser pro leu asn gly lys val
 ACG AAT GAG GGG ACC ACA TCT ACG CTG ACA ATG AAT CCT GTT AGT TTT GGG AAC GAA CAC
 thr asn glu gly thr thr ser thr leu thr met asn pro val ser phe gly asn glu his
 TCT TAC CTG TGC ACA GCA ACT TGT GAA TCT AGG AAA TTG GAA AAA GGA ATC CAG GTG GAG
 ser tyr leu cys thr ala thr cys glu ser arg lys leu glu lys gly ile gln val glu
 ATC TAC TCT TTT CCT AAG GAT CCA GAG ATT CAT TTG AGT GGC CCT CTG GAG GCT GGG AAG
 ile tyr ser phe pro lys asp pro glu ile his leu ser gly pro leu glu ala gly lys
 CCG ATC ACA GTC AAG TGT TCA GTT GCT GAT GTA TAC CCA TTT GAC AGG CTG GAG ATA GAC
 pro ile thr val lys cys ser val ala asp val tyr pro phe asp arg leu glu ile asp
 TTA CTG AAA GGA GAT CAT CTC ATG AAG AGT CAG GAA TTT CTG GAG GAT GCA GAC AGG AAG
 leu leu lys gly asp his leu met lys ser gln glu phe leu glu asp ala asp arg lys
 TCC CTG GAA ACC AAG AGT TTG GAA GTA ACC TTT ACT CCT GTC ATT GAG GAT ATT GGA AAA
 ser leu glu thr lys ser leu glu val thr phe thr pro val ile glu asp ile gly lys
 GTT CTT GTT TGC CGA GCT AAA TTA CAC ATT GAT GAA ATG GAT TCT GTG CCC ACA GTA AGG
 val leu val cys arg ala lys leu his ile asp glu met asp ser val pro thr val arg

CAG GCT GTA AAA GAA TTG CAA GTC TAC ATA TCA CCC AAG AAT ACA GTT ATT TCT GTG AAT
 gln ala val lys glu leu gln val tyr ile ser pro lys asn thr val ile ser val asn

 CCA TCC ACA AAG CTG CAA GAA GGT GGC TCT GTG ACC ATG ACC TGT TCC AGC GAG GGT CTA
 pro ser thr lys leu gln glu gly ser val thr met thr cys ser ser glu gly leu

 CCA GCT CCA GAG ATT TTC TGG AGT AAG AAA TTA CAT AAT GGG AAT CTA CAG CAC CTT TCT
 pro ala pro glu ile phe trp ser lys lys leu asp asn gly asn leu gln his leu ser

 GGA AAT GCA ACT CTC ACC TTA ATT GCT ATG AGG ATG GAA GAT TCT GGA ATT TAT GTG TGT
 gly asn ala thr leu thr leu ile ala met arg met glu asp ser gly ile tyr val cys

 GAA GGA GTT AAT TTG ATT GGG AAA AAC AGA AAA GAG GTG GAA TTA ATT GTT CAA GCA TTC
 glu gly val asn leu ile gly lys asn arg lys glu val glu leu ile val gln ala phe

 CCT AGA GAT CCA GAA ATC GAG ATG AGT GGT GGC CTC GTG AAT GGG AGC TCT GTC ACT GTA
 pro arg asp pro glu ile glu met ser gly gly leu val asn gly ser ser val thr val

 AGC TGC AAG GTT CCT AGC GTG TAC CCC CTT GAC CGG CTG GAG ATT GAA TTA CTT AAG GGG
 ser cys lys val pro ser val tyr pro leu asp arg leu glu ile glu leu lys gly

 GAG ACT ATT CTG GAG AAT ATA GAG TTT TTG GAG GAT ACG GAT ATG AAA TCT CTA GAG AAC
 glu thr ile leu glu asn ile glu phe leu glu asp thr asp met lys ser leu glu asn

 AAA AGT TTG GAA ATG ACC TTC ATC CCT ACC ATT GAA GAT ACT GGA AAA GCT CTT GTT TGT
 lys ser leu glu met thr phe ile pro thr ile glu asp thr gly lys ala leu val cys

 CAG GCT AAG TTA CAT ATT GAT GAC ATG GAA TTC GAA CCC AAA CAG AGG CAG AGT ACG CAA
 gln ala lys leu his ile asp asp met glu phe glu pro lys gln arg gln ser thr gln

 ACA CTT TAT GTC AAT GTT GCC CCC AGA GAT ACA ACC GTC TTG GTC AGC CCT TCC TCC ATC
 thr leu tyr val asn val ala pro arg asp thr thr val leu val ser pro ser ser ile

 CTG GAG GAA GGC AGT TCT GTG AAT ATG ACA TGC TTG AGC CAG GGC TTT CCT GCT CCG AAA
 leu glu glu gly ser ser val asn met thr cys leu ser gln gly phe pro ala pro lys

FIG. 3B

ATC CTG TGG AGC AGG CAG CTC CCT AAC GGG GAG CTA CAG CCT CTT TCT GAG AAT GCA ACT
ile leu trp ser arg gln leu pro asn gly glu leu gln pro leu ser glu asn ala thr
CTC ACC TTA ATT TCT ACA AAA ATG GAA GAT TCT GGG GTT TAT TTA TGT GAA GGA ATT AAC
leu thr leu ile ser thr lys met glu asp ser gly val tyr leu cys glu gly ile asn
CAG GCT GGA AGA AGC AGA AAG GAA GTG GAA TTA ATT ATC CAA GTT ACT CCA AAA GAC ATA
gln ala gly arg ser arg lys glu val glu leu ile ile gln val thr pro lys asp ile
AAA CTT ACA GCT TTT CCT TCT GAG AGT GTC AAA GAA GGA GAC ACT GTC ATC ATC TCT TGT
lys leu thr ala phe pro ser glu ser val lys glu gly asp thr val ile ile ser cys
ACA TGT GGA AAT GTT CCA GAA ACA TGG ATA ATC CTG AAG AAA AAG GCG GAG ACA GGA GAC
thr cys gly asn val pro glu thr trp ile ile leu lys lys ala glu thr gly asp
ACA GTA CTA AAA TCT ATA GAT GGC GCC TAT ACC ATC CGA AAG GCC CAG TTG AAG GAT GCG
thr val leu lys ser ile asp gly ala tyr thr ile arg lys ala gln leu lys asp ala
GGA GTA TAT GAA TGT GAA TCT AAA AAC AAA GGT GGC TCA CAA TTA AGA AGT TTA ACA CTT
gly val tyr glu cys glu ser lys asn lys val gly ser gln leu arg ser leu thr leu
GAT GTT CAA GGA AGA GAA AAC AAC AAA GAC TAT TTT TCT CCT GAG CTT CTC GTG CTC TAT
asp val gln gly arg glu asn asn lys asp tyr phe ser pro glu leu val leu tyr
TTT GCA TCC TCC TTA ATA ATA CCT GCC ATT GGA ATG ATA ATT TAC TTT GCA AGA AAA GCC
phe ala ser ser leu ile ile pro ala ile gly met ile ile tyr phe ala arg lys ala
AAC ATG AAG GGG TCA TAT AGT CTT GTA GAA GCA CAG AAA TCA AAA GTG TAG CTAATGCTTG
asn met lys gly ser tyr ser leu val glu ala gln lys ser lys val ***
ATATGTTCAA CTGGAGACAC TATTATCTG TGCAATCCT TGATACTGCT CATCATTCCT TGAGAAAAAC AAT
GAGCTGA GAGGCAGACT TCCCTGAATG TATTGAACCT GGAAGAANAAT GCCCATCTAT GTCCCTTGCT GTGAGC
AAGA AGTCAAAGTA AAACTTGCTG CCTGAAGAAC AGTAACTGCC ATCAAGATGA GAGAACTGGA GGAGTTCCT
T GATCTGTATA TACAATAACA TAATTGTGAC ATATGTAAAA TAAATTTATG CCATAGCAAG ATTGCTTAAAA

FIG. 3C

TAGCAACAC TCTATATTTA GATTGTTAAA ATAACTAGTG TTGCTTGGAC TATTATAATT TAATGCATGT TAGG
AAAAAT TCACATTAAT ATTTGCTGAC AGCTGACCTT TGTCACTCTT CTTCTATTTT ATTCCCTTTC ACAAAT
TTT ATTCCCTATAT AGTTTATTGA CAATAATTTC AGGTTTGTGTA AAGATGCCCG GTTTTATATT TTTATAGACA
AATAATAAGC AAAGGGAGCA CTGGGTTGAC TTTCAGGTAC TAAATACCTC AACCTATGGT ATAATGGTTG AC
TGGGTTTC TCTGTATAGT ACTGGCATGG TACGGAGATG TTTCACGAAG TTGTGTCATC AGACTCCCTGT GCAAC
TTTCC CAATGTGGCC TAAAAATGCA ACTTCTTTTT ATTTCTTTTT GTAAATGTTT AGGTTTTTTT GTATAGTA
AA GTGATAATTT CTGGAATTAA AAA

FIG. 3D




FIG. 4






FIG. 5

**FIG. 6A****FIG. 6B**







FIG. 7



● 1570 ○ 3067 ▽ 1931 □ 1932
× 1939 ◇ 2307 △ 2302 ⊗ 1938

FIG. 8

**FIG. 9**



• T_m + % INHIBITION
100 nM OLIGONUCLEOTIDE

FIG. 10




FIG. 12




FIG. 13





FIG. 14

**FIG. 16**




FIG. 17




FIG. 18

27/28




FIG. 19




FIG. 20

SEQUENCE LISTING

<110> C. Frank Bennett
Christopher K. Mirabelli
Isis Pharmaceuticals, Inc.

<120> OLIGONUCLEOTIDE MODULATION OF CELL ADHESION

<130> ISPH-0852

<150> 10/454,663

<151> 2003-06-04

<160> 146

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tgggagccat agcgaggc

18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

gaggagctca gcgtcgactg

20

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 3

gacactcaat aaatagctgg t

21

<210> 4

<211> 18

<212> DNA

<213> Artificial sequence

<220>

<223> Antisense Oligonucleotide

<400> 4

gaggctgagg tgggagga

18

<210> 5

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 5
cgatgggcag tgggaaag 18

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 6
gggcgcgtga tccttatagc 20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 7
catagcgagg ctgaggttgc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 8
cgggggctgc tgggagccat 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 9
agagccccga gcaggaccag 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 10

tgcccatcag ggcagtttga

20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 11

ggtcacactg actgaggcct

20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 12

ctcgcgggtg acctcccctt

20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 13

tcaggaggagc gtggcttgtg

20

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 14

cctgtcccgg gataggttca

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 15

ccccaccac ttcccctctc

20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 16
ttgagaaagc tttattaact 20

<210> 17
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
agccatagcg aggc 14

<210> 18
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
ccatagcgag gc 12

<210> 19
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
atagcgaggc 10

<210> 20
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
tgggagccat agcgag 16

<210> 21
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
ggagccatag cgagggc 16

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
gcccaagctg gcatccgtca 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
tctgtaagtc tgtgggcctc 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
agtcttgctc cttcctcttg 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
ctcatcaggc tagactttaa 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
tgtcctcatg gtggggctat 20

<210> 27
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
tctgagtagc agaggagctc ga 22

<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
caatcatgac ttcaagagtt ct 22

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
accacactgg tatttcacac 20

<210> 30
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
gtatggaaga ttataatata t 21

<210> 31
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
cacaatcctt aagaactctt t 21

<210> 32
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
acctctgctg ttctgatcc 19

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
ctgctgcctc tgtctcaggt 20

<210> 34
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
ggtatttgac acagc 15

<210> 35
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
aatcatgact tcaagagttc t 21

<210> 36
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
tgaagcaatc atgacttcaa g 21

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37

tataggagtt ttgatgtgaa 20

<210> 38
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
acaatgaggg ggtaatctac a 21

<210> 39
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
gacaatatac aaaccttcca t 21

<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
ccaggcattt taagttgctg t 21

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
cctgaagcca gtgaggcccg 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
cctgaagcca gtgaggcccg 20

<210> 43
<211> 19
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

ctgagcaaga tatctagat

19

<210> 44

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

ctacactttt gatttctgt

19

<210> 45

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45

ttgaacatat caagcattag ct

22

<210> 46

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

tttacatatg tacaattat gt

22

<210> 47

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

aattatcact ttactataca aa

22

<210> 48

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

10

<400> 48
agggctgacc aagacggttg t 21

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 49
ccatcttccc aggcatttta 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 50
aaccagtgcc tccctttgct 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 51
aaccagtgcc tccctttgct 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
gaagtcagcc aagaacagct 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
acaggatctc tcagggtgggt 20

<210> 54
<211> 20

11

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 54
ccaaagtgag agctgagaga 20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 55
ctgattcaag gctttggcag 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 56
ttccccagat gcacctgttt 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 57
gggccagaga cccgaggaga 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 58
acgtttggcc tcatggaagt 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 59
ggaatgcaaa gcacatccat 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 60
cgatgcagat accgcggagt 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 61
gcctgggagg gtattcagct 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 62
cctgtgtgtg cctgggaggg 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 63
ggcattttta gttgctgtcg 20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 64
cagcctgcct tactgtgggc 20

<210> 65

13

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 65
cttgaacaat taattccacc t 21

<210> 66
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 66
ttaccattga cataaagtgt t 21

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 67
ctgtgtctcc tgtctccgct 20

<210> 68
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 68
gtctttgttg tttctcttc c 21

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69
tgaacatatc aagcattagc 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

14

<223> Antisense Oligonucleotide

<400> 70

gcaatcttgc tatggcataa

20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71

cccggcatct ttacaaaacc

20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72

aacatctccg taccatgcca

20

<210> 73

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

tcactgctgc ctctgtctca gg

22

<210> 74

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

tgattctttt gaacttaaaa gga

23

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

ttaaaggatg taagaaggct

20

15

<210> 76
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 76
cataagcaca tttattgtc 19

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 77
ttttgggaag cagttgttca 20

<210> 78
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 78
aactgtgaag caatcatgac t 21

<210> 79
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 79
ccttgagtgg tgcattcaac ct 22

<210> 80
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 80
aatgcttgct cacacaggca tt 22

<210> 81
<211> 18
<212> DNA
<213> Artificial Sequence

16

<220>
<223> Antisense Oligonucleotide

<400> 81
gcctcgctat ggctccca 18

<210> 82
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
catggcgcg ggcgcggg 18

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
tgcaccccc aggccacat 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
tctgagtagc agaggagctc 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
tatgtctccc ccaccacttc 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
agggccactg ctcgtccaca 20

17

<210> 87
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 87
 cgagaggcgg acgggaccg 19

<210> 88
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 88
 cgagaggcgg acgggaccgt t 21

<210> 89
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 89
 ttgctctccg cctgccctgg c 21

<210> 90
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 90
 gctctccgcc tgccctggc 19

<210> 91
 <211> 2986
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> H.sapiens

<400> 91
 gcgccccagt cgacgctgag ctccctctgct actcagagtt gcaacctcag cctcgctatg 60
 gctcccagca gccccggcc cgcgctgccc gcactcctgg tcctgctcgg ggctctgttc 120
 ccaggacctg gcaatgccc gacatctgtg tccccctcaa aagtcacct gccccgggga 180
 ggctccgtgc tggtagcatg cagcacctcc tgtgaccagc ccaagttgtt gggcatagag 240
 acccggtgc ctaaaaagga gttgctcctg cctgggaaca accggaaggt gtatgaactg 300
 agcaatgtgc aagaagatag ccaaccaatg tgctattcaa actgccctga tgggcagtca 360

18

```

acagctaaaa ccttcctcac cgtgtactgg actccagaac ggggtggaact ggcaccctc 420
ccctcttggc agccagtggg caagaacctt accctacgct gccaggtgga ggggtgggca 480
ccccgggcca acctcaccgt ggtgctgctc cgtggggaga aggagctgaa acgggagcca 540
gctgtggggg agcccgtga ggtcacgacc acggtgctgg tgaggagaga tcaccatgga 600
gccaatctct cgtgccgcac tgaactggac ctgcggcccc aagggtgga gctgtttgag 660
aacacctcgg cccctacca gctccagacc ttgtcctgc cagcgactcc ccacaaactt 720
gtcagccccg ggttcctaga ggtggacacg caggggaccg tggctctgtt cctggacggg 780
ctgttcccag tctcggaggc ccagggtccac ctggcactgg gggaccagag gttgaacccc 840
acagtcacct atggcaacga ctcttctcgc gccaaaggct cagtcagtgt gaccgcagag 900
gacgagggca ccagcggct gacgtgtgca gtaatactgg ggaaccagag ccaggagaca 960
ctgcagacag tgaccatcta cagctttccg gcgccaacg tgattctgac gaagccagag 1020
gtctcagaag ggaccgaggt gacagtgaag tgtgaggccc accctagagc caaggtgacg 1080
ctgaatgggg ttccagccca gccactgggc ccgaggggcc agctcctgct gaaggccacc 1140
ccagaggaca acgggcgcag cttctcctgc tctgcaacct tggaggtggc cggccagctt 1200
atacacaaga accagaccgg ggagcttcgt gtctgtatg gccccgact ggacgagagg 1260
gattgtccgg gaaactggac gtggccagaa aattcccagc agactccaat gtgccaggct 1320
tgggggaacc cattgcccga gctcaagtgt ctaaaggatg gcactttccc actgcccatt 1380
ggggaatcag tgactgtcac tcgagatctt gagggcacct acctctgtcg ggccaggagc 1440
actcaagggg aggtcacccg cgaggtgacc gtgaatgtgc tctccccccg gtatgagatt 1500
gtcatcatca ctgtggtagc agccgcagtc ataatgggca ctgcaggcct cagcacgtac 1560
ctctataacc gccagcggaa gatcaagaaa tacagactac aacaggccca aaaagggacc 1620
cccatgaaac cgaacacaca agccacgcct cctgaacct atccggggac agggcctctt 1680
cctcggcctt cccatattgg tggcagtggt gccacactga acagagtggg agacatatgc 1740
catgcagcta cacctaccgg ccctgggacg ccggaggaca gggcattgtc ctcagtcaga 1800
tacaacagca tttggggcca tggtaacctg acacctaaaa cactaggcca cgcattctgat 1860
ctgtagtcat atgactaagc caagaggaag gagcaagact caagacatga ttgatggatg 1920
ttaaagtcta gcctgatgag aggggaagtg gtgggggaga catagcccca ccatgaggac 1980
atacaactgg gaaatactga aacttgctgc ctattgggta tgctgaggcc cacagactta 2040
cagaagaagt ggccctccat agacatgtgt agcatcaaaa caaaaggcc cactcttctt 2100
gacggatgcc agcttgggca ctgctgtcta ctgaccccaa cccttgatga tatgtattta 2160
ttcatttgtt attttaccag ctatttattg agtgtctttt atgtaggcta aatgaacata 2220
ggtctctggc ctacaggagc tccagttcca tgtcacattc aaggtaacca ggtacagttg 2280
tacaggttgt acactgcagg agagtgcctg gcaaaaagat caaatggggc tgggacttct 2340
cattggccaa cctgcctttc ccagaagga gtgatttttc tatcggcaca aaagcactat 2400
atggactggt aatggttcac aggttcagag attaccaggt gaggccttat tcctcccttc 2460
ccccaaaaac tgacaccttt gttagccacc tccccacca catacatttc tgccagtgtt 2520
cacaatgaca ctcagcggtc atgtctggac atgagtgcc aggggaatat cccaagctat 2580
gccttgtcct cttgtcctgt ttgcatttca ctgggagctt gcactattgc agctccagtt 2640
tctgcagtg atcagggtec tgcaagcagt ggggaagggg gccaaaggat tggaggactc 2700
cctcccagct ttggaagggt catccgcgtg tgtgtgtgtg tgtatgtgta gacaagctct 2760
cgctctgtca ccaggtctg agtgacagtg tgcaatcatg gttcactgca gtcttgacct 2820
tttgggctca agtgatcctc ccacctcagc ctctgagta gctgggacca taggctcaca 2880
acaccacacc tggcaaattt gatTTTTTTT ttttttttca gagacggggt ctcgcaacat 2940
tgcccagact tcctttgtgt tagttaataa agctttctca actgcc 2986

```

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92

agaggagctc agcgtcgact

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 93
ggctgaggtt gcaactctga 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 94
ccaggcagga gcaactcctt 20

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 95
ttgaatagca cattggttgg 20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 96
gcccactggc tgccaagagg 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 97
tctctctca ccagcacctt 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 98

20

aaaggtctgg agctggtagg 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 99
gcgtgtccac ctctaggacc 20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 100
ccagtgccag gtggacctgg 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 101
ccagtattac tgcacacgtc 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 102
cctctggctt cgtcagaatc 20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 103
ggtggccttc agcaggagct 20

<210> 104
<211> 20
<212> DNA

21

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 104

catacaggac acgaagctcc

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 105

catccttttag acacttgagc

20

<210> 106

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 106

gctcctggcc cgacagaggt t

21

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 107

gctaccacag tgatgatgac

20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 108

ttgtgtgttc ggtttcatgg

20

<210> 109

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

22

<400> 109
ggaggcgtgg cttgtgtgtt 20

<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 110
cctgtcccgg gataggttca 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 111
cgaggaagag gccctgtccc 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 112
tccactctgt tcagtgtggc 20

<210> 113
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 113
tctgactgag gacaatgccc 20

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 114
taggtgtgca ggtaccatgg 20

<210> 115
<211> 20

23

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 115
cctctcatca ggctagactt 20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 116
ccagttgtat gtctcatgg 20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 117
gggcctcagc atacccaata 20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 118
atgctacaca tgtctatgga 20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 119
gcccaagctg gcatccgtca 20

<210> 120
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 120
agtgcccaag ctggcatccg 20

<210> 121
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 121
gctccgtgag gccagagacc 20

<210> 122
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 122
caggcactct cctgcagtgt 20

<210> 123
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 123
gaaaggcagg ttggccaatg 20

<210> 124
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 124
ggtaatctct gaacctgtga 20

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 125
gtccagacat gaccgctgag 20

<210> 126

25

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 126
ctggagctgc aatagtgcaa 20

<210> 127
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 127
tacacataca cacacacaca 20

<210> 128
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 128
gctgaggtgg gaggatcact 20

<210> 129
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 129
ggtgtggtgt tgtgagccta 20

<210> 130
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 130
ctaacacaaa ggaagtctgg 20

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

26

<223> Antisense Oligonucleotide

<400> 131
cagtgcccaa gctggcatcc 20

<210> 132
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 132
ggtctctatg cccaacaact t 21

<210> 133
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 133
cagttcatatc accttccggt t 21

<210> 134
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 134
gtacgtgctg aggctgcat t 21

<210> 135
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 135
tctgactgag gacaatgccc 20

<210> 136
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 136
tctgactgag gacaatgccc 20

27

<210> 137
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 137
taggtgtgca ggtaccatgg 20

<210> 138
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 138
taggtgtgca ggtaccatgg 20

<210> 139
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 139
catagagacc ccgttgcccta aa 22

<210> 140
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 140
tggctatctt cttgcacatt gc 22

<210> 141
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 141
ctcctgcctg ggaacaaccg gaa 23

<210> 142
<211> 20
<212> DNA
<213> Artificial Sequence

28

<220>
<223> Antisense Oligonucleotide

<400> 142
tgcattcccc aggccaccat 20

<210> 143
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 143
tccacagcag cttgcacga 19

<210> 144
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 144
gcccaagctg gcatccatca 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 145
gcccaagctg gcatccgtca 20

<210> 146
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 146
tctgagtagc agaggagctc 20